U.S. patent application number 14/456139 was filed with the patent office on 2015-01-29 for antimicrobial peptide variants and polynucleotides encoding same.
This patent application is currently assigned to ADDENIUM BIOTECH APS. The applicant listed for this patent is ADDENIUM BIOTECH A/S. Invention is credited to Hans-Henrik Kristensen Hoegenhaug, Thomas Kruse, Per Holse Mygind, Soren Neve, Dorthe Hoj Sandvang, Dorotea Raventos Segura.
Application Number | 20150031601 14/456139 |
Document ID | / |
Family ID | 44246475 |
Filed Date | 2015-01-29 |
United States Patent
Application |
20150031601 |
Kind Code |
A1 |
Hoegenhaug; Hans-Henrik Kristensen
; et al. |
January 29, 2015 |
Antimicrobial Peptide Variants and Polynucleotides Encoding
Same
Abstract
The present invention relates to variants of a parent
antimicrobial peptide. The present invention also relates to
polynucleotides encoding the variants; nucleic acid constructs,
vectors, and host cells comprising the polynucleotides; and methods
of using the variants.
Inventors: |
Hoegenhaug; Hans-Henrik
Kristensen; (Holte, DK) ; Mygind; Per Holse;
(Vaerloese, DK) ; Kruse; Thomas; (Copenhagen,
DK) ; Segura; Dorotea Raventos; (Rungsted Kyst,
DK) ; Sandvang; Dorthe Hoj; (Slangerup, DK) ;
Neve; Soren; (Lyngby, DK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ADDENIUM BIOTECH A/S |
Copenhagen |
|
DK |
|
|
Assignee: |
ADDENIUM BIOTECH APS
Copenhagen
DK
|
Family ID: |
44246475 |
Appl. No.: |
14/456139 |
Filed: |
August 11, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13151600 |
Jun 2, 2011 |
8835604 |
|
|
14456139 |
|
|
|
|
61382118 |
Sep 13, 2010 |
|
|
|
61357243 |
Jun 22, 2010 |
|
|
|
61357230 |
Jun 22, 2010 |
|
|
|
Current U.S.
Class: |
514/2.3 ;
435/252.3; 435/252.31; 435/252.33; 435/252.34; 435/252.35;
435/254.11; 435/254.2; 435/254.21; 435/254.22; 435/254.23;
435/254.3; 435/254.4; 435/254.5; 435/254.6; 435/254.7; 435/254.8;
435/320.1; 435/325; 435/419; 435/69.1; 530/326; 536/23.5 |
Current CPC
Class: |
A61P 31/04 20180101;
A61K 45/06 20130101; A61K 38/00 20130101; C07K 14/43536 20130101;
A61K 38/1767 20130101; A61P 31/00 20180101 |
Class at
Publication: |
514/2.3 ;
530/326; 536/23.5; 435/320.1; 435/69.1; 435/252.3; 435/252.31;
435/252.35; 435/252.33; 435/252.34; 435/325; 435/419; 435/254.11;
435/254.2; 435/254.22; 435/254.23; 435/254.21; 435/254.3;
435/254.7; 435/254.8; 435/254.4; 435/254.5; 435/254.6 |
International
Class: |
A61K 38/17 20060101
A61K038/17; A61K 45/06 20060101 A61K045/06; C07K 14/435 20060101
C07K014/435 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 12, 2010 |
EP |
10165773.2 |
Jun 18, 2010 |
EP |
10166483.7 |
Sep 10, 2010 |
EP |
10176204.5 |
Claims
1. An isolated variant of an antimicrobial peptide having the amino
acid sequence of SEQ ID NO: 2, comprising a substitution at one or
more positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17,
19, and 21 of the amino acid sequence of SEQ ID NO: 2; wherein the
variant has antimicrobial activity, and the number of substitutions
is 1-11, wherein when said variant comprises a substitution
selected from G1R or G1K, said variant further comprises a
substitution at positions 5 or 17.
2. The variant of claim 1, wherein the number of substitutions are
1-10, 1-9 substitutions, 1-8 substitutions, 1-7 substitutions, 1-6
substitutions, 1-5 substitutions, 1-4 substitutions, 1-3
substitutions, or 1-2 substitutions.
3. The variant of any claim 1, which further comprises one or more
(several) substitutions selected from the group consisting of G1A,
G1D, G1F, G1H, G1I, G1K, G1M, G1Q, G1R, G1S, G1T, G1V, G1W, G1Y,
F2A, F2G, F2H, F2I, F2L, F2M, F2P, F2S, F2V, F2W, F2Y, C3L, W4A,
W4E, W4F, W4G, W41, W4L, W4M, W4N, W4Q, W4S, W4T, W4V, W4Y, Y5E,
Y5F, Y5G, Y5H, Y5K, Y5N, Y5R, Y5S, Y5W, V6A, V6C, V6E, V6F, V6G,
V6H, V61, V6L, V6M, V6N, V6Q, V6R, V6S, V6T, V6W, V6Y, C7V, V8A,
V8F, V8G, V8H, V81, V8L, V8N, V85, V8T, V8W, V8Y, Y9A, Y9D, Y9F,
Y9G, Y9H, Y91, Y9K, Y9M, Y9Q, Y9R, Y9S, Y9T, Y9V, Y9W, R10K, R10P,
R10S, R10T, N11A, N11G, N11H, N11Q, N11R, N115, N11Y, G12A, G12D,
G12E, G12F, G12H, G12K, G12N, G12R, G125, G12Y, V13A, V13C, V13F,
V13G, V13H, V13K, V13L, V13P, V13Q, V13R, V135, V13T, V13W, V13Y,
V15A, V15C, V15F, V15G, V15H, V15I, V15K, V15L, V15M, V15N, V15P,
V15Q, V15R, V155, V15T, V15W, V15Y, Y17C, Y17F, Y17G, Y17H, Y17I,
Y17K, Y17L, Y17M, Y17N, Y17Q, Y17R, Y17S, Y17T, Y17V, Y17W, R19D,
R19H, R19K, R19M, R19T, R19Y, N21A, N21C, N21F, N21G, N21H, N21I,
N21K, N21L, N21M, N21P, N21Q, N21R, N21S, N21T, N21W, and N21Y.
4. The variant of claim 1, which comprises a substitution at two of
positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19,
and 21.
5. The variant of claim 1, which comprises a substitution at three
of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19,
and 21.
6. The variant of claim 1, which comprises a substitution at four
of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19,
and 21.
7. The variant of claim 1, which comprises a substitution at one or
more (several) of positions 1, 2, 4, 5, 6, 8, 9, 12, 13, 15, 17,
and 21.
8. The variant of claim 1, which comprises the amino acid sequence
of any of SEQ ID NO: 3-9, 13-25, 29-46, 50-55, 57, 59-60, 62,
65-66, 79-85, 88-91, 93-94, 96-116, 118-119, 126, 128-129, 138-160,
167, 178, 183, 196-197, 205, 212-214, 216-219, 338-344, 347-349,
352-353, 356-357, 361-362, 369-370, 383, 390, 392, 494, 500, and
543.
9. The variant of claim 1, which comprises the amino acid sequence
of any of SEQ ID NO: 13-25, 46, 57, 59-60, 66, 89, 94, 96-116, 118,
129, 138-160, 167, 178, 183, 196-197, 205, 212-214, 216-219,
338-344, 347-349, 352-353, 356-357, 361-362, 369-370, 383, 390,
392, 494, 500, and 543.
10. An isolated polynucleotide encoding the variant of claim 1.
11. A nucleic acid construct comprising the polynucleotide of claim
10.
12. An expression vector comprising the polynucleotide of claim
10.
13. A host cell comprising the polynucleotide of claim 10.
14. A method of producing a variant of an antimicrobial peptide
having the amino acid sequence of SEQ ID NO: 2, comprising: a)
cultivating the host cell of claim 13 under conditions suitable for
the expression of the variant; and b) recovering the variant.
15. A method of treating a microbial infection in a subject in need
thereof comprising administering an amount of the variant of claim
1 effective to treat said microbial infection.
16. A composition comprising the variant of claim 1 and an
antibiotic.
Description
REFERENCE TO A SEQUENCE LISTING
[0001] This application contains a Sequence Listing in computer
readable form, which is incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to variants of an
antimicrobial peptide, polynucleotides encoding the variants,
methods of producing the variants, and methods of using the
variants.
[0004] 2. Description of the Related Art
[0005] Several classes of antimicrobial peptides (AMPs) have been
described in literature, examples of which include defensins and
alpha-helical peptides.
[0006] The present invention provides variants of an antimicrobial
peptide isolated from Arenicola marina, and described in WO
2007/023163.
[0007] The variant antimicrobial peptides of the present invention
exhibit improved antimicrobial activity as compared to the parent
antimicrobial peptide. In particular, the variants exhibit improved
antimicrobial activity in the presence of serum and blood proteins.
Another advantage of the variant peptides of the invention is a
reduced protein binding e.g. to serum and blood proteins, which
results in an improved bioavailability as compared to the parent
antimicrobial peptide.
SUMMARY OF THE INVENTION
[0008] The present invention relates to isolated variants of an
antimicrobial peptide having the amino acid sequence of SEQ ID NO:
2, comprising an alteration at one or more (several) of positions
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21 of
the mature peptide of SEQ ID NO: 2, wherein the variant has
antimicrobial activity.
[0009] The present invention also relates to isolated
polynucleotides encoding the variants; nucleic acid constructs,
vectors, and host cells comprising the polynucleotides; and methods
of producing the variants.
[0010] The present invention also relates to a method of treating a
microbial infection using the variants of the invention; and use of
variants for manufacturing a medicament for the treatment of a
microbial infection.
DETAILED DESCRIPTION OF THE INVENTION
[0011] The present invention relates to isolated variants of an
antimicrobial peptide having the amino acid sequence of SEQ ID NO:
2, comprising an alteration at one or more (several) of positions
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21 of
the mature peptide of SEQ ID NO: 2, wherein the variant has
antimicrobial activity.
DEFINITIONS
[0012] Antimicrobial activity: The term "antimicrobial activity" is
defined herein as an activity which is capable of killing or
inhibiting growth of microbial cells. In the context of the present
invention the term "antimicrobial" is intended to mean that there
is a bactericidal and/or a bacteriostatic and/or fungicidal and/or
fungistatic effect and/or a virucidal effect, wherein the term
"bactericidal" is to be understood as capable of killing bacterial
cells. The term "bacteriostatic" is to be understood as capable of
inhibiting bacterial growth, i.e. inhibiting growing bacterial
cells. The term "fungicidal" is to be understood as capable of
killing fungal cells. The term "fungistatic" is to be understood as
capable of inhibiting fungal growth, i.e. inhibiting growing fungal
cells. The term "virucidal" is to be understood as capable of
inactivating virus. The term "microbial cells" denotes bacterial or
fungal cells (including yeasts).
[0013] In the context of the present invention the term "inhibiting
growth of microbial cells" is intended to mean that the cells are
in the non-growing state, i.e., that they are not able to
propagate.
[0014] In a preferred embodiment, the term "antimicrobial activity"
is defined as bactericidal and/or bacteriostatic activity. More
preferably, "antimicrobial activity" is defined as bactericidal
and/or bacteriostatic activity against Escherichia, preferably
Escherichia coli.
[0015] For purposes of the present invention, antimicrobial
activity may be determined according to the procedure described by
Lehrer et al., 1991, Journal of Immunological Methods 137(2):
167-174. Alternatively, antimicrobial activity may be determined
according to the NCCLS guidelines from CLSI (Clinical and
Laboratory Standards Institute; formerly known as National
Committee for Clinical and Laboratory Standards).
[0016] Peptides having antimicrobial activity may be capable of
reducing the number of living cells of Escherichia coli (DSM 1576)
to 1/100 after 8 hours (preferably after 4 hours, more preferably
after 2 hours, most preferably after 1 hour, and in particular
after 30 minutes) incubation at 37.degree. C. in a relevant
microbial growth substrate at a concentration of 500 micrograms/ml;
preferably at a concentration of 250 micrograms/ml; more preferably
at a concentration of 100 micrograms/ml; even more preferably at a
concentration of 50 micrograms/ml; most preferably at a
concentration of 25 micrograms/ml; and in particular at a
concentration of 10 micrograms/ml of the peptides having
antimicrobial activity.
[0017] Peptides having antimicrobial activity may also be capable
of inhibiting the outgrowth of Escherichia coli (DSM 1576) for 8
hours at 37.degree. C. in a relevant microbial growth substrate,
when added in a concentration of 500 micrograms/ml; preferably when
added in a concentration of 250 micrograms/ml; more preferably when
added in a concentration of 100 micrograms/ml; even more preferably
when added in a concentration of 50 micrograms/ml; most preferably
when added in a concentration of 10 micrograms/ml; and in
particular when added in a concentration of 5 micrograms/ml.
[0018] The variant peptides of the present invention have improved
antimicrobial activity compared to the antimicrobial peptide of SEQ
ID NO: 2. In an embodiment, the variant peptides of the present
invention have more than 100% of the antimicrobial activity of the
peptide of SEQ ID NO: 2 in the presence of blood serum.
[0019] Variant: The term "variant" means a peptide having
antimicrobial activity comprising an alteration, i.e., a
substitution, insertion, and/or deletion, at one or more (several)
positions. A substitution means a replacement of an amino acid
occupying a position with a different amino acid; a deletion means
removal of an amino acid occupying a position; and an insertion
means adding 1-3 amino acids adjacent to an amino acid occupying a
position.
[0020] Mutant: The term "mutant" means a polynucleotide encoding a
variant.
[0021] Wild-type antimicrobial peptide: The term "wild-type"
antimicrobial peptide means an antimicrobial peptide expressed by a
naturally occurring microorganism, such as a bacterium, yeast, or
filamentous fungus found in nature.
[0022] Parent or Parent antimicrobial peptide: The term "parent" or
"parent antimicrobial peptide" means an antimicrobial peptide to
which an alteration is made to produce the enzyme variants of the
present invention. The parent may be a naturally occurring
(wild-type) peptide or a variant thereof.
[0023] Isolated variant: The term "isolated variant" means a
variant that is modified by the hand of man. In one aspect, the
variant is at least 1% pure, e.g., at least 5% pure, at least 10%
pure, at least 20% pure, at least 40% pure, at least 60% pure, at
least 80% pure, and at least 90% pure, as determined by
SDS-PAGE.
[0024] Substantially pure variant: The term "substantially pure
variant" means a preparation that contains at most 10%, at most 8%,
at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most
1%, and at most 0.5% by weight of other peptide material with which
it is natively or recombinantly associated. Preferably, the variant
is at least 92% pure, e.g., at least 94% pure, at least 95% pure,
at least 96% pure, at least 97% pure, at least 98% pure, at least
99%, at least 99.5% pure, and 100% pure by weight of the total
peptide material present in the preparation. The variants of the
present invention are preferably in a substantially pure form. This
can be accomplished, for example, by preparing the variant by well
known recombinant methods or by classical purification methods.
[0025] Mature peptide: The term "mature peptide" means a peptide in
its final form following translation and any post-translational
modifications, such as N-terminal processing, C-terminal
truncation, glycosylation, phosphorylation, etc.
[0026] Mature peptide coding sequence: The term "mature peptide
coding sequence" means a polynucleotide that encodes a mature
peptide having antimicrobial activity.
[0027] Sequence Identity: The relatedness between two amino acid
sequences or between two nucleotide sequences is described by the
parameter "sequence identity".
[0028] For purposes of the present invention, the degree of
sequence identity between two amino acid sequences is determined
using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970,
J. Mol. Biol. 48: 443-453) as implemented in the Needle program of
the EMBOSS package (EMBOSS: The European Molecular Biology Open
Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277),
preferably version 3.0.0 or later. The optional parameters used are
gap open penalty of 10, gap extension penalty of 0.5, and the
EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The
output of Needle labeled "longest identity" (obtained using the
-nobrief option) is used as the percent identity and is calculated
as follows:
(Identical Residues.times.100)/(Length of Alignment-Total Number of
Gaps in Alignment)
[0029] For purposes of the present invention, the degree of
sequence identity between two deoxyribonucleotide sequences is
determined using the Needleman-Wunsch algorithm (Needleman and
Wunsch, 1970, supra) as implemented in the Needle program of the
EMBOSS package (EMBOSS: The European Molecular Biology Open
Software Suite, Rice et al., 2000, supra), preferably version 3.0.0
or later. The optional parameters used are gap open penalty of 10,
gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of
NCBI NUC4.4) substitution matrix. The output of Needle labeled
"longest identity" (obtained using the -nobrief option) is used as
the percent identity and is calculated as follows:
(Identical Deoxyribonucleotides.times.100)/(Length of
Alignment-Total Number of Gaps in Alignment)
[0030] Fragment: The term "fragment" means a peptide having one or
more (several) amino acids deleted from the amino and/or carboxyl
terminus of a mature peptide; wherein the fragment has
antimicrobial activity. In one aspect, a fragment contains at least
15 amino acid residues, e.g., at least 17 and at least 19 amino
acid residues (e.g., amino acids 1 to 20 of SEQ ID NO: 2).
[0031] Subsequence: The term "subsequence" means a polynucleotide
having one or more (several) nucleotides deleted from the 5'-
and/or 3'-end of a mature peptide coding sequence; wherein the
subsequence encodes a fragment having antimicrobial activity.
[0032] Allelic variant: The term "allelic variant" means any of two
or more alternative forms of a gene occupying the same chromosomal
locus. Allelic variation arises naturally through mutation, and may
result in polymorphism within populations. Gene mutations can be
silent (no change in the encoded peptide) or may encode peptides
having altered amino acid sequences. An allelic variant of a
peptide is a peptide encoded by an allelic variant of a gene.
[0033] Isolated polynucleotide: The term "isolated polynucleotide"
means a polynucleotide that is modified by the hand of man. In one
aspect, the isolated polynucleotide is at least 1% pure, e.g., at
least 5% pure, at least 10% pure, at least 20% pure, at least 40%
pure, at least 60% pure, at least 80% pure, at least 90% pure, and
at least 95% pure, as determined by agarose electrophoresis. The
polynucleotides may be of genomic, cDNA, RNA, semisynthetic,
synthetic origin, or any combinations thereof.
[0034] Substantially pure polynucleotide: The term "substantially
pure polynucleotide" means a polynucleotide preparation free of
other extraneous or unwanted nucleotides and in a form suitable for
use within genetically engineered peptide production systems. Thus,
a substantially pure polynucleotide contains at most 10%, at most
8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at
most 1%, and at most 0.5% by weight of other polynucleotide
material with which it is natively or recombinantly associated. A
substantially pure polynucleotide may, however, include naturally
occurring 5'- and 3'-untranslated regions, such as promoters and
terminators. It is preferred that the substantially pure
polynucleotide is at least 90% pure, e.g., at least 92% pure, at
least 94% pure, at least 95% pure, at least 96% pure, at least 97%
pure, at least 98% pure, at least 99% pure, and at least 99.5% pure
by weight. The polynucleotides of the present invention are
preferably in a substantially pure form.
[0035] Coding sequence: The term "coding sequence" means a
polynucleotide, which directly specifies the amino acid sequence of
its peptide product. The boundaries of the coding sequence are
generally determined by an open reading frame, which usually begins
with the ATG start codon or alternative start codons such as GTG
and TTG and ends with a stop codon such as TAA, TAG, and TGA. The
coding sequence may be a DNA, cDNA, synthetic, or recombinant
polynucleotide.
[0036] cDNA: The term "cDNA" means a DNA molecule that can be
prepared by reverse transcription from a mature, spliced, mRNA
molecule obtained from a eukaryotic cell. cDNA lacks intron
sequences that may be present in the corresponding genomic DNA. The
initial, primary RNA transcript is a precursor to mRNA that is
processed through a series of steps, including splicing, before
appearing as mature spliced mRNA.
[0037] Nucleic acid construct: The term "nucleic acid construct"
means a nucleic acid molecule, either single- or double-stranded,
which is isolated from a naturally occurring gene or is modified to
contain segments of nucleic acids in a manner that would not
otherwise exist in nature or which is synthetic. The term nucleic
acid construct is synonymous with the term "expression cassette"
when the nucleic acid construct contains the control sequences
required for expression of a coding sequence of the present
invention.
[0038] Control sequences: The term "control sequences" means all
components necessary for the expression of a polynucleotide
encoding a variant of the present invention. Each control sequence
may be native or foreign to the polynucleotide encoding the variant
or native or foreign to each other. Such control sequences include,
but are not limited to, a leader, polyadenylation sequence,
propeptide sequence, promoter, signal peptide sequence, and
transcription terminator. At a minimum, the control sequences
include a promoter, and transcriptional and translational stop
signals. The control sequences may be provided with linkers for the
purpose of introducing specific restriction sites facilitating
ligation of the control sequences with the coding region of the
polynucleotide encoding a variant.
[0039] Operably linked: The term "operably linked" means a
configuration in which a control sequence is placed at an
appropriate position relative to the coding sequence of a
polynucleotide such that the control sequence directs the
expression of the coding sequence.
[0040] Expression: The term "expression" includes any step involved
in the production of the variant including, but not limited to,
transcription, post-transcriptional modification, translation,
post-translational modification, and secretion.
[0041] Expression vector: The term "expression vector" means a
linear or circular DNA molecule that comprises a polynucleotide
encoding a variant and is operably linked to additional nucleotides
that provide for its expression.
[0042] Host cell: The term "host cell" means any cell type that is
susceptible to transformation, transfection, transduction, and the
like with a nucleic acid construct or expression vector comprising
a polynucleotide of the present invention. The term "host cell"
encompasses any progeny of a parent cell that is not identical to
the parent cell due to mutations that occur during replication.
Conventions for Designation of Variants
[0043] For purposes of the present invention, the mature peptide
disclosed in SEQ ID NO: 2 is used to determine the corresponding
amino acid residue in another antimicrobial peptide. The amino acid
sequence of another antimicrobial peptide is aligned with the
mature peptide disclosed in SEQ ID NO: 2, and based on the
alignment, the amino acid position number corresponding to any
amino acid residue in the mature peptide disclosed in SEQ ID NO: 2
is determined using the Needleman-Wunsch algorithm (Needleman and
Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the
Needle program of the EMBOSS package (EMBOSS: The European
Molecular Biology Open Software Suite, Rice et al., 2000, Trends
Genet. 16: 276-277), preferably version 3.0.0 or later.
[0044] Identification of the corresponding amino acid residue in
another antimicrobial peptide can be confirmed by an alignment of
multiple peptide sequences using "ClustalW" (Larkin et al., 2007,
Bioinformatics 23: 2947-2948).
[0045] When the other enzyme has diverged from the mature peptide
of SEQ ID NO: 2 such that traditional sequence-based comparison
fails to detect their relationship (Lindahl and Elofsson, 2000, J.
Mol. Biol. 295: 613-615), other pairwise sequence comparison
algorithms can be used. Greater sensitivity in sequence-based
searching can be attained using search programs that utilize
probabilistic representations of peptide families (profiles) to
search databases. For example, the PSI-BLAST program generates
profiles through an iterative database search process and is
capable of detecting remote homologs (Atschul et al., 1997, Nucleic
Acids Res. 25: 3389-3402). Even greater sensitivity can be achieved
if the family or superfamily for the peptide has one or more
representatives in the protein structure databases. Programs such
as GenTHREADER (Jones, 1999, J. Mol. Biol. 287: 797-815; McGuffin
and Jones, 2003, Bioinformatics 19: 874-881) utilize information
from a variety of sources (PSI-BLAST, secondary structure
prediction, structural alignment profiles, and solvation
potentials) as input to a neural network that predicts the
structural fold for a query sequence. Similarly, the method of
Gough et al., 2000, J. Mol. Biol. 313: 903-919, can be used to
align a sequence of unknown structure with the superfamily models
present in the SCOP database. These alignments can in turn be used
to generate homology models for the peptide, and such models can be
assessed for accuracy using a variety of tools developed for that
purpose.
[0046] For proteins of known structure, several tools and resources
are available for retrieving and generating structural alignments.
For example the SCOP superfamilies of proteins have been
structurally aligned, and those alignments are accessible and
downloadable. Two or more protein structures can be aligned using a
variety of algorithms such as the distance alignment matrix (Holm
and Sander, 1998, Proteins 33: 88-96) or combinatorial extension
(Shindyalov and Bourne, 1998, Protein Engineering 11: 739-747), and
implementations of these algorithms can additionally be utilized to
query structure databases with a structure of interest in order to
discover possible structural homologs (e.g., Holm and Park, 2000,
Bioinformatics 16: 566-567).
[0047] In describing the antimicrobial peptide variants of the
present invention, the nomenclature described below is adapted for
ease of reference. The accepted IUPAC single letter or three letter
amino acid abbreviation is employed.
[0048] Substitutions.
[0049] For an amino acid substitution, the following nomenclature
is used: Original amino acid, position, substituted amino acid.
Accordingly, the substitution of threonine with alanine at position
226 is designated as "Thr226Ala" or "T226A". Multiple mutations are
separated by addition marks ("+"), e.g., "Gly205Arg+Ser411Phe" or
"G205R+S411F", representing substitutions at positions 205 and 411
of glycine (G) with arginine (R) and serine (S) with phenylalanine
(F), respectively.
[0050] Deletions.
[0051] For an amino acid deletion, the following nomenclature is
used: Original amino acid, position, *. Accordingly, the deletion
of glycine at position 195 is designated as "Gly195*" or "G195*".
Multiple deletions are separated by addition marks ("+"), e.g.,
"Gly195*+Ser411*" or "G195*+S411*".
[0052] Insertions.
[0053] For an amino acid insertion, the following nomenclature is
used: Original amino acid, position, original amino acid, inserted
amino acid. Accordingly the insertion of lysine after glycine at
position 195 is designated "Gly195GlyLys" or "G195GK". An insertion
of multiple amino acids is designated [Original amino acid,
position, original amino acid, inserted amino acid #1, inserted
amino acid #2; etc.]. For example, the insertion of lysine and
alanine after glycine at position 195 is indicated as
"Gly195GlyLysAla" or "G195GKA". In such cases the inserted amino
acid residue(s) are numbered by the addition of lower case letters
to the position number of the amino acid residue preceding the
inserted amino acid residue(s). In the above example, the sequence
would thus be:
TABLE-US-00001 Parent: Variant: 195 195 195a 195b G G - K - A
[0054] Multiple Alterations.
[0055] Variants comprising multiple alterations are separated by
addition marks ("+"), e.g., "Arg170Tyr+Gly195Glu" or "R170Y+G195E"
representing a substitution of tyrosine and glutamic acid for
arginine and glycine at positions 170 and 195, respectively.
[0056] Different Substitutions.
[0057] Where different substitutions can be introduced at a
position, the different substitutions are separated by a comma,
e.g., "Arg170Tyr,Glu" or "R170Y,E" represents a substitution of
arginine with tyrosine or glutamic acid at position 170. Thus,
"Tyr167Gly,Ala+Arg170Gly,Ala" or "Y167G,A+R170G,A" designates the
following variants: "Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala",
"Tyr167Ala+Arg170Gly", and "Tyr167Ala+Arg170Ala".
Parent Antimicrobial Peptides
[0058] The parent antimicrobial peptide is (a) a peptide with at
least 60% sequence identity with the mature peptide of SEQ ID NO:
2; (b) a peptide encoded by a polynucleotide that hybridizes under
medium stringency conditions with (i) the mature peptide coding
sequence of SEQ ID NO: 1, or (ii) the full-length complementary
strand of (i); or (c) a peptide encoded by a polynucleotide with at
least 60% sequence identity with the mature peptide coding sequence
of SEQ ID NO: 1.
[0059] In a first aspect, the parent has a sequence identity to the
mature peptide of SEQ ID NO: 2 of at least 60%, e.g., at least 65%,
at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 95%, at least 96%, at least 97%, at least 98%, at
least 99%, or 100%, which have antimicrobial activity. In one
aspect, the amino acid sequence of the parent differs by no more
than ten amino acids, e.g., by five amino acids, by four amino
acids, by three amino acids, by two amino acids, and by one amino
acid from the mature peptide of SEQ ID NO: 2.
[0060] The parent preferably comprises or consists of the amino
acid sequence of SEQ ID NO: 2.
[0061] In an embodiment, the parent is a fragment of the peptide of
SEQ ID NO: 2 containing at least 15 amino acid residues, e.g., at
least 17 and at least 19 amino acid residues.
[0062] In another embodiment, the parent is an allelic variant of
the peptide of SEQ ID NO: 2.
[0063] In a second aspect, the parent peptide is encoded by a
polynucleotide that hybridizes under medium stringency conditions,
medium-high stringency conditions, high stringency conditions, or
very high stringency conditions with (i) the mature peptide coding
sequence of SEQ ID NO: 1, or (ii) the full-length complementary
strand of (i) (J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989,
Molecular Cloning, A Laboratory Manual, 2d edition, Cold Spring
Harbor, N.Y.).
[0064] The polynucleotide of SEQ ID NO: 1 or a subsequence thereof,
as well as the amino acid sequence of SEQ ID NO: 2 or a fragment
thereof, may be used to design nucleic acid probes to identify and
clone DNA encoding a parent from strains of different genera or
species according to methods well known in the art. In particular,
such probes can be used for hybridization with the genomic or cDNA
of the genus or species of interest, following standard Southern
blotting procedures, in order to identify and isolate the
corresponding gene therein. Such probes can be considerably shorter
than the entire sequence, but should be at least 14, e.g., at least
25, or at least 35 nucleotides in length. Both DNA and RNA probes
can be used. The probes are typically labeled for detecting the
corresponding gene (for example, with .sup.32P, .sup.3H, .sup.35S,
biotin, or avidin). Such probes are encompassed by the present
invention.
[0065] A genomic DNA or cDNA library prepared from such other
organisms may be screened for DNA that hybridizes with the probes
described above and encodes a parent. Genomic or other DNA from
such other organisms may be separated by agarose or polyacrylamide
gel electrophoresis, or other separation techniques. DNA from the
libraries or the separated DNA may be transferred to and
immobilized on nitrocellulose or other suitable carrier material.
In order to identify a clone or DNA that is homologous with SEQ ID
NO: 1 or a subsequence thereof, the carrier material is used in a
Southern blot.
[0066] For purposes of the present invention, hybridization
indicates that the polynucleotide hybridizes to a labeled
nucleotide probe corresponding to the polynucleotide shown in SEQ
ID NO: 1, its complementary strand, or a subsequence thereof, under
low to very high stringency conditions. Molecules to which the
probe hybridizes can be detected using, for example, X-ray film or
any other detection means known in the art.
[0067] In one aspect, the nucleic acid probe is SEQ ID NO: 1.
[0068] For long probes of at least 60 nucleotides in length, very
low to very high stringency conditions are defined as
prehybridization and hybridization at 42.degree. C. in
5.times.SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured
salmon sperm DNA, and either 25% formamide for very low and low
stringencies, 35% formamide for medium and medium-high
stringencies, or 50% formamide for high and very high stringencies,
following standard Southern blotting procedures for 12 to 24 hours
optimally. The carrier material is finally washed three times each
for 15 minutes using 2.times.SSC, 0.2% SDS at 45.degree. C. (very
low stringency), 50.degree. C. (low stringency), 55.degree. C.
(medium stringency), 60.degree. C. (medium-high stringency),
65.degree. C. (high stringency), or 70.degree. C. (very high
stringency).
[0069] For short probes that are about 15 nucleotides to about 60
nucleotides in length, stringency conditions are defined as
prehybridization and hybridization at about 5.degree. C. to about
10.degree. C. below the calculated T.sub.m using the calculation
according to Bolton and McCarthy (1962, Proc. Natl. Acad. Sci. USA
48: 1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5%
NP-40, 1.times.Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM
sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per
ml following standard Southern blotting procedures for 12 to 24
hours optimally. The carrier material is finally washed once in
6.times.SCC plus 0.1% SDS for 15 minutes and twice each for 15
minutes using 6.times.SSC at 5.degree. C. to 10.degree. C. below
the calculated T.sub.m.
[0070] In a third aspect, the parent is encoded by a polynucleotide
with a sequence identity to the peptide coding sequence of SEQ ID
NO: 1 of at least 60%, e.g., at least 65%, at least 70%, at least
75%, at least 80%, at least 85%, at least 90%, at least 95%, at
least 96%, at least 97%, at least 98%, at least 99%, or 100%, which
encodes a peptide having antimicrobial activity.
[0071] The parent may be obtained from microorganisms of any genus.
For purposes of the present invention, the term "obtained from" as
used herein in connection with a given source shall mean that the
parent encoded by a polynucleotide is produced by the source or by
a cell in which the polynucleotide from the source has been
inserted. In one aspect, the parent is secreted
extracellularly.
[0072] The parent may be a bacterial antimicrobial peptide. For
example, the parent may be a gram-positive bacterial peptide such
as a Bacillus, Clostridium, Enterococcus, Geobacillus,
Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus,
Streptococcus, or Streptomyces antimicrobial peptide, or a
gram-negative bacterial peptide such as a Campylobacter, E. coli,
Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria,
Pseudomonas, Salmonella, or Ureaplasma antimicrobial peptide.
[0073] In one aspect, the parent is a Bacillus alkalophilus,
Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans,
Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus
lautus, Bacillus lentus, Bacillus licheniformis, Bacillus
megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus
subtilis, or Bacillus thuringiensis antimicrobial peptide.
[0074] In another aspect, the parent is a Streptococcus
equisimilis, Streptococcus pyogenes, Streptococcus uberis, or
Streptococcus equi subsp. Zooepidemicus antimicrobial peptide.
[0075] In another aspect, the parent is a Streptomyces
achromogenes, Streptomyces avermitilis, Streptomyces coelicolor,
Streptomyces griseus, or Streptomyces lividans antimicrobial
peptide.
[0076] The parent may be a fungal antimicrobial peptide. For
example, the parent may be a yeast antimicrobial peptide such as a
Candida, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces,
or Yarrowia antimicrobial peptide. For example, the parent may be a
filamentous fungal antimicrobial peptide such as an Acremonium,
Agaricus, Alternaria, Aspergillus, Aureobasidium, Botryospaeria,
Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps,
Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria,
Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella,
Holomastigotoides, Humicola, Irpex, Lentinula, Leptospaeria,
Magnaporthe, Melanocarpus, Meripilus, Mucor, Myceliophthora,
Neocallimastix, Neurospora, Paecilomyces, Penicillium,
Phanerochaete, Piromyces, Poitrasia, Pseudoplectania,
Pseudotrichonympha, Rhizomucor, Schizophyllum, Scytalidium,
Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma,
Trichophaea, Verticillium, Volvariella, or Xylaria antimicrobial
peptide.
[0077] In another aspect, the parent is a Saccharomyces
carlsbergensis, Saccharomyces cerevisiae, Saccharomyces
diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri,
Saccharomyces norbensis, or Saccharomyces oviformis antimicrobial
peptide.
[0078] In another aspect, the parent is an Acremonium
cellulolyticus, Aspergillus aculeatus, Aspergillus awamori,
Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus,
Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae,
Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium
lucknowense, Chrysosporium merdarium, Chrysosporium pannicola,
Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium
zonatum, Fusarium bactridioides, Fusarium cerealis, Fusarium
crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium
graminurn, Fusarium heterosporum, Fusarium negundi, Fusarium
oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium
sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides,
Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides,
Fusarium venenatum, Humicola grisea, Humicola insolens, Humicola
lanuginosa, Irpex lacteus, Mucor miehei, Myceliophthora
thermophila, Neurospora crassa, Penicillium funiculosum,
Penicillium purpurogenum, Phanerochaete chrysosporium, Thielavia
achromatica, Thielavia albomyces, Thielavia albopilosa, Thielavia
australeinsis, Thielavia fimeti, Thielavia microspora, Thielavia
ovispora, Thielavia peruviana, Thielavia setosa, Thielavia
spededonium, Thielavia subthermophila, Thielavia terrestris,
Trichoderma harzianum, Trichoderma koningii, Trichoderma
longibrachiatum, Trichoderma reesei, or Trichoderma viride
antimicrobial peptide.
[0079] In another aspect, the parent is an Arenicola marina
antimicrobial peptide, e.g., the antimicrobial peptide of SEQ ID
NO: 2.
[0080] It will be understood that for the aforementioned species,
the invention encompasses both the perfect and imperfect states,
and other taxonomic equivalents, e.g., anamorphs, regardless of the
species name by which they are known. Those skilled in the art will
readily recognize the identity of appropriate equivalents.
[0081] Strains of these species are readily accessible to the
public in a number of culture collections, such as the American
Type Culture Collection (ATCC), Deutsche Sammlung von
Mikroorganismen and Zellkulturen GmbH (DSM), Centraalbureau Voor
Schimmelcultures (CBS), and Agricultural Research Service Patent
Culture Collection, Northern Regional Research Center (NRRL).
[0082] The parent may be identified and obtained from other sources
including microorganisms isolated from nature (e.g., soil,
composts, water, etc.) or DNA samples obtained directly from
natural materials (e.g., soil, composts, water, etc,) using the
above-mentioned probes. Techniques for isolating microorganisms and
DNA directly from natural habitats are well known in the art. The
polynucleotide encoding a parent may then be derived by similarly
screening a genomic or cDNA library of another microorganism or
mixed DNA sample. Once a polynucleotide encoding a parent has been
detected with a probe(s), the polynucleotide may be isolated or
cloned by utilizing techniques that are known to those of ordinary
skill in the art (see, e.g., Sambrook et al., 1989, supra).
[0083] The parent may be a hybrid peptide in which a portion of one
peptide is fused at the N-terminus or the C-terminus of a portion
of another peptide.
[0084] The parent also may be a fused peptide or cleavable fusion
peptide in which one peptide is fused at the N-terminus or the
C-terminus of another peptide. A fused peptide is produced by
fusing a polynucleotide encoding one peptide to a polynucleotide
encoding another peptide. Techniques for producing fusion peptides
are known in the art, and include ligating the coding sequences
encoding the peptides so that they are in frame and that expression
of the fused peptide is under control of the same promoter(s) and
terminator. Fusion proteins may also be constructed using intein
technology in which fusions are created post-translationally
(Cooper et al., 1993, EMBO J. 12: 2575-2583; Dawson et al., 1994,
Science 266: 776-779).
[0085] A fusion peptide can further comprise a cleavage site
between the two peptides. Upon secretion of the fusion protein, the
site is cleaved releasing the two peptides. Examples of cleavage
sites include, but are not limited to, the sites disclosed in
Martin et al., 2003, J. Ind. Microbiol. Biotechnol. 3: 568-576;
Svetina et al., 2000, J. Biotechnol. 76: 245-251; Rasmussen-Wilson
et al., 1997, Appl. Environ. Microbiol. 63: 3488-3493; Ward et al.,
1995, Biotechnology 13: 498-503; and Contreras et al., 1991,
Biotechnology 9: 378-381; Eaton et al., 1986, Biochemistry 25:
505-512; Collins-Racie et al., 1995, Biotechnology 13: 982-987;
Carter et al., 1989, Proteins: Structure, Function, and Genetics 6:
240-248; and Stevens, 2003, Drug Discovery World 4: 35-48.
Preparation of Variants
[0086] The present invention also relates to methods for obtaining
a variant having antimicrobial activity, comprising: (a)
introducing into a parent antimicrobial peptide a substitution at
one or more (several) corresponding to positions 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21 of the mature peptide
of SEQ ID NO: 2, wherein the variant has antimicrobial activity;
and (b) recovering the variant.
[0087] The variants can be prepared using any mutagenesis procedure
known in the art, such as site-directed mutagenesis, synthetic gene
construction, semi-synthetic gene construction, random mutagenesis,
shuffling, etc.
[0088] Site-directed mutagenesis is a technique in which one or
more (several) mutations are created at one or more defined sites
in a polynucleotide encoding the parent.
[0089] Site-directed mutagenesis can be accomplished in vitro by
PCR involving the use of oligonucleotide primers containing the
desired mutation. Site-directed mutagenesis can also be performed
in vitro by cassette mutagenesis involving the cleavage by a
restriction enzyme at a site in the plasmid comprising a
polynucleotide encoding the parent and subsequent ligation of an
oligonucleotide containing the mutation in the polynucleotide.
Usually the restriction enzyme that digests at the plasmid and the
oligonucleotide is the same, permitting sticky ends of the plasmid
and insert to ligate to one another. See, e.g., Scherer and Davis,
1979, Proc. Natl. Acad. Sci. USA 76: 4949-4955; and Barton et al.,
1990, Nucleic Acids Res. 18: 7349-4966.
[0090] Site-directed mutagenesis can also be accomplished in vivo
by methods known in the art. See, e.g., U.S. Patent Application
Publication No. 2004/0171154; Storici et al., 2001, Nature
Biotechnol. 19: 773-776; Kren et al., 1998, Nat. Med. 4: 285-290;
and Calissano and Macino, 1996, Fungal Genet. Newslett. 43:
15-16.
[0091] Any site-directed mutagenesis procedure can be used in the
present invention. There are many commercial kits available that
can be used to prepare variants.
[0092] Synthetic gene construction entails in vitro synthesis of a
designed polynucleotide molecule to encode a peptide of interest.
Gene synthesis can be performed utilizing a number of techniques,
such as the multiplex microchip-based technology described by Tian
et al. (2004, Nature 432: 1050-1054) and similar technologies
wherein oligonucleotides are synthesized and assembled upon
photo-programmable microfluidic chips.
[0093] Single or multiple amino acid substitutions, deletions,
and/or insertions can be made and tested using known methods of
mutagenesis, recombination, and/or shuffling, followed by a
relevant screening procedure, such as those disclosed by
Reidhaar-Olson and Sauer, 1988, Science 241: 53-57; Bowie and
Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413;
or WO 95/22625. Other methods that can be used include error-prone
PCR, phage display (e.g., Lowman et al., 1991, Biochemistry 30:
10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204) and
region-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145;
Ner et al., 1988, DNA 7: 127).
[0094] Mutagenesis/shuffling methods can be combined with
high-throughput, automated screening methods to detect activity of
cloned, mutagenized peptides expressed by host cells (Ness et al.,
1999, Nature Biotechnology 17: 893-896). Mutagenized DNA molecules
that encode active peptides can be recovered from the host cells
and rapidly sequenced using standard methods in the art. These
methods allow the rapid determination of the importance of
individual amino acid residues in a peptide.
[0095] Semi-synthetic gene construction is accomplished by
combining aspects of synthetic gene construction, and/or
site-directed mutagenesis, and/or random mutagenesis, and/or
shuffling. Semi-synthetic construction is typified by a process
utilizing polynucleotide fragments that are synthesized, in
combination with PCR techniques. Defined regions of genes may thus
be synthesized de novo, while other regions may be amplified using
site-specific mutagenic primers, while yet other regions may be
subjected to error-prone PCR or non-error prone PCR amplification.
Polynucleotide subsequences may then be shuffled.
Variants
[0096] The present invention also provides variants of a parent
antimicrobial peptide comprising a substitution at one or more
(several) positions corresponding to positions 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 15, 17, 19, and 21 (preferably positions 1,
2, 4, 5, 6, 8, 9, 12, 13, 15, 17, and 21; more preferably positions
4, 5, 6, 8, 9, 12, 13, 15, and 17), wherein the variant has
antimicrobial activity. In an embodiment, the variant has improved
antimicrobial activity compared to the peptide of SEQ ID NO: 2;
preferably in the presence of blood or serum. In another
embodiment, the variant exhibit less protein binding compared to
the peptide of SEQ ID NO: 2. Preferably, the variant antimicrobial
peptides exhibit at the most 99% serum protein binding. The variant
antimicrobial peptides also exhibit improved bioavailability.
Preferably the subcutaneous bioavailability is at least 30%, more
preferably at least 40%, even more preferably at least 50%, and
most preferably at least 60%.
[0097] In an embodiment, the variant has sequence identity of at
least 60%, e.g., at least 65%, at least 70%, at least 75%, at least
80%, at least 85%, at least 90%, at least 95%, at least 96%, at
least 97%, at least 98%, or at least 99%, but less than 100%, to
the amino acid sequence of the parent antimicrobial peptide.
[0098] In another embodiment, the variant has at least 60%, e.g.,
at least 65%, at least 70%, at least 75%, at least 80%, at least
85%, at least 90%, at least 95%, such as at least 96%, at least
97%, at least 98%, and at least 99%, but less than 100%, sequence
identity with the mature peptide of SEQ ID NO: 2.
[0099] In one aspect, the number of substitutions in the variants
of the present invention is 1-11, e.g., 1-10 substitutions, 1-9
substitutions, 1-8 substitutions, 1-7 substitutions, 1-6
substitutions, 1-5 substitutions, 1-4 substitutions, 1-3
substitutions and 1-2 substitutions.
[0100] In one aspect, the variant comprises or consists of the
amino acid sequence shown as SEQ ID NO: 3 to SEQ ID NO: 548.
[0101] The term "SEQ ID NO: 3 to SEQ ID NO: 548" is intended to
mean any one of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID
NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ
ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO:
15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ
ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO:
24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ
ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO:
33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ
ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO:
42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ
ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO:
51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ
ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO:
60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ
ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO:
69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ
ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO:
78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ
ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO:
87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ
ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO:
96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100,
SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ
ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID
NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO:
113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO:
117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO:
121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO:
125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO:
129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO:
133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO:
137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO:
141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO:
145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO:
149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO:
153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO:
157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO:
161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO:
165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO:
169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO:
173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO:
177, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 180, SEQ ID NO:
181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO:
185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO:
189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO:
193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO:
197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO:
201, SEQ ID NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO:
205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ ID NO: 208, SEQ ID NO:
209, SEQ ID NO: 210, SEQ ID NO: 211, SEQ ID NO: 212, SEQ ID NO:
213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO:
217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO:
221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO:
225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO:
229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO:
233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO:
237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO:
241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO:
245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO:
249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO:
253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO:
257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO:
261, SEQ ID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO:
265, SEQ ID NO: 266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO:
269, SEQ ID NO: 270, SEQ ID NO: 271, SEQ ID NO: 272, SEQ ID NO:
273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO:
277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO:
281, SEQ ID NO: 282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO:
285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO:
289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO:
293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO:
297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ ID NO:
301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO:
305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO:
309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO:
313, SEQ ID NO: 314, SEQ ID NO: 315, SEQ ID NO: 316, SEQ ID NO:
317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO:
321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO:
325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO:
329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO:
333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO:
337, SEQ ID NO: 338, SEQ ID NO: 339, SEQ ID NO: 340, SEQ ID NO:
341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ ID NO: 344, SEQ ID NO:
345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348, SEQ ID NO:
349, SEQ ID NO: 350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO:
353, SEQ ID NO: 354, SEQ ID NO: 355, SEQ ID NO: 356, SEQ ID NO:
357, SEQ ID NO: 358, SEQ ID NO: 359, SEQ ID NO: 360, SEQ ID NO:
361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO: 364, SEQ ID NO:
365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO:
369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO:
373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO:
377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO:
381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO:
385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO:
389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO:
393, SEQ ID NO: 394, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO:
397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO:
401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404, SEQ ID NO:
405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ ID NO:
409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO:
413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, SEQ ID NO:
417, SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420, SEQ ID NO:
421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ ID NO:
425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO:
429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO:
433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO:
437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO:
441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO:
445, SEQ ID NO: 446, SEQ ID NO: 447, SEQ ID NO: 448, SEQ ID NO:
449, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 452, SEQ ID NO:
453, SEQ ID NO: 454, SEQ ID NO: 455, SEQ ID NO: 456, SEQ ID NO:
457, SEQ ID NO: 458, SEQ ID NO: 459, SEQ ID NO: 460, SEQ ID NO:
461, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO:
465, SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 468, SEQ ID NO:
469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472, SEQ ID NO:
473, SEQ ID NO: 474, SEQ ID NO: 475, SEQ ID NO: 476, SEQ ID NO:
477, SEQ ID NO: 478, SEQ ID NO: 479, SEQ ID NO: 480, SEQ ID NO:
481, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 484, SEQ ID NO:
485, SEQ ID NO: 486, SEQ ID NO: 487, SEQ ID NO: 488, SEQ ID NO:
489, SEQ ID NO: 490, SEQ ID NO: 491, SEQ ID NO: 492, SEQ ID NO:
493, SEQ ID NO: 494, SEQ ID NO: 495, SEQ ID NO: 496, SEQ ID NO:
497, SEQ ID NO: 498, SEQ ID NO: 499, SEQ ID NO: 500, SEQ ID NO:
501, SEQ ID NO: 502, SEQ ID NO: 503, SEQ ID NO: 504, SEQ ID NO:
505, SEQ ID NO: 506, SEQ ID NO: 507, SEQ ID NO: 508, SEQ ID NO:
509, SEQ ID NO: 510, SEQ ID NO: 511, SEQ ID NO: 512, SEQ ID NO:
513, SEQ ID NO: 514, SEQ ID NO: 515, SEQ ID NO: 516, SEQ ID NO:
517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO:
521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 524, SEQ ID NO:
525, SEQ ID NO: 526, SEQ ID NO: 527, SEQ ID NO: 528, SEQ ID NO:
529, SEQ ID NO: 530, SEQ ID NO: 531, SEQ ID NO: 532, SEQ ID NO:
533, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO:
537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, SEQ ID NO:
541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 544, SEQ ID NO:
545, SEQ ID NO: 546, SEQ ID NO: 547, and/or SEQ ID NO: 548.
[0102] In one aspect, a variant comprises a substitution at one or
more (several) positions corresponding to positions 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21; preferably
positions 1, 2, 4, 5, 6, 8, 9, 12, 13, 15, 17, and 21; and more
preferably positions 4, 5, 6, 8, 9, 12, 13, 15, and 17. In another
aspect, a variant comprises a substitution at two positions
corresponding to any of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 15, 17, 19, and 21; preferably positions 1, 2, 4, 5, 6,
8, 9, 12, 13, 15, 17, and 21; and more preferably positions 4, 5,
6, 8, 9, 12, 13, 15, and 17. In another aspect, a variant comprises
a substitution at three positions corresponding to any of positions
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21;
preferably positions 1, 2, 4, 5, 6, 8, 9, 12, 13, 15, 17, and 21;
and more preferably positions 4, 5, 6, 8, 9, 12, 13, 15, and 17. In
another aspect, a variant comprises a substitution at four
positions corresponding to any of positions 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 15, 17, 19, and 21; preferably positions 1, 2,
4, 5, 6, 8, 9, 12, 13, 15, 17, and 21; and more preferably
positions 4, 5, 6, 8, 9, 12, 13, 15, and 17. In another aspect, a
variant comprises a substitution at five positions corresponding to
any of positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 17,
19, and 21; preferably positions 1, 2, 4, 5, 6, 8, 9, 12, 13, 15,
17, and 21; and more preferably positions 4, 5, 6, 8, 9, 12, 13,
15, and 17. In another aspect, a variant comprises a substitution
at six positions corresponding to any of positions 1, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 15, 17, 19, and 21; preferably
positions 1, 2, 4, 5, 6, 8, 9, 12, 13, 15, 17, and 21; and more
preferably positions 4, 5, 6, 8, 9, 12, 13, 15, and 17.
[0103] In another aspect, the variant comprises the substitution
G1A,D,F,H,I,K,M,Q,R,S,T,V,W,Y of the mature peptide of SEQ ID NO:
2. In another aspect, the variant comprises the substitution
F2A,G,H,I,L,M,P,S,V,W,Y of the mature peptide of SEQ ID NO: 2. In
another aspect, the variant comprises the substitution C3L of the
mature peptide of SEQ ID NO: 2. In another aspect, the variant
comprises the substitution W4A,E,F,G,I,L,M,N,Q,S,T,V,Y of the
mature peptide of SEQ ID NO: 2. In another aspect, the variant
comprises the substitution Y5E,F,G,H,K,N,R,S,W of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution V6A,C,E,F,G,H,I,L,M,N,Q,R,S,T,W,Y of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution C7V of the mature peptide of SEQ ID NO: 2. In
another aspect, the variant comprises the substitution
V8A,F,G,H,I,L,N,S,T,W,Y of the mature peptide of SEQ ID NO: 2. In
another aspect, the variant comprises the substitution
Y9A,D,F,G,H,I,K,M,Q,R,S,T,V,W of the mature peptide of SEQ ID NO:
2. In another aspect, the variant comprises the substitution
R10K,P,S,T of the mature peptide of SEQ ID NO: 2. In another
aspect, the variant comprises the substitution N11A,G,H,Q,R,S,Y of
the mature peptide of SEQ ID NO: 2. In another aspect, the variant
comprises the substitution G12A,D,E,F,H,K,N,R,S,Y of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution V13A,C,F,G,H,K,L,P,Q,R,S,T,W,Y of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution V15A,C,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution Y17C,F,G,H,I,K,L,M,N,Q,R,S,T,V,W of the mature
peptide of SEQ ID NO: 2. In another aspect, the variant comprises
the substitution R19D,H,K,M,T,Y of the mature peptide of SEQ ID NO:
2. In another aspect, the variant comprises the substitution
N21A,C,F,G,H,I,K,L,M,P,Q,R,S,T,W,Y of the mature peptide of SEQ ID
NO: 2.
[0104] In one aspect, the variant comprises a substitution at
position 1. In another aspect, the amino acid at position 1 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Asp, Phe, His, Ile, Lys, Met, Gln, Arg, Ser, Thr, Val,
Trp, or Tyr. In another aspect, the variant comprises the
substitution G1A,D,F,H,I,K,M,Q,R,S,T,V,W,Y of the mature peptide of
SEQ ID NO: 2.
[0105] In one aspect, the variant comprises a substitution at
position 2. In another aspect, the amino acid at position 2 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Gly, His, Ile, Leu, Met, Pro, Ser, Val, Trp, or Tyr. In
another aspect, the variant comprises the substitution
F2A,G,H,I,L,M,P,S,V,W,Y of the mature peptide of SEQ ID NO: 2.
[0106] In one aspect, the variant comprises a substitution at
position 3. In another aspect, the amino acid at position 3 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Leu. In another aspect, the variant comprises the substitution
C3L of the mature peptide of SEQ ID NO: 2.
[0107] In one aspect, the variant comprises a substitution at
position 4. In another aspect, the amino acid at position 4 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Glu, Phe, Gly, Ile, Leu, Met, Asn, Gln, Ser, Thr, Val, or
Tyr. In another aspect, the variant comprises the substitution
W4A,E,F,G,I,L,M,N,Q,S,T,V,Y of the mature peptide of SEQ ID NO:
2.
[0108] In another aspect, the variant comprises a substitution at
position 5. In another aspect, the amino acid at position 5 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Glu, Phe, Gly, His, Lys, Asn, Arg, Ser, or Trp. In another
aspect, the variant comprises the substitution Y5E,F,G,H,K,N,R,S,W
of the mature peptide of SEQ ID NO: 2.
[0109] In another aspect, the variant comprises a substitution at
position 6. In another aspect, the amino acid at position 6 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Cys, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Gln, Arg,
Ser, Thr, Trp, or Tyr. In another aspect, the variant comprises the
substitution V6A,C,E,F,G,H,I,L,M,N,Q,R,S,T,W,Y of the mature
peptide of SEQ ID NO: 2.
[0110] In one aspect, the variant comprises a substitution at
position 7. In another aspect, the amino acid at position 7 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Val. In another aspect, the variant comprises the substitution
C7V of the mature peptide of SEQ ID NO: 2.
[0111] In another aspect, the variant comprises a substitution at
position 8. In another aspect, the amino acid at position 8 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Phe, Gly, His, Ile, Leu, Asn, Ser, Thr, Trp, or Tyr. In
another aspect, the variant comprises the substitution
V8A,F,G,H,I,L,N,S,T,W,Y of the mature peptide of SEQ ID NO: 2.
[0112] In another aspect, the variant comprises a substitution at
position 9. In another aspect, the amino acid at position 9 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Asp, Phe, Gly, His, Ile, Lys, Met, Gln, Arg, Ser, Thr,
Val, or Trp. In another aspect, the variant comprises the
substitution Y9A,D,F,G,H,I,K,M,Q,R,S,T,V,W of the mature peptide of
SEQ ID NO: 2.
[0113] In one aspect, the variant comprises a substitution at
position 10. In another aspect, the amino acid at position 10 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Lys, Pro, Ser, or Thr. In another aspect, the variant
comprises the substitution R10K,P,S,T of the mature peptide of SEQ
ID NO: 2.
[0114] In one aspect, the variant comprises a substitution at
position 11. In another aspect, the amino acid at position 11 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Gly, His, Gln, Arg, Ser, or Tyr. In another aspect, the
variant comprises the substitution N11A,G,H,Q,R,S,Y of the mature
peptide of SEQ ID NO: 2.
[0115] In another aspect, the variant comprises a substitution at
position 12. In another aspect, the amino acid at position 12 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Asp, Glu, Phe, His, Lys, Asn, Arg, Ser, or Tyr. In
another aspect, the variant comprises the substitution
G12A,D,E,F,H,K,N,R,S,Y of the mature peptide of SEQ ID NO: 2.
[0116] In one aspect, the variant comprises a substitution at
position 13. In another aspect, the amino acid at position 13 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Cys, Phe, Gly, His, Lys, Leu, Pro, Gln, Arg, Ser, Thr,
Trp, or Tyr. In another aspect, the variant comprises the
substitution V13A,C,F,G,H,K,L,P,Q,R,S,T,W,Y of the mature peptide
of SEQ ID NO: 2.
[0117] In another aspect, the variant comprises a substitution at
position 15. In another aspect, the amino acid at position 15 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Cys, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln,
Arg, Ser, Thr, Trp, or Tyr. In another aspect, the variant
comprises the substitution V15A,C,F,G,H,I,K,L,M,N,P,Q,R,S,T,W,Y of
the mature peptide of SEQ ID NO: 2.
[0118] In one aspect, the variant comprises a substitution at
position 17. In another aspect, the amino acid at position 17 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Cys, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser,
Thr, Val, or Trp. In another aspect, the variant comprises the
substitution Y17C,F,G,H,I,K,L,M,N,Q,R,S,T,V,W of the mature peptide
of SEQ ID NO: 2.
[0119] In one aspect, the variant comprises a substitution at
position 19. In another aspect, the amino acid at position 19 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Asp, His, Lys, Met, Thr, or Tyr. In another aspect, the
variant comprises the substitution R19D,H,K,M,T,Y of the mature
peptide of SEQ ID NO: 2.
[0120] In one aspect, the variant comprises a substitution at
position 21. In another aspect, the amino acid at position 21 is
substituted with Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, or Val, preferably
with Ala, Cys, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg,
Ser, Thr, Trp, or Tyr. In another aspect, the variant comprises the
substitution N21A,C,F,G,H,I,K,L,M,P,Q,R,S,T,W,Y of the mature
peptide of SEQ ID NO: 2.
[0121] In another aspect, the variant comprises a substitution at
positions corresponding to positions 5 and 17, such as those
described above.
[0122] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5 and 9, such as those
described above.
[0123] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5 and 15, such as those
described above.
[0124] In another aspect, the variant comprises substitutions at
positions corresponding to positions 17 and 9, such as those
described above.
[0125] In another aspect, the variant comprises substitutions at
positions corresponding to positions 17 and 15, such as those
described above.
[0126] In another aspect, the variant comprises substitutions at
positions corresponding to positions 9 and 15, such as those
described above.
[0127] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5, 17, and 9, such as those
described above.
[0128] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5, 17, and 15, such as those
described above.
[0129] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5, 9, and 15, such as those
described above.
[0130] In another aspect, the variant comprises substitutions at
positions corresponding to positions 17, 9, and 15, such as those
described above.
[0131] In another aspect, the variant comprises substitutions at
positions corresponding to positions 5, 17, 9, and 15, such as
those described above.
[0132] In another aspect, the variant comprises one or more
(several) substitutions selected from the group consisting of
G1A, G1D, G1F, G1H, G1I, G1K, G1M, G1Q, G1R, G1S, G1T, G1V, G1W,
G1Y,
F2A, F2G, F2H, F2I, F2L, F2M, F2P, F2S, F2V, F2W, F2Y,
C3L,
W4A, W4E, W4F, W4G, W41, W4L, W4M, W4N, W4Q, W4S, W4T, W4V,
W4Y,
Y5E, Y5F, Y5G, Y5H, Y5K, Y5N, Y5R, Y5S, Y5W, V6A, V6C, V6E, V6F,
V6G, V6H, V61, V6L, V6M, V6N, V6Q, V6R, V6S, V6T, V6W, V6Y,
C7V,
V8A, V8F, V8G, V8H, V81, V8L, V8N, V8S, V8T, V8W, V8Y,
Y9A, Y9D, Y9F, Y9G, Y9H, Y91, Y9K, Y9M, Y9Q, Y9R, Y9S, Y9T, Y9V,
Y9W,
R10K, R10P, R10S, R10T,
N11A, N11G, N11H, N11Q, N11R, N115, N11Y,
G12A, G12D, G12E, G12F, G12H, G12K, G12N, G12R, G12S, G12Y,
V13A, V13C, V13F, V13G, V13H, V13K, V13L, V13P, V13Q, V13R, V13S,
V13T, V13W,
V13Y,
V15A, V15C, V15F, V15G, V15H, V151, V15K, V15L, V15M, V15N, V15P,
V15Q, V15R, V15S,
V15T, V15W, V15Y,
Y17C, Y17F, Y17G, Y17H, Y171, Y17K, Y17L, Y17M, Y17N, Y17Q, Y17R,
Y17S, Y17T, Y17V,
Y17W,
R19D, R19H, R19K, R19M, R19T, R19Y,
N21A, N21C, N21F, N21G, N21H, N21I, N21K, N21L, N21M, N21P, N21Q,
N21R, N21S,
N21T, N21W, and N21Y;
[0133] preferably
W4A, Y5H, Y5N, Y5R, V6A, V6F, V8A, Y9K, Y9R, G12R, G12K, V13A,
V151, V15S, and Y17H.
[0134] In another aspect, the variant comprises the substitutions
Y5N+Y17H of the mature peptide of SEQ ID NO: 2.
[0135] In another aspect, the variant comprises the substitutions
Y5N+Y9R of the mature peptide of SEQ ID NO: 2.
[0136] In another aspect, the variant comprises the substitutions
Y5N+Y9K of the mature peptide of SEQ ID NO: 2.
[0137] In another aspect, the variant comprises the substitutions
Y17H+Y9R of the mature peptide of SEQ ID NO: 2.
[0138] In another aspect, the variant comprises the substitutions
Y17H+Y9K of the mature peptide of SEQ ID NO: 2.
[0139] In another aspect, the variant comprises the substitutions
Y5N+Y17H+Y9R of the mature peptide of SEQ ID NO: 2.
[0140] In another aspect, the variant comprises the substitutions
Y5N+Y17H+Y9K of the mature peptide of SEQ ID NO: 2.
[0141] In another aspect, the variant comprises the substitutions
Y5N+V6A+Y9K or V8A+Y9R+V13A or Y5N+Y9R+Y17H or Y9K+V155 or
W4A+Y5R+Y9K or Y5N+G12R+Y17H or Y5N+V6F+Y17H or Y5N+V15I+Y17H or
Y5H+V8A+Y9R or Y5N+G12K+Y17H of the mature peptide of SEQ ID NO:
2.
[0142] Essential amino acids in a parent can be identified
according to procedures known in the art, such as site-directed
mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells,
1989, Science 244: 1081-1085). In the latter technique, single
alanine mutations are introduced at every residue in the molecule,
and the resultant mutant molecules are tested for antimicrobial
activity to identify amino acid residues that are critical to the
activity of the molecule. See also, Hilton et al., 1996, J. Biol.
Chem. 271: 4699-4708. The identities of essential amino acids can
also be inferred from analysis of identities with peptides that are
related to the parent.
Polynucleotides
[0143] The present invention also relates to isolated
polynucleotides that encode any of the variants of the present
invention.
Nucleic Acid Constructs
[0144] The present invention also relates to nucleic acid
constructs comprising a polynucleotide encoding a variant of the
present invention operably linked to one or more (several) control
sequences that direct the expression of the coding sequence in a
suitable host cell under conditions compatible with the control
sequences.
[0145] A polynucleotide may be manipulated in a variety of ways to
provide for expression of a variant. Manipulation of the
polynucleotide prior to its insertion into a vector may be
desirable or necessary depending on the expression vector. The
techniques for modifying polynucleotides utilizing recombinant DNA
methods are well known in the art.
[0146] The control sequence may be a promoter sequence, which is
recognized by a host cell for expression of the polynucleotide. The
promoter sequence contains transcriptional control sequences that
mediate the expression of the variant. The promoter may be any
nucleic acid sequence that shows transcriptional activity in the
host cell including mutant, truncated, and hybrid promoters, and
may be obtained from genes encoding extracellular or intracellular
peptides either homologous or heterologous to the host cell.
[0147] Examples of suitable promoters for directing the
transcription of the nucleic acid constructs of the present
invention in a bacterial host cell are the promoters obtained from
the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus
licheniformis alpha-amylase gene (amyL), Bacillus licheniformis
penicillinase gene (penP), Bacillus stearothermophilus maltogenic
amylase gene (amyM), Bacillus subtilis levansucrase gene (sacB),
Bacillus subtilis xylA and xylB genes, E. coli lac operon,
Streptomyces coelicolor agarase gene (dagA), and prokaryotic
beta-lactamase gene (VIIIa-Kamaroff et al., 1978, Proc. Natl. Acad.
Sci. USA 75: 3727-3731), as well as the tac promoter (DeBoer et
al., 1983, Proc. Natl. Acad. Sci. USA 80: 21-25). Further promoters
are described in "Useful proteins from recombinant bacteria" in
Gilbert et al., 1980, Scientific American 242: 74-94; and in
Sambrook et al., 1989, supra.
[0148] Examples of suitable promoters for directing the
transcription of the nucleic acid constructs of the present
invention in a filamentous fungal host cell are the promoters
obtained from the genes for Aspergillus nidulans acetamidase,
Aspergillus niger neutral alpha-amylase, Aspergillus niger acid
stable alpha-amylase, Aspergillus niger or Aspergillus awamori
glucoamylase (glaA), Aspergillus oryzae TAKA amylase, Aspergillus
oryzae alkaline protease, Aspergillus oryzae triose phosphate
isomerase, Fusarium oxysporum trypsin-like protease (WO 96/00787),
Fusarium venenatum amyloglucosidase (WO 00/56900), Fusarium
venenatum Dana (WO 00/56900), Fusarium venenatum Quinn (WO
00/56900), Rhizomucor miehei lipase, Rhizomucor miehei aspartic
proteinase, Trichoderma reesei beta-glucosidase, Trichoderma reesei
cellobiohydrolase I, Trichoderma reesei cellobiohydrolase II,
Trichoderma reesei endoglucanase I, Trichoderma reesei
endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma
reesei endoglucanase IV, Trichoderma reesei endoglucanase V,
Trichoderma reesei xylanase I, Trichoderma reesei xylanase II,
Trichoderma reesei beta-xylosidase, as well as the NA2-tpi promoter
(a modified promoter including a gene encoding a neutral
alpha-amylase in Aspergilli in which the untranslated leader has
been replaced by an untranslated leader from a gene encoding triose
phosphate isomerase in Aspergilli; non-limiting examples include
modified promoters including the gene encoding neutral
alpha-amylase in Aspergillus niger in which the untranslated leader
has been replaced by an untranslated leader from the gene encoding
triose phosphate isomerase in Aspergillus nidulans or Aspergillus
oryzae); and mutant, truncated, and hybrid promoters thereof.
[0149] In a yeast host, useful promoters are obtained from the
genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces
cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol
dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1,
ADH2/GAP), Saccharomyces cerevisiae triose phosphate isomerase
(TPI), Saccharomyces cerevisiae metallothionein (CUP1), and
Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful
promoters for yeast host cells are described by Romanos et al.,
1992, Yeast 8: 423-488.
[0150] The control sequence may also be a suitable transcription
terminator sequence, which is recognized by a host cell to
terminate transcription. The terminator sequence is operably linked
to the 3'-terminus of the polynucleotide encoding the variant. Any
terminator that is functional in the host cell may be used.
[0151] Preferred terminators for filamentous fungal host cells are
obtained from the genes for Aspergillus nidulans anthranilate
synthase, Aspergillus niger alpha-glucosidase, Aspergillus niger
glucoamylase, Aspergillus oryzae TAKA amylase, and Fusarium
oxysporum trypsin-like protease.
[0152] Preferred terminators for yeast host cells are obtained from
the genes for Saccharomyces cerevisiae enolase, Saccharomyces
cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae
glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators
for yeast host cells are described by Romanos et al., 1992,
supra.
[0153] The control sequence may also be a suitable leader sequence,
a nontranslated region of an mRNA that is important for translation
by the host cell. The leader sequence is operably linked to the
5'-terminus of the polynucleotide encoding the variant. Any leader
sequence that is functional in the host cell may be used.
[0154] Preferred leaders for filamentous fungal host cells are
obtained from the genes for Aspergillus oryzae TAKA amylase and
Aspergillus nidulans triose phosphate isomerase. Suitable leaders
for yeast host cells are obtained from the genes for Saccharomyces
cerevisiae enolase (ENO-1), Saccharomyces cerevisiae
3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor,
and Saccharomyces cerevisiae alcohol
dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase
(ADH2/GAP).
[0155] The control sequence may also be a polyadenylation sequence,
a sequence operably linked to the 3'-terminus of the
variant-encoding sequence and, when transcribed, is recognized by
the host cell as a signal to add polyadenosine residues to
transcribed mRNA. Any polyadenylation sequence that is functional
in the host cell may be used.
[0156] Preferred polyadenylation sequences for filamentous fungal
host cells are obtained from the genes for Aspergillus nidulans
anthranilate synthase, Aspergillus niger glucoamylase, Aspergillus
niger alpha-glucosidase, Aspergillus oryzae TAKA amylase, and
Fusarium oxysporum trypsin-like protease.
[0157] Useful polyadenylation sequences for yeast host cells are
described by Guo and Sherman, 1995, Mol. Cellular Biol. 15:
5983-5990.
[0158] The control sequence may also be a signal peptide coding
region that encodes a signal peptide linked to the N-terminus of a
variant and directs the variant into the cell's secretory pathway.
The 5'-end of the coding sequence of the polynucleotide may
inherently contain a signal peptide coding region naturally linked
in translation reading frame with the segment of the coding region
that encodes the variant. Alternatively, the 5'-end of the coding
sequence may contain a signal peptide coding region that is foreign
to the coding sequence. The foreign signal peptide coding region
may be required where the coding sequence does not naturally
contain a signal peptide coding region. Alternatively, the foreign
signal peptide coding region may simply replace the natural signal
peptide coding region in order to enhance secretion of the variant.
However, any signal peptide coding region that directs the
expressed variant into the secretory pathway of a host cell may be
used.
[0159] Effective signal peptide coding sequences for bacterial host
cells are the signal peptide coding sequences obtained from the
genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus
licheniformis subtilisin, Bacillus licheniformis beta-lactamase,
Bacillus stearothermophilus alpha-amylase, Bacillus
stearothermophilus neutral proteases (nprT, nprS, nprM), and
Bacillus subtilis prsA. Further signal peptides are described by
Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
[0160] Effective signal peptide coding sequences for filamentous
fungal host cells are the signal peptide coding sequences obtained
from the genes for Aspergillus niger neutral amylase, Aspergillus
niger glucoamylase, Aspergillus oryzae TAKA amylase, Humicola
insolens cellulase, Humicola insolens endoglucanase V, Humicola
lanuginosa lipase, and Rhizomucor miehei aspartic proteinase.
[0161] Useful signal peptides for yeast host cells are obtained
from the genes for Saccharomyces cerevisiae alpha-factor and
Saccharomyces cerevisiae invertase. Other useful signal peptide
coding sequences are described by Romanos et al., 1992, supra.
[0162] The control sequence may also be a propeptide coding region
that encodes a propeptide positioned at the N-terminus of a
variant. The resultant peptide is known as a proenzyme or
propeptide (or a zymogen in some cases). A propeptide is generally
inactive and can be converted to an active peptide by catalytic or
autocatalytic cleavage of the propeptide from the propeptide. The
propeptide coding region may be obtained from the genes for
Bacillus subtilis alkaline protease (aprE), Bacillus subtilis
neutral protease (nprT), Myceliophthora thermophila laccase (WO
95/33836), Rhizomucor miehei aspartic proteinase, and Saccharomyces
cerevisiae alpha-factor.
[0163] Where both signal peptide and propeptide regions are present
at the N-terminus of a variant, the propeptide region is positioned
next to the N-terminus of the variant and the signal peptide region
is positioned next to the N-terminus of the propeptide region.
[0164] It may also be desirable to add regulatory sequences that
allow the regulation of the expression of the variant relative to
the growth of the host cell. Examples of regulatory systems are
those that cause the expression of the gene to be turned on or off
in response to a chemical or physical stimulus, including the
presence of a regulatory compound. Regulatory systems in
prokaryotic systems include the lac, tac, and trp operator systems.
In yeast, the ADH2 system or GAL1 system may be used. In
filamentous fungi, the Aspergillus niger glucoamylase promoter,
Aspergillus oryzae TAKA alpha-amylase promoter, and Aspergillus
oryzae glucoamylase promoter may be used. Other examples of
regulatory sequences are those that allow for gene amplification.
In eukaryotic systems, these regulatory sequences include the
dihydrofolate reductase gene that is amplified in the presence of
methotrexate, and the metallothionein genes that are amplified with
heavy metals. In these cases, the polynucleotide encoding the
variant would be operably linked with the regulatory sequence.
Expression Vectors
[0165] The present invention also relates to recombinant expression
vectors comprising a polynucleotide of the present invention, a
promoter, and transcriptional and translational stop signals. The
various nucleotide and control sequences may be joined together to
produce a recombinant expression vector that may include one or
more (several) convenient restriction sites to allow for insertion
or substitution of the polynucleotide encoding the variant at such
sites. Alternatively, the polynucleotide may be expressed by
inserting the polynucleotide or a nucleic acid construct comprising
the polynucleotide into an appropriate vector for expression. In
creating the expression vector, the coding sequence is located in
the vector so that the coding sequence is operably linked with the
appropriate control sequences for expression.
[0166] The recombinant expression vector may be any vector (e.g., a
plasmid or virus) that can be conveniently subjected to recombinant
DNA procedures and can bring about the expression of the
polynucleotide. The choice of the vector will typically depend on
the compatibility of the vector with the host cell into which the
vector is to be introduced. The vector may be a linear or closed
circular plasmid.
[0167] The vector may be an autonomously replicating vector, i.e.,
a vector that exists as an extrachromosomal entity, the replication
of which is independent of chromosomal replication, e.g., a
plasmid, an extrachromosomal element, a minichromosome, or an
artificial chromosome. The vector may contain any means for
assuring self-replication. Alternatively, the vector may be one
that, when introduced into the host cell, is integrated into the
genome and replicated together with the chromosome(s) into which it
has been integrated. Furthermore, a single vector or plasmid or two
or more vectors or plasmids that together contain the total DNA to
be introduced into the genome of the host cell, or a transposon,
may be used.
[0168] The vector preferably contains one or more (several)
selectable markers that permit easy selection of transformed,
transfected, transduced, or the like cells. A selectable marker is
a gene the product of which provides for biocide or viral
resistance, resistance to heavy metals, prototrophy to auxotrophs,
and the like.
[0169] Examples of bacterial selectable markers are the dal genes
from Bacillus licheniformis or Bacillus subtilis, or markers that
confer antibiotic resistance such as ampicillin, chloramphenicol,
kanamycin, or tetracycline resistance. Suitable markers for yeast
host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
Selectable markers for use in a filamentous fungal host cell
include, but are not limited to, amdS (acetamidase), argB
(ornithine carbamoyltransferase), bar (phosphinothricin
acetyltransferase), hph (hygromycin phosphotransferase), niaD
(nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase),
sC (sulfate adenyltransferase), and trpC (anthranilate synthase),
as well as equivalents thereof. Preferred for use in an Aspergillus
cell are the amdS and pyrG genes of Aspergillus nidulans or
Aspergillus oryzae and the bar gene of Streptomyces
hygroscopicus.
[0170] The vector preferably contains an element(s) that permits
integration of the vector into the host cell's genome or autonomous
replication of the vector in the cell independent of the
genome.
[0171] For integration into the host cell genome, the vector may
rely on the polynucleotide's sequence encoding the variant or any
other element of the vector for integration into the genome by
homologous or nonhomologous recombination. Alternatively, the
vector may contain additional nucleotide sequences for directing
integration by homologous recombination into the genome of the host
cell at a precise location(s) in the chromosome(s). To increase the
likelihood of integration at a precise location, the integrational
elements should contain a sufficient number of nucleic acids, such
as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to
10,000 base pairs, which have a high degree of identity to the
corresponding target sequence to enhance the probability of
homologous recombination. The integrational elements may be any
sequence that is homologous with the target sequence in the genome
of the host cell. Furthermore, the integrational elements may be
non-encoding or encoding nucleotide sequences. On the other hand,
the vector may be integrated into the genome of the host cell by
non-homologous recombination.
[0172] For autonomous replication, the vector may further comprise
an origin of replication enabling the vector to replicate
autonomously in the host cell in question. The origin of
replication may be any plasmid replicator mediating autonomous
replication that functions in a cell. The term "origin of
replication" or "plasmid replicator" means a nucleotide sequence
that enables a plasmid or vector to replicate in vivo.
[0173] Examples of bacterial origins of replication are the origins
of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184
permitting replication in E. coli, and pUB110, pE194, pTA1060, and
pAM.beta.1 permitting replication in Bacillus.
[0174] Examples of origins of replication for use in a yeast host
cell are the 2 micron origin of replication, ARS1, ARS4, the
combination of ARS1 and CEN3, and the combination of ARS4 and
CEN6.
[0175] Examples of origins of replication useful in a filamentous
fungal cell are AMA1 and ANSI (Gems et al., 1991, Gene 98: 61-67;
Cullen et al., 1987, Nucleic Acids Res. 15: 9163-9175; WO
00/24883). Isolation of the AMA1 gene and construction of plasmids
or vectors comprising the gene can be accomplished according to the
methods disclosed in WO 00/24883.
[0176] More than one copy of a polynucleotide of the present
invention may be inserted into the host cell to increase production
of a variant. An increase in the copy number of the polynucleotide
can be obtained by integrating at least one additional copy of the
sequence into the host cell genome or by including an amplifiable
selectable marker gene with the polynucleotide where cells
containing amplified copies of the selectable marker gene, and
thereby additional copies of the polynucleotide, can be selected
for by cultivating the cells in the presence of the appropriate
selectable agent.
[0177] The procedures used to ligate the elements described above
to construct the recombinant expression vectors of the present
invention are well known to one skilled in the art (see, e.g.,
Sambrook et al., 1989, supra) to obtain substantially pure
variants.
Host Cells
[0178] The present invention also relates to recombinant host
cells, comprising a polynucleotide of the present invention
operably linked to one or more (several) control sequences that
direct the production of a variant of the present invention. A
construct or vector comprising a polynucleotide is introduced into
a host cell so that the construct or vector is maintained as a
chromosomal integrant or as a self-replicating extra-chromosomal
vector as described earlier. The term "host cell" encompasses any
progeny of a parent cell that is not identical to the parent cell
due to mutations that occur during replication. The choice of a
host cell will to a large extent depend upon the gene encoding the
variant and its source.
[0179] The host cell may be any cell useful in the recombinant
production of a variant, e.g., a prokaryote or a eukaryote.
[0180] The prokaryotic host cell may be any gram-positive or
gram-negative bacterium. Gram-positive bacteria include, but are
not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus,
Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus,
Streptococcus, and Streptomyces. Gram-negative bacteria include,
but are not limited to, Campylobacter, E. coli, Flavobacterium,
Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas,
Salmonella, and Ureaplasma.
[0181] The bacterial host cell may be any Bacillus cell, including,
but not limited to, Bacillus alkalophilus, Bacillus
amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus
clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus,
Bacillus lentus, Bacillus licheniformis, Bacillus megaterium,
Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis,
and Bacillus thuringiensis cells.
[0182] The bacterial host cell may also be any Streptococcus cell,
including, but not limited to, Streptococcus equisimilis,
Streptococcus pyogenes, Streptococcus uberis, and Streptococcus
equi subsp. Zooepidemicus cells.
[0183] The bacterial host cell may also be any Streptomyces cell,
including, but not limited to, Streptomyces achromogenes,
Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces
griseus, and Streptomyces lividans cells.
[0184] The introduction of DNA into a Bacillus cell may, for
instance, be effected by protoplast transformation (see, e.g.,
Chang and Cohen, 1979, Mol. Gen. Genet. 168: 111-115), by using
competent cells (see, e.g., Young and Spizizen, 1961, J. Bacteriol.
81: 823-829, or Dubnau and Davidoff-Abelson, 1971, J. Mol. Biol.
56: 209-221), by electroporation (see, e.g., Shigekawa and Dower,
1988, Biotechniques 6: 742-751), or by conjugation (see, e.g.,
Koehler and Thorne, 1987, J. Bacteriol. 169: 5271-5278). The
introduction of DNA into an E. coli cell may, for instance, be
effected by protoplast transformation (see, e.g., Hanahan, 1983, J.
Mol. Biol. 166: 557-580) or electroporation (see, e.g., Dower et
al., 1988, Nucleic Acids Res. 16: 6127-6145). The introduction of
DNA into a Streptomyces cell may, for instance, be effected by
protoplast transformation and electroporation (see, e.g., Gong et
al., 2004, Folia Microbiol. (Praha) 49: 399-405), by conjugation
(see, e.g., Mazodier et al., 1989, J. Bacteriol. 171: 3583-3585),
or by transduction (see, e.g., Burke et al., 2001, Proc. Natl.
Acad. Sci. USA 98: 6289-6294). The introduction of DNA into a
Pseudomonas cell may, for instance, be effected by electroporation
(see, e.g., Choi et al., 2006, J. Microbiol. Methods 64: 391-397)
or by conjugation (see, e.g., Pinedo and Smets, 2005, Appl.
Environ. Microbiol. 71: 51-57). The introduction of DNA into a
Streptococcus cell may, for instance, be effected by natural
competence (see, e.g., Perry and Kuramitsu, 1981, Infect. Immun.
32: 1295-1297), by protoplast transformation (see, e.g., Catt and
Jollick, 1991, Microbios 68: 189-2070, by electroporation (see,
e.g., Buckley et al., 1999, Appl. Environ. Microbiol. 65:
3800-3804) or by conjugation (see, e.g., Clewell, 1981, Microbiol.
Rev. 45: 409-436). However, any method known in the art for
introducing DNA into a host cell can be used.
[0185] The host cell may also be a eukaryote, such as a mammalian,
insect, plant, or fungal cell.
[0186] The host cell may be a fungal cell. "Fungi" as used herein
includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and
Zygomycota as well as the Oomycota and all mitosporic fungi (as
defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary
of The Fungi, 8th edition, 1995, CAB International, University
Press, Cambridge, UK).
[0187] The fungal host cell may be a yeast cell. "Yeast" as used
herein includes ascosporogenous yeast (Endomycetales),
basidiosporogenous yeast, and yeast belonging to the Fungi
Imperfecti (Blastomycetes). Since the classification of yeast may
change in the future, for the purposes of this invention, yeast
shall be defined as described in Biology and Activities of Yeast
(Skinner, F. A., Passmore, S. M., and Davenport, R. R., eds, Soc.
App. Bacteriol. Symposium Series No. 9, 1980).
[0188] The yeast host cell may be a Candida, Hansenula,
Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or
Yarrowia cell such as a Kluyveromyces lactis, Saccharomyces
carlsbergensis, Saccharomyces cerevisiae, Saccharomyces
diastaticus, Saccharomyces douglasii, Saccharomyces kluyveri,
Saccharomyces norbensis, Saccharomyces oviformis, or Yarrowia
lipolytica cell.
[0189] The fungal host cell may be a filamentous fungal cell.
"Filamentous fungi" include all filamentous forms of the
subdivision Eumycota and Oomycota (as defined by Hawksworth et al.,
1995, supra). The filamentous fungi are generally characterized by
a mycelial wall composed of chitin, cellulose, glucan, chitosan,
mannan, and other complex polysaccharides. Vegetative growth is by
hyphal elongation and carbon catabolism is obligately aerobic. In
contrast, vegetative growth by yeasts such as Saccharomyces
cerevisiae is by budding of a unicellular thallus and carbon
catabolism may be fermentative.
[0190] The filamentous fungal host cell may be an Acremonium,
Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis,
Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium,
Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora,
Neocallimastix, Neurospora, Paecilomyces, Penicillium,
Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum,
Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or
Trichoderma cell.
[0191] For example, the filamentous fungal host cell may be an
Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus,
Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger,
Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina,
Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis
pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa,
Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium
keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium,
Chrysosporium pannicola, Chrysosporium queenslandicum,
Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus,
Coriolus hirsutus, Fusarium bactridioides, Fusarium cerealis,
Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum,
Fusarium graminurn, Fusarium heterosporum, Fusarium negundi,
Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium
sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides,
Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides,
Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor
miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium
purpurogenum, Phanerochaete chrysosporium, Phlebia radiata,
Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes
versicolor, Trichoderma harzianum, Trichoderma koningii,
Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma
viride cell.
[0192] Fungal cells may be transformed by a process involving
protoplast formation, transformation of the protoplasts, and
regeneration of the cell wall in a manner known per se. Suitable
procedures for transformation of Aspergillus and Trichoderma host
cells are described in EP 238023 and Yelton et al., 1984, Proc.
Natl. Acad. Sci. USA 81: 1470-1474. Suitable methods for
transforming Fusarium species are described by Malardier et al.,
1989, Gene 78: 147-156, and WO 96/00787. Yeast may be transformed
using the procedures described by Becker and Guarente, In Abelson,
J. N. and Simon, M. I., editors, Guide to Yeast Genetics and
Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187,
Academic Press, Inc., New York; Ito et al., 1983, J. Bacteriol.
153: 163; and Hinnen et al., 1978, Proc. Natl. Acad. Sci. USA 75:
1920.
Methods of Production
[0193] The present invention also relates to methods of producing a
variant, comprising: (a) cultivating a host cell of the present
invention under conditions suitable for the expression of the
variant; and (b) recovering the variant.
[0194] The host cells are cultivated in a nutrient medium suitable
for production of the variant using methods known in the art. For
example, the cell may be cultivated by shake flask cultivation, or
small-scale or large-scale fermentation (including continuous,
batch, fed-batch, or solid state fermentations) in laboratory or
industrial fermentors performed in a suitable medium and under
conditions allowing the peptide to be expressed and/or isolated.
The cultivation takes place in a suitable nutrient medium
comprising carbon and nitrogen sources and inorganic salts, using
procedures known in the art. Suitable media are available from
commercial suppliers or may be prepared according to published
compositions (e.g., in catalogues of the American Type Culture
Collection). If the variant is secreted into the nutrient medium,
the variant can be recovered directly from the medium. If the
variant is not secreted, it can be recovered from cell lysates.
[0195] The variant may be detected using methods known in the art
that are specific for the variants. These detection methods may
include use of specific antibodies, formation of an enzyme product,
or disappearance of an enzyme substrate. For example, an enzyme
assay may be used to determine the activity of the variant.
[0196] The variant may be recovered by methods known in the art.
For example, the variant may be recovered from the nutrient medium
by conventional procedures including, but not limited to,
collection, centrifugation, filtration, extraction, spray-drying,
evaporation, or precipitation.
[0197] The variant may be purified by a variety of procedures known
in the art including, but not limited to, chromatography (e.g., ion
exchange, affinity, hydrophobic, chromatofocusing, and size
exclusion), electrophoretic procedures (e.g., preparative
isoelectric focusing), differential solubility (e.g., ammonium
sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein
Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers,
New York, 1989) to obtain substantially pure variants.
[0198] In an alternative aspect, the variant is not recovered, but
rather a host cell of the present invention expressing a variant is
used as a source of the variant.
In Vitro Synthesis
[0199] The polypeptides of the invention may also be prepared by in
vitro synthesis, using conventional methods as known in the art.
Various commercial synthetic apparatuses are available, for example
automated synthesizers by Applied Biosystems Inc., Beckman, etc. By
using synthesizers, naturally occurring amino acids may be
substituted with unnatural amino acids, particularly D-isomers (or
D-forms) e.g. D-alanine and D-isoleucine, diastereoisomers, side
chains having different lengths or functionalities, and the like.
The particular sequence and the manner of preparation will be
determined by convenience, economics, purity required, and the
like.
[0200] Chemical linking may be provided to various peptides or
proteins comprising convenient functionalities for bonding, such as
amino groups for amide or substituted amine formation, e.g.
reductive amination, thiol groups for thioether or disulfide
formation, carboxyl groups for amide formation, and the like.
[0201] If desired, various groups may be introduced into the
peptide during synthesis or during expression, which allow for
linking to other molecules or to a surface. Thus cysteines can be
used to make thioethers, histidines for linking to a metal ion
complex, carboxyl groups for forming amides or esters, amino groups
for forming amides, and the like.
[0202] The polypeptides may also be isolated and purified in
accordance with conventional methods of recombinant synthesis. A
lysate may be prepared of the expression host and the lysate
purified using HPLC, exclusion chromatography, gel electrophoresis,
affinity chromatography, or other purification technique. For the
most part, the compositions which are used will comprise at least
20% by weight of the desired product, more usually at least about
75% by weight, preferably at least about 95% by weight, and for
therapeutic purposes, usually at least about 99.5% by weight, in
relation to contaminants related to the method of preparation of
the product and its purification. Usually, the percentages will be
based upon total protein.
Plants
[0203] The present invention also relates to plants, e.g., a
transgenic plant, plant part, or plant cell, comprising a
polynucleotide of the present invention so as to express and
produce the variant in recoverable quantities. The variant may be
recovered from the plant or plant part. Alternatively, the plant or
plant part containing the variant may be used as such for improving
the quality of a food or feed, e.g., improving nutritional value,
palatability, and rheological properties, or to destroy an
antinutritive factor.
[0204] The transgenic plant can be dicotyledonous (a dicot) or
monocotyledonous (a monocot). Examples of monocot plants are
grasses, such as meadow grass (blue grass, Poa), forage grass such
as Festuca, Lolium, temperate grass, such as Agrostis, and cereals,
e.g., wheat, oats, rye, barley, rice, sorghum, and maize
(corn).
[0205] Examples of dicot plants are tobacco, legumes, such as
lupins, potato, sugar beet, pea, bean and soybean, and cruciferous
plants (family Brassicaceae), such as cauliflower, rape seed, and
the closely related model organism Arabidopsis thaliana.
[0206] Examples of plant parts are stem, callus, leaves, root,
fruits, seeds, and tubers as well as the individual tissues
comprising these parts, e.g., epidermis, mesophyll, parenchyme,
vascular tissues, meristems. Specific plant cell compartments, such
as chloroplasts, apoplasts, mitochondria, vacuoles, peroxisomes and
cytoplasm are also considered to be a plant part. Furthermore, any
plant cell, whatever the tissue origin, is considered to be a plant
part. Likewise, plant parts such as specific tissues and cells
isolated to facilitate the utilization of the invention are also
considered plant parts, e.g., embryos, endosperms, aleurone and
seeds coats.
[0207] Also included within the scope of the present invention are
the progeny of such plants, plant parts, and plant cells.
[0208] The transgenic plant or plant cell expressing a variant may
be constructed in accordance with methods known in the art. In
short, the plant or plant cell is constructed by incorporating one
or more (several) expression constructs encoding a variant into the
plant host genome or chloroplast genome and propagating the
resulting modified plant or plant cell into a transgenic plant or
plant cell.
[0209] The expression construct is conveniently a nucleic acid
construct that comprises a polynucleotide encoding a variant
operably linked with appropriate regulatory sequences required for
expression of the polynucleotide in the plant or plant part of
choice. Furthermore, the expression construct may comprise a
selectable marker useful for identifying plant cells into which the
expression construct has been integrated and DNA sequences
necessary for introduction of the construct into the plant in
question (the latter depends on the DNA introduction method to be
used).
[0210] The choice of regulatory sequences, such as promoter and
terminator sequences and optionally signal or transit sequences, is
determined, for example, on the basis of when, where, and how the
variant is desired to be expressed. For instance, the expression of
the gene encoding a variant may be constitutive or inducible, or
may be developmental, stage or tissue specific, and the gene
product may be targeted to a specific tissue or plant part such as
seeds or leaves. Regulatory sequences are, for example, described
by Tague et al., 1988, Plant Physiol. 86: 506.
[0211] For constitutive expression, the 35S-CaMV, the maize
ubiquitin 1, and the rice actin 1 promoter may be used (Franck et
al., 1980, Cell 21: 285-294; Christensen et al., 1992, Plant Mol.
Biol. 18: 675-689; Zhang et al., 1991, Plant Cell 3: 1155-1165).
Organ-specific promoters may be, for example, a promoter from
storage sink tissues such as seeds, potato tubers, and fruits
(Edwards and Coruzzi, 1990, Ann. Rev. Genet. 24: 275-303), or from
metabolic sink tissues such as meristems (Ito et al., 1994, Plant
Mol. Biol. 24: 863-878), a seed specific promoter such as the
glutelin, prolamin, globulin, or albumin promoter from rice (Wu et
al., 1998, Plant Cell Physiol. 39: 885-889), a Vicia faba promoter
from the legumin B4 and the unknown seed protein gene from Vicia
faba (Conrad et al., 1998, J. Plant Physiol. 152: 708-711), a
promoter from a seed oil body protein (Chen et al., 1998, Plant
Cell Physiol. 39: 935-941), the storage protein napA promoter from
Brassica napus, or any other seed specific promoter known in the
art, e.g., as described in WO 91/14772. Furthermore, the promoter
may be a leaf specific promoter such as the rbcs promoter from rice
or tomato (Kyozuka et al., 1993, Plant Physiol. 102: 991-1000), the
chlorella virus adenine methyltransferase gene promoter (Mitra and
Higgins, 1994, Plant Mol. Biol. 26: 85-93), the aldP gene promoter
from rice (Kagaya et al., 1995, Mol. Gen. Genet. 248: 668-674), or
a wound inducible promoter such as the potato pin2 promoter (Xu et
al., 1993, Plant Mol. Biol. 22: 573-588). Likewise, the promoter
may inducible by abiotic treatments such as temperature, drought,
or alterations in salinity or induced by exogenously applied
substances that activate the promoter, e.g., ethanol, oestrogens,
plant hormones such as ethylene, abscisic acid, and gibberellic
acid, and heavy metals.
[0212] A promoter enhancer element may also be used to achieve
higher expression of a variant in the plant. For instance, the
promoter enhancer element may be an intron that is placed between
the promoter and the polynucleotide encoding a variant. For
instance, Xu et al., 1993, supra, disclose the use of the first
intron of the rice actin 1 gene to enhance expression.
[0213] The selectable marker gene and any other parts of the
expression construct may be chosen from those available in the
art.
[0214] The nucleic acid construct is incorporated into the plant
genome according to conventional techniques known in the art,
including Agrobacterium-mediated transformation, virus-mediated
transformation, microinjection, particle bombardment, biolistic
transformation, and electroporation (Gasser et al., 1990, Science
244: 1293; Potrykus, 1990, Bio/Technology 8: 535; Shimamoto et al.,
1989, Nature 338: 274).
[0215] Presently, Agrobacterium tumefaciens-mediated gene transfer
is the method of choice for generating transgenic dicots (for a
review, see Hooykas and Schilperoort, 1992, Plant Mol. Biol. 19:
15-38) and can also be used for transforming monocots, although
other transformation methods are often used for these plants.
Presently, the method of choice for generating transgenic monocots
is particle bombardment (microscopic gold or tungsten particles
coated with the transforming DNA) of embryonic calli or developing
embryos (Christou, 1992, Plant J. 2: 275-281; Shimamoto, 1994,
Curr. Opin. Biotechnol. 5: 158-162; Vasil et al., 1992,
Bio/Technology 10: 667-674). An alternative method for
transformation of monocots is based on protoplast transformation as
described by Omirulleh et al., 1993, Plant Mol. Biol. 21: 415-428.
Additional transformation methods for use in accordance with the
present disclosure include those described in U.S. Pat. Nos.
6,395,966 and 7,151,204 (both of which are herein incorporated by
reference in their entirety).
[0216] Following transformation, the transformants having
incorporated the expression construct are selected and regenerated
into whole plants according to methods well known in the art. Often
the transformation procedure is designed for the selective
elimination of selection genes either during regeneration or in the
following generations by using, for example, co-transformation with
two separate T-DNA constructs or site specific excision of the
selection gene by a specific recombinase.
[0217] In addition to direct transformation of a particular plant
genotype with a construct prepared according to the present
invention, transgenic plants may be made by crossing a plant having
the construct to a second plant lacking the construct. For example,
a construct encoding a variant can be introduced into a particular
plant variety by crossing, without the need for ever directly
transforming a plant of that given variety. Therefore, the present
invention encompasses not only a plant directly regenerated from
cells which have been transformed in accordance with the present
invention, but also the progeny of such plants. As used herein,
progeny may refer to the offspring of any generation of a parent
plant prepared in accordance with the present invention. Such
progeny may include a DNA construct prepared in accordance with the
present invention, or a portion of a DNA construct prepared in
accordance with the present invention. Crossing results in the
introduction of a transgene into a plant line by cross pollinating
a starting line with a donor plant line. Non-limiting examples of
such steps are further articulated in U.S. Pat. No. 7,151,204.
[0218] Plants may be generated through a process of backcross
conversion. For example, plants include plants referred to as a
backcross converted genotype, line, inbred, or hybrid.
[0219] Genetic markers may be used to assist in the introgression
of one or more transgenes of the invention from one genetic
background into another. Marker assisted selection offers
advantages relative to conventional breeding in that it can be used
to avoid errors caused by phenotypic variations. Further, genetic
markers may provide data regarding the relative degree of elite
germplasm in the individual progeny of a particular cross. For
example, when a plant with a desired trait which otherwise has a
non-agronomically desirable genetic background is crossed to an
elite parent, genetic markers may be used to select progeny which
not only possess the trait of interest, but also have a relatively
large proportion of the desired germplasm. In this way, the number
of generations required to introgress one or more traits into a
particular genetic background is minimized.
[0220] The present invention also relates to methods of producing a
variant of the present invention comprising: (a) cultivating a
transgenic plant or a plant cell comprising a polynucleotide
encoding the variant under conditions conducive for production of
the variant; and (b) recovering the variant.
Methods and Uses
[0221] The present invention is also directed to methods for using
the polypeptides having antimicrobial activity. The antimicrobial
polypeptides are typically useful at any locus subject to
contamination by microorganisms. Typically, loci are in aqueous
systems such as cooling water systems, where microorganisms need to
be killed or where their growth needs to be controlled. However,
the present invention may also be used in all applications for
which known antimicrobial compositions are useful, such as
protection of wood, latex, adhesive, glue, paper, cardboard,
textile, leather and feed.
[0222] Other uses include preservation of foods, beverages,
cosmetics such as lotions, creams, gels, ointments, soaps,
shampoos, conditioners, antiperspirants, deodorants, mouth wash,
contact lens products or food ingredients.
[0223] In general it is contemplated that the antimicrobial
polypeptides of the present invention are useful for cleaning,
disinfecting or inhibiting microbial growth on any surface.
Examples of surfaces, which may advantageously be contacted with
the antimicrobial polypeptides of the invention, are surfaces of
process equipment used e.g. dairies, chemical or pharmaceutical
process plants. The antimicrobial polypeptides of the invention
should be used in an amount, which is effective for cleaning,
disinfecting or inhibiting microbial growth on the surface in
question.
[0224] The antimicrobial polypeptides of the invention may
additionally be used for cleaning surfaces and cooking utensils in
food processing plants and in any area in which food is prepared or
served such as hospitals, nursing homes and restaurants.
[0225] The invention also relates to the use of an antimicrobial
polypeptide or composition of the invention as a medicament.
Further, an antimicrobial polypeptide or composition of the
invention may also be used for the manufacture of a medicament for
controlling or combating microorganisms, such as fungal organisms
or bacteria, preferably gram negative bacteria.
[0226] The composition and antimicrobial polypeptide of the
invention may be used as an antimicrobial veterinarian or human
therapeutic or prophylactic agent. Thus, the composition and
antimicrobial polypeptide of the invention may be used in the
preparation of veterinarian or human therapeutic agents or
prophylactic agents for the treatment of microbial infections, such
as bacterial or fungal infections, preferably gram positive
bacterial infections. In particular the microbial infections may be
associated with lung diseases including, but not limited to,
tuberculosis, pneumonia and cystic fibrosis; skin infections and
infections in the eye or the mouth; and sexually transmitted
diseases including, but not limited to, gonorrhea and
chlamydia.
[0227] The invention also relates to wound healing compositions or
products such as bandages, medical devices such as, e.g.,
catheters.
[0228] The composition of the invention comprises an effective
amount of the antimicrobial polypeptide of the invention.
[0229] The term "effective amount" when used herein is intended to
mean an amount of the antimicrobial polypeptides of the invention,
which is sufficient to inhibit growth of the microorganisms in
question.
[0230] Formulations of the antimicrobial polypeptides of the
invention are administered to a host suffering from or predisposed
to a microbial infection. Administration may be topical, localized
or systemic, depending on the specific microorganism, preferably it
will be localized. Generally the dose of the antimicrobial
polypeptides of the invention will be sufficient to decrease the
microbial population by at least about 50%, usually by at least 1
log, and may be by 2 or more logs of killing. The compounds of the
present invention are administered at a dosage that reduces the
microbial population while minimizing any side-effects. It is
contemplated that the composition will be obtained and used under
the guidance of a physician for in vivo use. The antimicrobial
polypeptides of the invention are particularly useful for killing
gram negative bacteria, including Pseudomonas aeruginosa, and
Chlamydia trachomatis; and gram-positive bacteria, including
streptococci such as Streptococcus pneumonia, S. uberis, S.
hyointestinalis, S. pyogenes and S. agalactiae; and staphylococci
such as Staphylococcus aureus, S. epidermidis, S. simulans, S.
xylosus and S. carnosus.
[0231] Formulations of the antimicrobial polypeptides of the
invention may be administered to a host suffering from or
predisposed to a microbial lung infection, such as pneumonia; or to
a microbial wound infection, such as a bacterial wound
infection.
[0232] Formulations of the antimicrobial polypeptides of the
invention may also be administered to a host suffering from or
predisposed to a skin infection, such as acne, atopic dermatitis or
seborrheic dermatitis; preferably the skin infection is a bacterial
skin infection, e.g. caused by Staphylococcus epidermidis,
Staphylococcus aureus, Propionibacterium acnes, Pityrosporum ovale
or Malassezia furfur.
[0233] The antimicrobial polypeptides of the invention are also
useful for in vitro formulations to kill microbes, particularly
where one does not wish to introduce quantities of conventional
antibiotics. For example, the antimicrobial polypeptides of the
invention may be added to animal and/or human food preparations; or
they may be included as an additive for in vitro cultures of cells,
to prevent the overgrowth of microbes in tissue culture.
[0234] The susceptibility of a particular microbe to killing with
the antimicrobial polypeptides of the invention may be determined
by in vitro testing, as detailed in the experimental section.
Typically a culture of the microbe is combined with the
antimicrobial polypeptide at varying concentrations for a period of
time sufficient to allow the protein to act, usually between about
one hour and one day. The viable microbes are then counted, and the
level of killing determined.
[0235] Microbes of interest include, but are not limited to,
Gram-negative bacteria, for example: Citrobacter sp.; Enterobacter
sp.; Escherichia sp., e.g. E. coli; Klebsiella sp.; Morganella sp.;
Proteus sp.; Providencia sp.; Salmonella sp., e.g. S. typhi, S.
typhimurium; Serratia sp.; Shigella sp.; Pseudomonas sp., e.g. P.
aeruginosa; Yersinia sp., e.g. Y. pestis, Y. pseudotuberculosis, Y.
enterocolitica; Franciscella sp.; Pasturella sp.; Vibrio sp., e.g.
V. cholerae, V. parahemolyticus; Campylobacter sp., e.g. C. jejuni;
Haemophilus sp., e.g. H. influenzae, H. ducreyi; Bordetella sp.,
e.g. B. pertussis, B. bronchiseptica, B. parapertussis; Brucella
sp., Neisseria sp., e.g. N. gonorrhoeae, N. meningitidis, etc.
Other bacteria of interest include Legionella sp., e.g. L.
pneumophila; Listeria sp., e.g. L. monocytogenes; Mycoplasma sp.,
e.g. M. hominis, M. pneumoniae; Mycobacterium sp., e.g. M.
tuberculosis, M. leprae; Treponema sp., e.g. T. pallidum; Borrelia
sp., e.g. B. burgdorferi; Leptospirae sp.; Rickettsia sp., e.g. R.
rickettsii, R. typhi; Chlamydia sp., e.g. C. trachomatis, C.
pneumoniae, C. psittaci; Helicobacter sp., e.g. H. pylori, etc.
[0236] Non-bacterial pathogens of interest include fungal and
protozoan pathogens, e.g. Plasmodia sp., e.g. P. falciparum,
Trypanosoma sp., e.g. T. brucei; shistosomes; Entaemoeba sp.,
Cryptococcus sp., Candida sp., e.g. C. albicans; etc.
[0237] Various methods for administration may be employed. The
polypeptide formulation may be given orally, or may be injected
intravascularly, subcutaneously, peritoneally, by aerosol,
opthalmically, intra-bladder, topically, etc. For example, methods
of administration by inhalation are well-known in the art. The
dosage of the therapeutic formulation will vary widely, depending
on the specific antimicrobial polypeptide to be administered, the
nature of the disease, the frequency of administration, the manner
of administration, the clearance of the agent from the host, and
the like. The initial dose may be larger, followed by smaller
maintenance doses. The dose may be administered as infrequently as
weekly or biweekly, or fractionated into smaller doses and
administered once or several times daily, semi-weekly, etc. to
maintain an effective dosage level. In many cases, oral
administration will require a higher dose than if administered
intravenously. The amide bonds, as well as the amino and carboxy
termini, may be modified for greater stability on oral
administration. For example, the carboxy terminus may be
amidated.
Formulations
[0238] The compounds of this invention can be incorporated into a
variety of formulations for therapeutic administration. More
particularly, the compounds of the present invention can be
formulated into pharmaceutical compositions by combination with
appropriate, pharmaceutically acceptable carriers or diluents, and
may be formulated into preparations in solid, semi-solid, liquid or
gaseous forms, such as tablets, capsules, powders, granules,
ointments, creams, foams, solutions, suppositories, injections,
inhalants, gels, microspheres, lotions, and aerosols. As such,
administration of the compounds can be achieved in various ways,
including oral, buccal, rectal, parenteral, intraperitoneal,
intradermal, transdermal, intracheal, etc., administration. The
antimicrobial polypeptides of the invention may be systemic after
administration or may be localized by the use of an implant or
other formulation that acts to retain the active dose at the site
of implantation.
[0239] The compounds of the present invention can be administered
alone, in combination with each other, or they can be used in
combination with other known compounds (e.g., perforin,
anti-inflammatory agents, antibiotics, etc.). In pharmaceutical
dosage forms, the compounds may be administered in the form of
their pharmaceutically acceptable salts. The following methods and
excipients are merely exemplary and are in no way limiting.
[0240] For oral preparations, the compounds can be used alone or in
combination with appropriate additives to make tablets, powders,
granules or capsules, for example, with conventional additives,
such as lactose, mannitol, corn starch or potato starch; with
binders, such as crystalline cellulose, cellulose derivatives,
acacia, corn starch or gelatins; with disintegrators, such as corn
starch, potato starch or sodium carboxymethylcellulose; with
lubricants, such as talc or magnesium stearate; and if desired,
with diluents, buffering agents, moistening agents, preservatives
and flavoring agents.
[0241] The compounds can be formulated into preparations for
injections by dissolving, suspending or emulsifying them in an
aqueous or nonaqueous solvent, such as vegetable or other similar
oils, synthetic aliphatic acid glycerides, esters of higher
aliphatic acids or propylene glycol; and if desired, with
conventional additives such as solubilizers, isotonic agents,
suspending agents, emulsifying agents, stabilizers and
preservatives.
[0242] The compounds can be utilized in aerosol formulation to be
administered via inhalation. The compounds of the present invention
can be formulated into pressurized acceptable propellants such as
dichlorodifluoromethane, propane, nitrogen and the like.
[0243] Furthermore, the compounds can be made into suppositories by
mixing with a variety of bases such as emulsifying bases or
water-soluble bases. The compounds of the present invention can be
administered rectally via a suppository. The suppository can
include vehicles such as cocoa butter, carbowaxes and polyethylene
glycols, which melt at body temperature, yet are solidified at room
temperature.
[0244] Unit dosage forms for oral or rectal administration such as
syrups, elixirs, and suspensions may be provided wherein each
dosage unit, for example, teaspoonful, tablespoonful, tablet or
suppository, contains a predetermined amount of the composition
containing one or more compounds of the present invention.
Similarly, unit dosage forms for injection or intravenous
administration may comprise the compound of the present invention
in a composition as a solution in sterile water, normal saline or
another pharmaceutically acceptable carrier.
[0245] Implants for sustained release formulations are well-known
in the art. Implants are formulated as microspheres, slabs, etc.
with biodegradable or non-biodegradable polymers. For example,
polymers of lactic acid and/or glycolic acid form an erodible
polymer that is well-tolerated by the host. The implant containing
the antimicrobial polypeptides of the invention is placed in
proximity to the site of infection, so that the local concentration
of active agent is increased relative to the rest of the body.
[0246] The term "unit dosage form", as used herein, refers to
physically discrete units suitable as unitary dosages for human and
animal subjects, each unit containing a predetermined quantity of
compounds of the present invention calculated in an amount
sufficient to produce the desired effect in association with a
pharmaceutically acceptable diluent, carrier or vehicle. The
specifications for the unit dosage forms of the present invention
depend on the particular compound employed and the effect to be
achieved, and the pharmacodynamics associated with the compound in
the host.
[0247] The pharmaceutically acceptable excipients, such as
vehicles, adjuvants, carriers or diluents, are readily available to
the public. Moreover, pharmaceutically acceptable auxiliary
substances, such as pH adjusting and buffering agents, tonicity
adjusting agents, stabilizers, wetting agents and the like, are
readily available to the public.
[0248] Typical dosages for systemic administration range from 0.1
pg to 100 milligrams per kg weight of subject per administration. A
typical dosage may be one tablet taken from two to six times daily,
or one time-release capsule or tablet taken once a day and
containing a proportionally higher content of active ingredient.
The time-release effect may be obtained by capsule materials that
dissolve at different pH values, by capsules that release slowly by
osmotic pressure, or by any other known means of controlled
release.
[0249] Those of skill will readily appreciate that dose levels can
vary as a function of the specific compound, the severity of the
symptoms and the susceptibility of the subject to side effects.
Some of the specific compounds are more potent than others.
Preferred dosages for a given compound are readily determinable by
those of skill in the art by a variety of means. A preferred means
is to measure the physiological potency of a given compound.
[0250] The use of liposomes as a delivery vehicle is one method of
interest. The liposomes fuse with the cells of the target site and
deliver the contents of the lumen intracellularly. The liposomes
are maintained in contact with the cells for sufficient time for
fusion, using various means to maintain contact, such as isolation,
binding agents, and the like. In one aspect of the invention,
liposomes are designed to be aerosolized for pulmonary
administration. Liposomes may be prepared with purified proteins or
peptides that mediate fusion of membranes, such as Sendai virus or
influenza virus, etc. The lipids may be any useful combination of
known liposome forming lipids, including cationic or zwitterionic
lipids, such as phosphatidylcholine. The remaining lipid will be
normally be neutral or acidic lipids, such as cholesterol,
phosphatidyl serine, phosphatidyl glycerol, and the like.
[0251] For preparing the liposomes, the procedure described by Kato
et al., 1991, J. Biol. Chem. 266:3361 may be used. Briefly, the
lipids and lumen composition containing peptides are combined in an
appropriate aqueous medium, conveniently a saline medium where the
total solids will be in the range of about 1-10 weight percent.
After intense agitation for short periods of time, from about 5-60
seconds, the tube is placed in a warm water bath, from about
25-40.degree. C. and this cycle repeated from about 5-10 times. The
composition is then sonicated for a convenient period of time,
generally from about 1-10 seconds and may be further agitated by
vortexing. The volume is then expanded by adding aqueous medium,
generally increasing the volume by about from 1-2 fold, followed by
shaking and cooling. This method allows for the incorporation into
the lumen of high molecular weight molecules.
Formulations with Other Active Agents
[0252] For use in the subject methods, the antimicrobial
polypeptides of the invention may be formulated with other
pharmaceutically active agents, particularly other antimicrobial
agents. Other agents of interest include a wide variety of
antibiotics, as known in the art. Classes of antibiotics include
penicillins, e.g., penicillin G, penicillin V, methicillin,
oxacillin, carbenicillin, nafcillin, ampicillin, etc.; penicillins
in combination with beta-lactamase inhibitors, cephalosporins,
e.g., cefaclor, cefazolin, cefuroxime, moxalactam, etc.;
carbapenems; monobactams; aminoglycosides; tetracyclines;
macrolides; lincomycins; polymyxins; sulfonamides; quinolones;
chloramphenical; metronidazole; spectinomycin; trimethoprim;
vancomycin; etc.
[0253] Anti-mycotic agents are also useful, including polyenes,
e.g., amphotericin B, nystatin; 5-flucosyn; and azoles, e.g.,
miconazol, ketoconazol, itraconazol and fluconazol.
Antituberculotic drugs include isoniazid, ethambutol, streptomycin
and rifampin. Cytokines may also be included in a formulation of
the antimicrobial polypeptides of the invention, e.g. interferon
gamma, tumor necrosis factor alpha, interleukin 12, etc.
[0254] The present invention is further described by the following
examples that should not be construed as limiting the scope of the
invention.
EXAMPLES
[0255] NZ17074 is the antimicrobial peptide of SEQ ID NO: 70.
Example 1
Isolation of Variants of SEQ ID NO: 2 Having Improved Antimicrobial
Activity
[0256] The cDNA encoding SEQ ID NO: 2 was fused to the proregion of
plectasin (see Mygind et al., 2005, Nature 437: 975-980) and the
Mating Factor alpha-leader from Saccharomyces cerevisiae and
introduced into the inducible S. cerevisiae expression vector,
pYES2, and transformed into S. cerevisiae. This system takes
advantage of the GAL1 promoter which is repressed by glucose and
activated by galactose.
[0257] Several strategies were used for variant generation of the
polynucleotide of SEQ ID NO:1. The resulting libraries were cloned
and expressed in S. cerevisiae. Transformed clones were screened on
a plate assay containing growth media supplemented with 1.5%
galactose and 0.5% glucose and either horse blood (2.5-5%) or serum
(5%), overlayed with the target organism, E. coli ATCC 10536 (See
Raventos et al., 2005, Comb Chem High Throughput Screen.
8:219-33).
[0258] The plate assay conditions fully inhibited the activity of
the antimicrobial peptide of SEQ ID NO: 2 (the parent antimicrobial
peptide). Variants exhibiting improved antimicrobial activity
(giving rise to clearing zones) in the presence of 2.5% blood, 5%
blood or 5% serum were picked and sequenced, and are shown in Table
1.
Plate Assay Screening Procedure
[0259] Approximately, 300 Saccharomyces cerevisiae colonies
expressing arenicin variants were spread on screening plates
containing either horse blood (2.5% or 5%) or 5% horse serum (see
composition of the plates below). Plates were incubated 3 hours at
30.degree. C. to allow them to dry. Next, 25 ml overlay temperate
at 42.degree. C. was added to the plates. After the media had
solidified, the plates were incubated 3 days at 30.degree. C.
[0260] On day 4, plates were overlayed with pre-warmed media at
42.degree. C. containing either 2.5% or 5% horse blood or 5% horse
serum and the target bacteria, E. coli ATCC 10536 (see below for
details on media composition). After the overlay solidified, plates
were incubated 16 hours at 37.degree. C. Next day, plates were
colored by adding 10 ml of 1.5 mM MTT to the plates and incubated
at room temperature for 30 minutes. Clones giving rise to clearing
zones were picked and sequenced.
Plate and Media Composition
[0261] Three different types of screening plates a), b) and c) were
used in the screening:
a) Plates+2.5% Horse Blood
[0262] The bottom layer contains 50 ml of 1.5% agarose+1/4 SC
media+2.5% blood+1.5% galactose+0.5% glucose. The first overlay
contains 25 ml of 1% agarose+1/4 SC media+2.5% blood+1.5%
galactose+0.5% glucose. The top overlay contains 25 ml 0.2% MHB
(#212322; BD)+1% agarose (Sigma A-4718)+2.5% horse blood and
1.25.times.10.sup.6 colony forming units (cfu) of E. coli ATCC
10536.
B) Plates+5% Horse Blood
[0263] The bottom layer contains 50 ml of 1.5% agarose+1/4 SC
media+5% blood+1.5% galactose+0.5% glucose. The first overlay
contains 25 ml of 1% agarose+1/4 SC media+5% blood+1.5%
galactose+0.5% glucose. The top overlay contains 25 ml 0.2% MHB
(#212322; BD)+1% agarose (Sigma A-4718)+5% horse blood and
1.25.times.10.sup.6 colony forming units (cfu) of E. coli ATCC
10536.
C) Plates+5% Horse Serum
[0264] The bottom layer contains 50 ml of 1.5% agarose+1/2 SC
media+5% serum+1.5% galactose+0.5% glucose. The first overlay
contains 25 ml of 1% agarose+1/2 SC media+5% serum+1.5%
galactose+0.5% glucose. The top overlay contains 25 ml 0.2% MHB
(#212322; BD)+1% agarose (Sigma A-4718)+5% horse serum and
1.25.times.10.sup.6 colony forming units (cfu) of E. coli ATCC
10536.
Composition of SC Media (450 ml)
[0265] Yeast Nitrogen Base w/o amino acids: 3.75 g Succinic acid:
5.65 g Sodium hydroxide: 3.4 g Casamino acid vitamin assay: 2.8
g
L-Tryptophan: 0.05 g
Water: 450 ml
[0266] pH was adjusted to 6 and the media was autoclaved and
diluted 1/4 when preparing the blood plates and 1/2 when preparing
the serum plates. MIT:
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide,
Sigma 13, 503-8)
Determination of the Protein Binding
[0267] Protein binding assays were performed as follows. The
purified peptides were mixed with 90% serum and centrifuged through
a 30 kDa filter. The ultra-filtrate and the non filtrated serum
samples were quantified by HPLC measurements and the protein
binding was subsequently calculated.
[0268] The antimicrobial peptide of SEQ ID NO: 2 (the parent
antimicrobial peptide) exhibited a protein binding of 99.5% in this
assay. As shown in Table 1, all exemplified variants exhibit a
lower protein binding than the antimicrobial peptide of SEQ ID NO:
2.
TABLE-US-00002 TABLE 1 Variants exhibiting improved antimicrobial
activity and reduced protein binding. SEQ ID Protein binding NO:
Substitution Amino acid sequence (%) 3 F2A GACWYVCVYRNGVRVCYRRCN 86
4 W4A GFCAYVCVYRNGVRVCYRRCN 89 5 W4E GFCEYVCVYRNGVRVCYRRCN -- 6 W4G
GFCGYVCVYRNGVRVCYRRCN -- 7 W4S GFCSYVCVYRNGVRVCYRRCN 68 8 W4T
GFCAYVCVYRNGVRVCYRRCN -- 9 W4Y GFCYYVCVYRNGVRVCYRRCN -- 10 Y5K
GFCWKVCVYRNGVRVCYRRCN 64 11 Y5N GFCWNVCVYRNGVRVCYRRCN 73 12 Y5R
GFCWRVCVYRNGVRVCYRRCN -- 13 V6A GFCWYACVYRNGVRVCYRRCN -- 14 V6E
GFCWYECVYRNGVRVCYRRCN -- 15 V6G GFCWYGCVYRNGVRVCYRRCN 96 16 V6L
GFCWYLCVYRNGVRVCYRRCN -- 17 V6N GFCWYNCVYRNGVRVCYRRCN -- 18 V6R
GFCWYRCVYRNGVRVCYRRCN -- 19 V6S GFCWYSCVYRNGVRVCYRRCN 89 20 V6W
GFCWYWCVYRNGVRVCYRRCN 99 21 V8A GFCWYVCAYRNGVRVCYRRCN 98.5 22 V8G
GFCWYVCGYRNGVRVCYRRCN -- 23 V8H GFCWYVCHYRNGVRVCYRRCN 98 24 V8S
GFCWYVCSYRNGVRVCYRRCN 85 25 V8Y GFCWYVCYYRNGVRVCYRRCN 98 26 Y9I
GFCWYVCVIRNGVRVCYRRCN -- 27 Y9K GFCWYVCVKRNGVRVCYRRCN -- 28 Y9R
GFCWYVCVRRNGVRVCYRRCN 92 29 V13A GFCWYVCVYRNGARVCYRRCN 99 30 V13G
GFCWYVCVYRNGGRVCYRRCN 99 31 V13K GFCWYVCVYRNGKRVCYRRCN -- 32 V13L
GFCWYVCVYRNGLRVCYRRCN -- 33 V13P GFCWYVCVYRNGPRVCYRRCN 99 34 V13Q
GFCWYVCVYRNGQRVCYRRCN -- 36 V13R GFCWYVCVYRNGRRVCYRRCN -- 36 V13S
GFCWYVCVYRNGSRVCYRRCN 60 37 V15A GFCWYVCVYRNGVRACYRRCN -- 38 V15G
GFCWYVCVYRNGVRGCYRRCN 93 39 V15H GFCWYVCVYRNGVRHCYRRCN 98 40 V15K
GFCWYVCVYRNGVRKCYRRCN -- 41 V15N GFCWYVCVYRNGVRNCYRRCN 97 42 V15Q
GFCWYVCVYRNGVRQCYRRCN 96 43 V15R GFCWYVCVYRNGVRRCYRRCN -- 44 V15S
GFCWYVCVYRNGVRSCYRRCN 85 45 V15T GFCWYVCVYRNGVRTCYRRCN 98 46 Yl7H
GFCWYVCVYRNGVRVCHRRCN 88 47 Yl7K GFCWYVCVYRNGVRVCKRRCN 89 48 Yl7N
GFCWYVCVYRNGVRVCNRRCN 68 49 Yl7R GFCWYVCVYRNGVRVCRRRCN -- 50 N21H
GFCWYVCVYRNGVRVCYRRCH -- 51 N21K GFCWYVCVYRNGVRVCYRRCK -- 52 N21R
GFCWYVCVYRNGVRVCYRRCR -- 53 N21S GFCWYVCVYRNGVRVCYRRCS 99 54 N21T
GFCWYVCVYRNGVRVCYRRCT 99 55 G1R + N21R RFCWYVCVYRNGVRVCYRRCR -- 56
W4F + Y17R GFCFYVCVYRNGVRVCRRRCN 94 57 W4A + Y5H
GFCAHVCVYRNGVRVCYRRCN -- 58 W4A + Y5R GFCARVCVYRNGVRVCYRRCN -- 59
W4F + Y9R GFCFYVCVRRNGVRVCYRRCN -- 60 W4G + Y5H
GFCGHVCVYRNGVRVCYRRCN 64 61 W4G + Y5R GFCGRVCVYRNGVRVCYRRCN 72 62
W4S + V15A GFCSYVCVYRNGVRACYRRCN -- 63 W4S + Y5R
GFCSRVCVYRNGVRVCYRRCN -- 64 W4Y + Y5R GFCYRVCVYRNGVRVCYRRCN -- 65
Y5F + V15Q GFCWFVCVYRNGVRQCYRRCN -- 66 Y5H + V15S
GFCWHVCVYRNGVRSCYRRCN -- 67 Y5H + Y17R GFCWHVCVYRNGVRVCRRRCN -- 68
Y5K + Y17S GFCWKVCVYRNGVRVCSRRCN 87 69 Y5N + V15S
GFCWNVCVYRNGVRSCYRRCN -- 70 Y5N + Y17H GFCWNVCVYRNGVRVCHRRCN 79 71
Y5R + V15P GFCWRVCVYRNGVRPCYRRCN -- 72 Y5R + V6A
GFCWRACVYRNGVRVCYRRCN 97 73 Y5R + V8G GFCWRVCGYRNGVRVCYRRCN -- 74
Y5R + V8H GFCWRVCHYRNGVRVCYRRCN 99 75 Y5R + V8S
GFCWRVCSYRNGVRVCYRRCN -- 76 Y5R + Y17H GFCWRVCVYRNGVRVCHRRCN 92 77
Y5R + Y17N GFCWRVCVYRNGVRVCNRRCN -- 78 Y5S + V15S
GFCWSVCVYRNGVRSCYRRCN -- 79 V6A + V13A GFCWYACVYRNGARVCYRRCN -- 80
V6A + V13K GFCWYACVYRNGKRVCYRRCN 96 81 V6A + V15A
GFCWYACVYRNGVRACYRRCN -- 82 V6A + Y17H GFCWYACVYRNGVRVCHRRCN -- 83
V6M + V8G GFCWYMCGYRNGVRVCYRRCN -- 84 V8A + V15A
GFCWYVCAYRNGVRACYRRCN -- 85 V8S + V13K GFCWYVCSYRNGKRVCYRRCN -- 86
Y9K + V13A GFCWYVCVKRNGARVCYRRCN -- 87 Y9K + V15S
GFCWYVCVKRNGVRSCYRRCN 93 88 R10K + V15S GFCWYVCVYKNGVRSCYRRCN -- 89
R10K + Y17H GFCWYVCVYKNGVRVCHRRCN 90 90 R10P + V13G
GFCWYVCVYPNGGRVCYRRCN -- 91 N11R + V15Q GFCWYVCVYRRGVRQCYRRCN -- 92
V13A + Y17C GFCWYVCVYRNGARVCCRRCN -- 93 V13G + V15K
GFCWYVCVYRNGGRKCYRRCN -- 94 V15L + Y17H GFCWYVCVYRNGVRLCHRRCN -- 95
G1A + Y5N + Y17H AFCWNVCVYRNGVRVCHRRCN -- 96 G1D + Y5N + Y17H
DFCWNVCVYRNGVRVCHRRCN -- 97 G1F + Y5N + Y17H FFCWNVCVYRNGVRVCHRRCN
-- 98 G1H + Y5N + Y17H HFCWNVCVYRNGVRVCHRRCN 77 99 G1I + Y5N + Y17H
IFCWNVCVYRNGVRVCHRRCN -- 100 G1K + Y5N + Y17H KFCWNVCVYRNGVRVCHRRCN
78 101 G1M + Y5N + Y17H MFCWNVCVYRNGVRVCHRRCN 81 102 G1Q + Y5N +
Y17H QFCWNVCVYRNGVRVCHRRCN -- 103 G1R + Y5N + Y17H
RFCWNVCVYRNGVRVCHRRCN -- 104 G1S + Y5N + Y17H SFCWNVCVYRNGVRVCHRRCN
-- 105 G1T + Y5N + Y17H TFCWNVCVYRNGVRVCHRRCN -- 106 G1V + Y5N +
Y17H VFCWNVCVYRNGVRVCHRRCN -- 107 G1W + Y5N + Y17H
WFCWNVCVYRNGVRVCHRRCN -- 108 GlY + Y5N + Y17H YFCWNVCVYRNGVRVCHRRCN
-- 109 F2G + Y5N + Y17H GGCWNVCVYRNGVRVCHRRCN -- 110 F2H + Y5N +
Y17H GHCWNVCVYRNGVRVCHRRCN -- 111 F2I + Y5N + Y17H
GICWNVCVYRNGVRVCHRRCN -- 112 F2L + Y5N + Y17H GLCWNVCVYRNGVRVCHRRCN
-- 113 F2M + Y5N + Y17H GMCWNVCVYRNGVRVCHRRCN -- 114 F2P + Y5N +
Y17H GPCWNVCVYRNGVRVCHRRCN -- 115 F2V + Y5N + Y17H
GVCWNVCVYRNGVRVCHRRCN -- 116 F2W + Y5N + Y17H GWCWNVCVYRNGVRVCHRRCN
-- 117 F2Y + Y5N + Y17H GYCWNVCVYRNGVRVCHRRCN -- 118 C3L + W4Q +
Y17H GFLQYVCVYRNGVRVCHRRCN -- 119 W4A + V6A + Y9K
GFCAYACVKRNGVRVCYRRCN -- 120 W4A + Y5K + V15S GFCAKVCVYRNGVRSCYRRCN
69 121 W4A + Y5R + V15A GFCARVCVYRNGVRACYRRCN -- 122 W4A + Y5R +
V15S GFCARVCVYRNGVRSCYRRCN 81 123 W4A + Y5R + V15T
GFCARVCVYRNGVRTCYRRCN -- 124 W4A + Y5R + V8S GFCARVCSYRNGVRVCYRRCN
--
125 W4A + Y5R + Y9K GFCARVCVKRNGVRVCYRRCN 90 126 W4A + Y5W + V15Q
GFCAWVCVYRNGVRQCYRRCN -- 127 W4A + Y9R + V15S GFCAYVCVRRNGVRSCYRRCN
-- 128 W4F + V8A + V15S GFCFYVCAYRNGVRSCYRRCN -- 129 W4F + Y5H +
V15S GFCFHVCVYRNGVRSCYRRCN -- 130 W4F + Y5N + V15S
GFCFNVCVYRNGVRSCYRRCN -- 131 W4F + Y5N + Y17H GFCFNVCVYRNGVRVCHRRCN
-- 132 W4F + Y5R + V15K GFCFRVCVYRNGVRKCYRRCN -- 133 W4F + Y5R +
V15Q GFCFRVCVYRNGVRQCYRRCN -- 134 W4F + Y5R + V15S
GFCFRVCVYRNGVRSCYRRCN -- 135 W4F + Y5R + Y17H GFCFRVCVYRNGVRVCHRRCN
-- 136 W4F + Y5R + Y17Q GFCFRVCVYRNGVRVCQRRCN -- 137 W4F + Y9K +
Y17H GFCFYVCVKRNGVRVCHRRCN 86 138 W4G + Y5H + N21A
GFCGHVCVYRNGVRVCYRRCA -- 139 W4G + Y5H + N21K GFCGHVCVYRNGVRVCYRRCK
-- 140 W4G + Y5H + N21L GFCGHVCVYRNGVRVCYRRCL -- 141 W4G + Y5H +
N21M GFCGHVCVYRNGVRVCYRRCM -- 142 W4G + Y5H + N21P
GFCGHVCVYRNGVRVCYRRCP -- 143 W4G + Y5H + N21R GFCGHVCVYRNGVRVCYRRCR
-- 144 W4G + Y5H + N21S GFCGHVCVYRNGVRVCYRRCS 68 145 W4G + Y5H +
N21Y GFCGHVCVYRNGVRVCYRRCY -- 146 W4G + Y5H + V15A
GFCGHVCVYRNGVRACYRRCN -- 147 W4G + Y5H + V15F GFCGHVCVYRNGVRFCYRRCN
-- 148 W4G + Y5H + V15G GFCGHVCVYRNGVRGCYRRCN -- 149 W4G + Y5H +
V15H GFCGHVCVYRNGVRHCYRRCN -- 150 W4G + Y5H + V15I
GFCGHVCVYRNGVRICYRRCN -- 151 W4G + Y5H + V15L GFCGHVCVYRNGVRLCYRRCN
-- 152 W4G + Y5H + V15M GFCGHVCVYRNGVRMCYRRCN -- 153 W4G + Y5H +
V15N GFCGHVCVYRNGVRNCYRRCN -- 154 W4G + Y5H + V15Q
GFCGHVCVYRNGVRQCYRRCN -- 155 W4G + Y5H + V15R GFCGHVCVYRNGVRRCYRRCN
83 156 W4G + Y5H + V15S GFCGHVCVYRNGVRSCYRRCN -- 157 W4G + Y5H +
V15T GFCGHVCVYRNGVRTCYRRCN -- 158 W4G + Y5H + V15W
GFCGHVCVYRNGVRWCYRRCN -- 159 W4G + Y5H + V15Y GFCGHVCVYRNGVRYCYRRCN
-- 160 W4G + Y5H + Y17F GFCGHVCVYRNGVRVCFRRCN -- 161 W4G + Y5H +
Y17G GFCGHVCVYRNGVRVCGRRCN -- 162 W4G + Y5H + Y17I
GFCGHVCVYRNGVRVCIRRCN -- 163 W4G + Y5H + Y17L GFCGHVCVYRNGVRVCLRRCN
-- 164 W4G + Y5H + Y17M GFCGHVCVYRNGVRVCMRRCN -- 165 W4G + Y5H +
Y17T GFCGHVCVYRNGVRVCTRRCN -- 166 W4G + Y5H + Y17V
GFCGHVCVYRNGVRVCVRRCN -- 167 W4G + Y5H + Y17W GFCGHVCVYRNGVRVCWRRCN
-- 168 W4G + Y5K + V15H GFCGKVCVYRNGVRHCYRRCN -- 169 W4G + Y5R +
V15L GFCGRVCVYRNGVRLCYRRCN -- 170 W4G + Y5R + V15R
GFCGRVCVYRNGVRRCYRRCN 87 171 W4G + Y5R + V15T GFCGRVCVYRNGVRTCYRRCN
84 172 W4G + Y5R + Y9R GFCGRVCVRRNGVRVCYRRCN 88 173 W4G + Y5S +
V15A GFCGSVCVYRNGVRACYRRCN -- 174 W4G + Y5S + V15K
GFCGSVCVYRNGVRKCYRRCN -- 175 W4G + Y5S + V15R GFCGSVCVYRNGVRRCYRRCN
-- 176 W4G + Y9R + V15S GFCGYVCVRRNGVRSCYRRCN -- 177 W4I + Y5N +
Y17H GFCINVCVYRNGVRVCHRRCN -- 178 W4L + Y5H + V15Q
GFCLHVCVYRNGVRQCYRRCN -- 179 W4L + Y5K + V15K GFCLKVCVYRNGVRKCYRRCN
-- 180 W4L + Y5R + V15Q GFCLRVCVYRNGVRQCYRRCN -- 181 W4L + Y5R +
V15S GFCLRVCVYRNGVRSCYRRCN -- 182 W4M + Y5E + Y17T
GFCMEVCVYRNGVRVCTRRCN -- 183 W4M + Y5H + V15S GFCMHVCVYRNGVRSCYRRCN
-- 184 W4M + Y5N + Y17H GFCMNVCVYRNGVRVCHRRCN -- 185 W4M + Y5R +
V15T GFCMRVCVYRNGVRTCYRRCN -- 186 W4M + Y5S + V15Q
GFCMSVCVYRNGVRQCYRRCN -- 187 W4M + Y5S + V15R GFCMSVCVYRNGVRRCYRRCN
-- 188 W4N + Y5R + V15I GFCNRVCVYRNGVRICYRRCN -- 189 W4S + Y5K +
V15R GFCSKVCVYRNGVRRCYRRCN -- 190 W4S + Y5R + V15I
GFCSRVCVYRNGVRICYRRCN -- 191 W4T + Y5N + V15A GFCTNVCVYRNGVRACYRRCN
-- 192 W4T + Y5R + V15R GFCTRVCVYRNGVRRCYRRCN -- 193 W4T + Y5R +
V151 GFCTRVCVYRNGVRTCYRRCN -- 194 W4T + Y5S + V15H
GFCTSVCVYRNGVRHCYRRCN -- 195 W4T + Y9K + V15K GFCTYVCVKRNGVRKCYRRCN
95 196 W4V + Y5H + V15P GFCVHVCVYRNGVRPCYRRCN -- 197 W4V + Y5H +
Y17H GFCVHVCVYRNGVRVCHRRCN -- 198 W4V + Y5K + V15Q
GFCVKVCVYRNGVRQCYRRCN -- 199 W4V + Y5N + Y17H GFCVNVCVYRNGVRVCHRRCN
-- 200 W4V + Y5R + V15G GFCVRVCVYRNGVRGCYRRCN -- 201 W4V + Y5R +
V15P GFCVRVCVYRNGVRPCYRRCN -- 202 W4V + Y5R + V15Q
GFCVRVCVYRNGVRQCYRRCN -- 203 W4V + Y5R + V15R GFCVRVCVYRNGVRRCYRRCN
-- 204 W4V + Y5R + V15T GFCVRVCVYRNGVRTCYRRCN -- 205 W4Y + Y5H +
V15Y GFCYHVCVYRNGVRYCYRRCN -- 206 W4Y + Y5K + V15S
GFCYKVCVYRNGVRSCYRRCN 86 207 W4Y + Y5N + V15R GFCYNVCVYRNGVRRCYRRCN
91 208 W4Y + Y5N + Y17H GFCYNVCVYRNGVRVCHRRCN -- 209 W4Y + Y5R +
V15T GFCYRVCVYRNGVRTCYRRCN 89 210 W4Y + Y5R + Y17H
GFCYRVCVYRNGVRVCHRRCN 89 211 W4Y + Y5R + Y17S GFCYRVCVYRNGVRVCSRRCN
96 212 W4Y + Y5W + V15S GFCYWVCVYRNGVRSCYRRCN -- 213 Y5H + V13A +
V15S GFCWHVCVYRNGARSCYRRCN 95 214 Y5H + V13S + V15S
GFCWHVCVYRNGSRSCYRRCN -- 215 Y5H + V15S + Y17S
GFCWHVCVYRNGVRSCSRRCN -- 216 Y5H + V8A + V13K GFCWHVCAYRNGKRVCYRRCN
-- 217 Y5H + V8A + V15S GFCWHVCAYRNGVRSCYRRCN -- 218 Y5H + V8A +
Y9R GFCWHVCARRNGVRVCYRRCN 99 219 Y5H + V8H + G12S
GFCWHVCHYRNSVRVCYRRCN 99 220 Y5H + Y9S + V15K GFCWHVCVSRNGVRKCYRRCN
-- 221 Y5K + Y9S + Y17S GFCWKVCVSRNGVRVCSRRCN -- 222 Y5N + G12A +
Y17H GFCWNVCVYRNAVRVCHRRCN -- 223 Y5N + Gl2D + Y17H
GFCWNVCVYRNDVRVCHRRCN -- 224 Y5N + G12E + Y17H
GFCWNVCVYRNEVRVCHRRCN -- 225 Y5N + Gl2F + Y17H
GFCWNVCVYRNFVRVCHRRCN -- 226 Y5N + Gl2H + Y17H
GFCWNVCVYRNHVRVCHRRCN -- 227 Y5N + G12K + Y17H
GFCWNVCVYRNKVRVCHRRCN 80 228 Y5N + Gl2R + Y17H
GFCWNVCVYRNRVRVCHRRCN 86 229 Y5N + G12Y + Y17H
GFCWNVCVYRNYVRVCHRRCN 91 230 Y5N + N11A + Y17H
GFCWNVCVYRAGVRVCHRRCN 71 231 Y5N + Nl1G + Y17H
GFCWNVCVYRGGVRVCHRRCN 66 232 Y5N + Nl1H + Y17H
GFCWNVCVYRHGVRVCHRRCN 85 233 Y5N + N11Q + Y17H
GFCWNVCVYRQGVRVCHRRCN 78 234 Y5N + Nl1R + Y17H
GFCWNVCVYRRGVRVCHRRCN 86 235 Y5N + V13A + Y17H
GFCWNVCVYRNGARVCHRRCN 64 236 Y5N + V13F + Y17H
GFCWNVCVYRNGFRVCHRRCN -- 237 Y5N + V13H + Y17H
GFCWNVCVYRNGHRVCHRRCN 40 238 Y5N + V13Q + Y17H
GFCWNVCVYRNGQRVCHRRCN -- 239 Y5N + V13R + Y17H
GFCWNVCVYRNGRRVCHRRCN 65 240 Y5N + V13T + Y17H
GFCWNVCVYRNGTRVCHRRCN -- 241 Y5N + V13W + Y17H
GFCWNVCVYRNGWRVCHRRCN -- 242 Y5N + V13Y + Y17H
GFCWNVCVYRNGYRVCHRRCN 83 243 Y5N + V15A + Y17H
GFCWNVCVYRNGVRACHRRCN -- 244 Y5N + V15C + Y17H
GFCWNVCVYRNGVRCCHRRCN -- 245 Y5N + V15F + Y17H
GFCWNVCVYRNGVRFCHRRCN 85 246 Y5N + V15G + Y17H
GFCWNVCVYRNGVRGCHRRCN 79 247 Y5N + V15H + Y17H
GFCWNVCVYRNGVRHCHRRCN -- 248 Y5N + V15I + Y17H
GFCWNVCVYRNGVRICHRRCN 58 249 Y5N + V15L + Y17H
GFCWNVCVYRNGVRLCHRRCN 83
250 Y5N + V15M + Y17H GFCWNVCVYRNGVRMCHRRCN -- 251 Y5N + V15N +
Y17H GFCWNVCVYRNGVRNCHRRCN 71 252 Y5N + V15R + Y17H
GFCWNVCVYRNGVRRCHRRCN 76 253 Y5N + V15W + Y17H
GFCWNVCVYRNGVRWCHRRCN 94 254 Y5N + V15Y + Y17H
GFCWNVCVYRNGVRYCHRRCN 77 255 Y5N + V6A + V15N GFCWNACVYRNGVRNCYRRCN
-- 256 Y5N + V6A + V15S GFCWNACVYRNGVRSCYRRCN -- 257 Y5N + V6A +
Y17H GFCWNACVYRNGVRVCHRRCN -- 258 Y5N + V6A + Y9K
GFCWNACVKRNGVRVCYRRCN 89 259 Y5N + V6C + Y17H GFCWNCCVYRNGVRVCHRRCN
-- 260 Y5N + V6F + Y17H GFCWNFCVYRNGVRVCHRRCN 84 261 Y5N + V6H +
Y17H GFCWNHCVYRNGVRVCHRRCN -- 262 Y5N + V61 + Y17H
GFCWNICVYRNGVRVCHRRCN 88 263 Y5N + V6L + Y17H GFCWNLCVYRNGVRVCHRRCN
80 264 Y5N + V6M + Y17H GFCWNMCVYRNGVRVCHRRCN -- 265 Y5N + V6Q +
Y17H GFCWNQCVYRNGVRVCHRRCN -- 266 Y5N + V6T + Y17H
GFCWNTCVYRNGVRVCHRRCN -- 267 Y5N + V6W + Y17H GFCWNWCVYRNGVRVCHRRCN
85 268 Y5N + V6Y + Y17H GFCWNYCVYRNGVRVCHRRCN -- 269 Y5N + V8A +
V13A GFCWNVCAYRNGARVCYRRCN -- 270 Y5N + V8A + V15S
GFCWNVCAYRNGVRSCYRRCN -- 271 Y5N + V8A + Y17H GFCWNVCAYRNGVRVCHRRCN
-- 272 Y5N + V8F + Y17H GFCWNVCFYRNGVRVCHRRCN 74 273 Y5N + V8G +
Y17H GFCWNVCGYRNGVRVCHRRCN -- 274 Y5N + V81 + Y17H
GFCWNVCIYRNGVRVCHRRCN -- 275 Y5N + V8L + Y17H GFCWNVCLYRNGVRVCHRRCN
80 276 Y5N + V8W + Y17H GFCWNVCWYRNGVRVCHRRCN -- 277 Y5N + V8Y +
Y17H GFCWNVCYYRNGVRVCHRRCN -- 278 Y5N + Y17H + N2lA
GFCWNVCVYRNGVRVCHRRCA -- 279 Y5N + Y17H + N21C
GFCWNVCVYRNGVRVCHRRCC -- 280 Y5N + Y17H + N21F
GFCWNVCVYRNGVRVCHRRCF -- 281 Y5N + Y17H + N21G
GFCWNVCVYRNGVRVCHRRCG 66 282 Y5N + Y17H + N21H
GFCWNVCVYRNGVRVCHRRCH 82 283 Y5N + Y17H + N21I
GFCWNVCVYRNGVRVCHRRCI -- 284 Y5N + Y17H + N21K
GFCWNVCVYRNGVRVCHRRCK 72 285 Y5N + Y17H + N21L
GFCWNVCVYRNGVRVCHRRCL -- 286 Y5N + Y17H + N21M
GFCWNVCVYRNGVRVCHRRCM -- 287 Y5N + Y17H + N21P
GFCWNVCVYRNGVRVCHRRCP -- 288 Y5N + Y17H + N21Q
GFCWNVCVYRNGVRVCHRRCQ -- 289 Y5N + Y17H + N21R
GFCWNVCVYRNGVRVCHRRCR 83 290 Y5N + Y17H + N21S
GFCWNVCVYRNGVRVCHRRCS -- 291 Y5N + Y17H + N21W
GFCWNVCVYRNGVRVCHRRCW 99 292 Y5N + Y17H + N21Y
GFCWNVCVYRNGVRVCHRRCY -- 293 Y5N + Y17H + R19D
GFCWNVCVYRNGVRVCHRDCN -- 294 Y5N + Y17H + R19H
GFCWNVCVYRNGVRVCHRHCN -- 295 Y5N + Y17H + R19K
GFCWNVCVYRNGVRVCHRKCN -- 296 Y5N + Y17H + R19M
GFCWNVCVYRNGVRVCHRMCN -- 297 Y5N + Y17H + R191
GFCWNVCVYRNGVRVCHRTCN -- 298 Y5N + Y17H + R19Y
GFCWNVCVYRNGVRVCHRYCN -- 299 Y5N + Y9A + Y17H GFCWNVCVARNGVRVCHRRCN
74 300 Y5N + Y9D + Y17H GFCWNVCVDRNGVRVCHRRCN -- 301 Y5N + Y9F +
Y17H GFCWNVCVFRNGVRVCHRRCN -- 302 Y5N + Y9G + Y17H
GFCWNVCVGRNGVRVCHRRCN -- 303 Y5N + Y9H + Y17H GFCWNVCVHRNGVRVCHRRCN
43 304 Y5N + Y9I + Y17H GFCWNVCVIRNGVRVCHRRCN -- 305 Y5N + Y9K +
Y17H GFCWNVCVKRNGVRVCHRRCN 76 306 Y5N + Y9M + Y17H
GFCWNVCVMRNGVRVCHRRCN -- 307 Y5N + Y9Q + Y17H GFCWNVCVQRNGVRVCHRRCN
-- 308 Y5N + Y9R + Y17H GFCWNVCVRRNGVRVCHRRCN 94 309 Y5N + Y9S +
Y17H GFCWNVCVSRNGVRVCHRRCN -- 310 Y5N + Y9I + Y17H
GFCWNVCVTRNGVRVCHRRCN -- 311 Y5N + Y9V + Y17H GFCWNVCVVRNGVRVCHRRCN
-- 312 Y5N + Y9W + Y17H GFCWNVCVWRNGVRVCHRRCN -- 313 Y5R + V13A +
V15K GFCWRVCVYRNGARKCYRRCN 98 314 Y5R + V13A + Y17S
GFCWRVCVYRNGARVCSRRCN -- 315 Y5R + V15K + Y17H
GFCWRVCVYRNGVRKCHRRCN 93 316 Y5R + V15S + Y17H
GFCWRVCVYRNGVRSCHRRCN 90 317 Y5R + V15S + Y17S
GFCWRVCVYRNGVRSCSRRCN -- 318 Y5R + V6A + G12S GFCWRACVYRNSVRVCYRRCN
-- 319 Y5R + V6A + V15A GFCWRACVYRNGVRACYRRCN 40 320 Y5R + V6A +
V15S GFCWRACVYRNGVRSCYRRCN 88 321 Y5R + V6A + Y17H
GFCWRACVYRNGVRVCHRRCN -- 322 Y5R + V6A + Y9K GFCWRACVKRNGVRVCYRRCN
-- 323 Y5R + V6C + V15S GFCWRCCVYRNGVRSCYRRCN -- 324 Y5R + V6S +
Y17H GFCWRSCVYRNGVRVCHRRCN -- 325 Y5R + V8A + V15S
GFCWRVCAYRNGVRSCYRRCN -- 326 Y5R + V8G + Y17H GFCWRVCGYRNGVRVCHRRCN
-- 327 Y5R + V8H + G12S GFCWRVCHYRNSVRVCYRRCN 98 328 Y5R + V8H +
V13K GFCWRVCHYRNGKRVCYRRCN -- 329 Y5R + V8S + V13A
GFCWRVCSYRNGARVCYRRCN -- 330 Y5R + V8S + V13S GFCWRVCSYRNGSRVCYRRCN
-- 331 Y5R + V8S + V15K GFCWRVCSYRNGVRKCYRRCN 95 332 Y5R + V8S +
Y9R GFCWRVCSRRNGVRVCYRRCN -- 333 Y5R + V8S + Y9S
GFCWRVCSSRNGVRVCYRRCN -- 334 Y5R + Y9R + V13A GFCWRVCVRRNGARVCYRRCN
-- 335 Y5R + Y9R + Y17H GFCWRVCVRRNGVRVCHRRCN 95 336 Y5R + Y9S +
Y17H GFCWRVCVSRNGVRVCHRRCN -- 337 Y5R + Y9S + Y17S
GFCWRVCVSRNGVRVCSRRCN -- 338 V6A + Gl2S + V13K
GFCWYACVYRNSKRVCYRRCN -- 339 V6A + V13A + V15S
GFCWYACVYRNGARSCYRRCN -- 340 V6A + V13K + V15A
GFCWYACVYRNGKRACYRRCN 98 341 V6A + V13K + Y17H
GFCWYACVYRNGKRVCHRRCN -- 342 V6A + V15K + Y17H
GFCWYACVYRNGVRKCHRRCN -- 343 V6A + V8A + V15A GFCWYACAYRNGVRACYRRCN
74 344 V6R + V8H + R10S GFCWYRCHYSNGVRVCYRRCN -- 345 V6S + Y9R +
V15S GFCWYSCVRRNGVRSCYRRCN -- 346 V6T + Y9K + V13L
GFCWYTCVKRNGLRVCYRRCN 86 347 V8A + R10K + Yl7H
GFCWYVCAYKNGVRVCHRRCN -- 348 V8A + V15A + Y17H
GFCWYVCAYRNGVRACHRRCN -- 349 V8A + V15S + Y17H
GFCWYVCAYRNGVRSCHRRCN -- 350 V8A + Y9R + V13A GFCWYVCARRNGARVCYRRCN
-- 351 V8A + Y9R + V15S GFCWYVCARRNGVRSCYRRCN -- 352 V8F + G12H +
Y17H GFCWYVCFYRNHVRVCHRRCN -- 353 Y9F + V15A + Y17H
GFCWYVCVFRNGVRACHRRCN -- 354 Y9K + V13A + Y17S
GFCWYVCVKRNGARVCSRRCN -- 355 Y9R + V15S + Y17S
GFCWYVCVRRNGVRSCSRRCN -- 356 R10K + V13K + V15S
GFCWYVCVYKNGKRSCYRRCN -- 357 V13K + V15A + Y17H
GFCWYVCVYRNGKRACHRRCN -- 358 G1R + Y5N + Nl1H + Y17H
RFCWNVCVYRHGVRVCHRRCN -- 359 G1R + Y5N + Y17H + R19H
RFCWNVCVYRNGVRVCHRHCN 80 360 W4A + V6A + Y9K + V13A
GFCAYACVKRNGARVCYRRCN -- 361 W4A + Y5H + V13A + V15K
GFCAHVCVYRNGARKCYRRCN -- 362 W4A + Y5H + Y9K + V13A
GFCAHVCVKRNGARVCYRRCN 76 363 W4A + Y5R + V8A + Y9K
GFCARVCAKRNGVRVCYRRCN 80 364 W4A + Y5R + Y9K + V15S
GFCARVCVKRNGVRSCYRRCN -- 365 W4A + Y5R + Y9R + V15K
GFCARVCVRRNGVRKCYRRCN -- 366 W4A + Y5R + Y9R + V15S
GFCARVCVRRNGVRSCYRRCN -- 367 W4F + V6A + Y9R + V15S
GFCFYACVRRNGVRSCYRRCN -- 368 W4F + V8A + Y9S + V15S
GFCFYVCASRNGVRSCYRRCN -- 369 W4F + Y5H + V8A + Y17H
GFCFHVCAYRNGVRVCHRRCN -- 370 W4F + Y5H + V8S + V15K
GFCFHVCSYRNGVRKCYRRCN -- 371 W4F + Y5N + V6A + V15S
GFCFNACVYRNGVRSCYRRCN -- 372 W4F + Y5N + V8A + Y9R
GFCFNVCARRNGVRVCYRRCN -- 373 W4F + Y5R + V15K + Y17H
GFCFRVCVYRNGVRKCHRRCN -- 374 W4F + Y5R + V15S + Y17S
GFCFRVCVYRNGVRSCSRRCN -- 375 W4F + Y5R + V6A + Y9K
GFCFRACVKRNGVRVCYRRCN --
376 W4F + Y5R + V6S + V13A GFCFRSCVYRNGARVCYRRCN -- 377 W4F + Y5R +
V6S + Y9R GFCFRSCVRRNGVRVCYRRCN 65 378 W4F + Y5R + V8A + V15K
GFCFRVCAYRNGVRKCYRRCN -- 379 W4F + Y5R + V8A + Y17H
GFCFRVCAYRNGVRVCHRRCN -- 380 W4F + Y5R + V8A + Y9S
GFCFRVCASRNGVRVCYRRCN -- 381 W4F + Y5R + Y9K + V15K
GFCFRVCVKRNGVRKCYRRCN 98 382 W4F + Y9R + V15S + Y17H
GFCFYVCVRRNGVRSCHRRCN -- 383 W4G + Y5H + V15M + N21H
GFCGHVCVYRNGVRMCYRRCH -- 384 W4G + Y5K + Y9R + V13L
GFCGKVCVRRNGLRVCYRRCN -- 385 W4G + Y5R + V13K + V15A
GFCGRVCVYRNGKRACYRRCN -- 386 W4G + Y5R + V13K + V15A
GFCGRVCVYRNGKRACYRRCN 81 387 W4G + Y5R + V13K + V15S
GFCGRVCVYRNGKRSCYRRCN -- 388 W4G + Y5R + Y9R + V15K
GFCGRVCVRRNGVRKCYRRCN -- 389 W4T + Y5R + Y9R + V13L
GFCTRVCVRRNGLRVCYRRCN -- 390 Y5H + R10K + V13K + V15S
GFCWHVCVYKNGKRSCYRRCN 87 391 Y5H + V6A + Y9R + V15S
GFCWHACVRRNGVRSCYRRCN -- 392 Y5H + V8A + V13K + V15A
GFCWHVCAYRNGKRACYRRCN -- 393 Y5H + V8A + Y9K + V13L
GFCWHVCAKRNGLRVCYRRCN -- 394 Y5H + V8A + Y9R + V13A
GFCWHVCARRNGARVCYRRCN 80 395 Y5H + V8A + Y9R + Y17H
GFCWHVCARRNGVRVCHRRCN -- 396 Y5H + V8S + Y9K + V13L
GFCWHVCSKRNGLRVCYRRCN 92 397 Y5H + Y9R + V13A + V15K
GFCWHVCVRRNGARKCYRRCN -- 398 Y5H + Y9R + V13A + V15S
GFCWHVCVRRNGARSCYRRCN -- 399 Y5H + Y9R + V13A + Y17S
GFCWHVCVRRNGARVCSRRCN -- 400 Y5H + Y9S + V13L + V15K
GFCWHVCVSRNGLRKCYRRCN -- 401 Y5K + V6A + R10K + Y17H
GFCWKACVYKNGVRVCHRRCN -- 402 Y5K + V6A + V13A + V15S
GFCWKACVYRNGARSCYRRCN -- 403 Y5K + V6A + V8A + V13A
GFCWKACAYRNGARVCYRRCN -- 404 Y5K + Y9K + V13A + V15K
GFCWKVCVKRNGARKCYRRCN -- 405 Y5K + Y9R + V13A + Y17S
GFCWKVCVRRNGARVCSRRCN -- 406 Y5N + V6A + V8A + V13K
GFCWNACAYRNGKRVCYRRCN -- 407 Y5N + V6A + V8A + Y9R
GFCWNACARRNGVRVCYRRCN 88 408 Y5N + V6A + Y9R + V15S
GFCWNACVRRNGVRSCYRRCN -- 409 Y5N + V6F + N11Y + Y17H
GFCWNFCVYRYGVRVCHRRCN -- 410 Y5N + V8A + N11Q + Y17H
GFCWNVCAYRQGVRVCHRRCN -- 411 Y5N + V8A + V13K + V15A
GFCWNVCAYRNGKRACYRRCN 86 412 Y5N + Y9R + V13A + V15S
GFCWNVCVRRNGARSCYRRCN -- 413 Y5R + Gl2S + V13K + Y17H
GFCWRVCVYRNSKRVCHRRCN -- 414 Y5R + R10K + V13K + Y17H
GFCWRVCVYKNGKRVCHRRCN -- 415 Y5R + V6A + V13K + V15S
GFCWRACVYRNGKRSCYRRCN -- 416 Y5R + V6A + V15A + Y17H
GFCWRACVYRNGVRACHRRCN -- 417 Y5R + V6A + V8A + V13K
GFCWRACAYRNGKRVCYRRCN 95 418 Y5R + V6A + V8A + V15A
GFCWRACAYRNGVRACYRRCN 92 419 Y5R + V6A + V8A + Y17H
GFCWRACAYRNGVRVCHRRCN -- 420 Y5R + V6A + V8A + Y9R
GFCWRACARRNGVRVCYRRCN -- 421 Y5R + V6A + V8H + V15S
GFCWRACHYRNGVRSCYRRCN -- 422 Y5R + V6A + Y9R + V15K
GFCWRACVRRNGVRKCYRRCN -- 423 Y5R + V6S + V13A + V15S
GFCWRSCVYRNGARSCYRRCN -- 424 Y5R + V8A + Gl2S + V15S
GFCWRVCAYRNSVRSCYRRCN -- 425 Y5R + V8A + R10S + V13K
GFCWRVCAYSNGKRVCYRRCN 69 426 Y5R + V8A + V13A + Yl7H
GFCWRVCAYRNGARVCHRRCN -- 427 Y5R + V8A + V13K + V15A
GFCWRVCAYRNGKRACYRRCN -- 428 Y5R + V8A + V13K + Yl7H
GFCWRVCAYRNGKRVCHRRCN -- 429 Y5R + V8A + V15A + Yl7H
GFCWRVCAYRNGVRACHRRCN -- 430 Y5R + V8A + V15S + Y17H
GFCWRVCAYRNGVRSCHRRCN -- 431 Y5R + V8A + Y9K + V15K
GFCWRVCAKRNGVRKCYRRCN -- 432 Y5R + V8A + Y9K + V15S
GFCWRVCAKRNGVRSCYRRCN -- 433 Y5R + V8A + Y9K + Y17H
GFCWRVCAKRNGVRVCHRRCN -- 434 Y5R + V8A + Y9R + V15S
GFCWRVCARRNGVRSCYRRCN -- 435 Y5R + V8A + Y9S + V13L
GFCWRVCASRNGLRVCYRRCN 85 436 Y5R + V8G + Gl2S + V13K
GFCWRVCGYRNSKRVCYRRCN -- 437 Y5R + V8H + Gl2S + V13K
GFCWRVCHYRNSKRVCYRRCN -- 438 Y5R + V8H + R10K + V13K
GFCWRVCHYKNGKRVCYRRCN -- 439 Y5R + V8H + R10S + V13K
GFCWRVCHYSNGKRVCYRRCN 92 440 Y5R + V8S + Y9K + V15K
GFCWRVCSKRNGVRKCYRRCN -- 441 Y5R + Y9K + V13A + V15K
GFCWRVCVKRNGARKCYRRCN -- 442 Y5R + Y9K + V15S + Y17S
GFCWRVCVKRNGVRSCSRRCN -- 443 Y5R + Y9R + V13A + V15K
GFCWRVCVRRNGARKCYRRCN -- 444 Y5R + Y9R + V13A + V15S
GFCWRVCVRRNGARSCYRRCN -- 445 Y5R + Y9R + V13L + V15K
GFCWRVCVRRNGLRKCYRRCN -- 446 Y5R + Y9R + V13L + Y17H
GFCWRVCVRRNGLRVCHRRCN -- 447 Y5R + Y9R + V15S + Y17S
GFCWRVCVRRNGVRSCSRRCN -- 448 Y5R + Y9R + Y17S + R19H
GFCWRVCVRRNGVRVCSRHCN -- 449 Y5R + Y9S + V13A + Y17S
GFCWRVCVSRNGARVCSRRCN -- 450 V6A + V8A + Y9K + V13L
GFCWYACAKRNGLRVCYRRCN 98 451 V6A + Y9S + V13L + V15S
GFCWYACVSRNGLRSCYRRCN -- 452 V8A + R10S + V15S + Y17H
GFCWYVCAYSNGVRSCHRRCN -- 453 V8A + Y9R + V13L + V15S
GFCWYVCARRNGLRSCYRRCN 92 454 Y9K + V13A + V15K + Y17H
GFCWYVCVKRNGARKCHRRCN 90 455 W4A + Y5R + Y9K + V13A + V15K
GFCARVCVKRNGARKCYRRCN -- 456 W4A + Y5R + Y9K + V13A + Y17H
GFCARVCVKRNGARVCHRRCN -- 457 W4A + Y5R + Y9S + V13L + V15K
GFCARVCVSRNGLRKCYRRCN -- 458 W4A + Y9S + V13A + V15S + Y17H
GFCAYVCVSRNGARSCHRRCN -- 459 W4F + Y5H + V8A + Y9R + V15K
GFCFHVCARRNGVRKCYRRCN -- 460 W4F + Y5H + V8A + Y9R + Y17H
GFCFHVCARRNGVRVCHRRCN -- 461 W4F + Y5H + Y9K + V15K + Y17S
GFCFHVCVKRNGVRKCSRRCN -- 462 W4F + Y5K + V8S + V13L + V15K
GFCFKVCSYRNGLRKCYRRCN -- 463 W4F + Y5K + V8S + Y9K + V15K
GFCFKVCSKRNGVRKCYRRCN -- 464 W4F + Y5N + V8A + Y9R + Y17S
GFCFNVCARRNGVRVCSRRCN -- 465 W4F + Y5R + V13A + V15K + Y17S
GFCFRVCVYRNGARKCSRRCN -- 466 W4F + Y5R + V6A + V8A + Y17H
GFCFRACAYRNGVRVCHRRCN -- 467 W4F + Y5R + V6A + V8T + Y9S
GFCFRACTSRNGVRVCYRRCN -- 468 W4F + Y5R + V6A + Y9K + V13A
GFCFRACVKRNGARVCYRRCN -- 469 W4F + Y5R + V6A + Y9R + Y17H
GFCFRACVRRNGVRVCHRRCN -- 470 W4F + Y5R + V6A + Y9S + V15S
GFCFRACVSRNGVRSCYRRCN -- 471 W4F + Y5R + V6S + V8A + Y9R
GFCFRSCARRNGVRVCYRRCN -- 472 W4F + Y5R + V6S + V8A + Y9S
GFCFRSCASRNGVRVCYRRCN -- 473 W4F + Y5R + V8A + V13A + V15S
GFCFRVCAYRNGARSCYRRCN -- 474 W4F + Y5R + V8A + V13A + Y17H
GFCFRVCAYRNGARVCHRRCN -- 475 W4F + Y5R + V8A + V13A + Y17S
GFCFRVCAYRNGARVCSRRCN -- 476 W4F + Y5R + V8A + V15K + Y17H
GFCFRVCAYRNGVRKCHRRCN -- 477 W4F + Y5R + V8A + Y9K + V13A
GFCFRVCAKRNGARVCYRRCN -- 478 W4F + Y5R + V8A + Y9K + V15K
GFCFRVCAKRNGVRKCYRRCN -- 479 W4F + Y5R + V8A + Y9K + Y17H
GFCFRVCAKRNGVRVCHRRCN -- 480 W4F + Y5R + V8A + Y9S + V15K
GFCFRVCASRNGVRKCYRRCN -- 481 W4F + Y5R + V8S + V13A + V15S
GFCFRVCSYRNGARSCYRRCN -- 482 W4F + Y5R + V8S + V13L + V15K
GFCFRVCSYRNGLRKCYRRCN -- 483 W4F + Y5R + V8S + Y9K + V13A
GFCFRVCSKRNGARVCYRRCN -- 484 W4F + Y5R + V8S + Y9K + Y17H
GFCFRVCSKRNGVRVCHRRCN -- 485 W4F + Y5R + V8S + Y9R + V13L
GFCFRVCSRRNGLRVCYRRCN -- 486 W4F + Y5R + V8S + Y9S + V13A
GFCFRVCSSRNGARVCYRRCN -- 487 W4F + Y5R + V8S + Y9S + V15K
GFCFRVCSSRNGVRKCYRRCN -- 488 W4F + Y5R + Y9K + V13A + V15S
GFCFRVCVKRNGARSCYRRCN -- 489 W4F + Y5R + Y9R + V15K + Y17S
GFCFRVCVRRNGVRKCSRRCN -- 490 W4F + Y9S + V13A + V15K + Y17H
GFCFYVCVSRNGARKCHRRCN -- 491 W4G + Y5K + Y9K + V13L + V15K
GFCGKVCVKRNGLRKCYRRCN -- 492 W4G + Y5R + Gl2S + V13K + V15S
GFCGRVCVYRNSKRSCYRRCN -- 493 W4G + Y5R + R10K + V13K + V15A
GFCGRVCVYKNGKRACYRRCN 77 494 W4S + V6S + V8A + V13S + V15S
GFCSYSCAYRNGSRSCYRRCN -- 495 W4S + Y5N + V6S + Y9K + Y17S
GFCSNSCVKRNGVRVCSRRCN -- 496 W4I + Y5N + V8A + Y9K + V13A
GFCTNVCAKRNGARVCYRRCN -- 497 Y5H + V6A + Y9R + V13A + V15S
GFCWHACVRRNGARSCYRRCN -- 498 Y5H + V6A + Y9R + V13L + V15K
GFCWHACVRRNGLRKCYRRCN -- 499 Y5H + V6A + Y9R + V13L + Y17H
GFCWHACVRRNGLRVCHRRCN -- 500 Y5H + V8A + R10K + V15A + Y17H
GFCWHVCAYKNGVRACHRRCN --
501 Y5H + V8A + Y9R + V13L + Y17S GFCWHVCARRNGLRVCSRRCN -- 502 Y5K
+ V6R + V13L + V15K + Y17H GFCWKRCVYRNGLRKCHRRCN -- 503 Y5K + V6S +
Y9R + V13L + V15S GFCWKSCVRRNGLRSCYRRCN -- 504 Y5K + V8A + Y9R +
V13A + V15S GFCWKVCARRNGARSCYRRCN 95 505 Y5K + V8S + Y9S + V13L +
V15S GFCWKVCSSRNGLRSCYRRCN -- 506 Y5K + Y9S + V13A + V15K + Y17S
GFCWKVCVSRNGARKCSRRCN -- 507 Y5N + V8A + Y9R + V13L + Y17H
GFCWNVCARRNGLRVCHRRCN -- 508 Y5N + Y9R + V13L + V15K + Y17H
GFCWNVCVRRNGLRKCHRRCN -- 509 Y5R + R10S + V13K + V15S + Y17H
GFCWRVCVYSNGKRSCHRRCN 87 510 Y5R + V6A + R10K + G12S + V13K
GFCWRACVYKNSKRVCYRRCN -- 511 Y5R + V6A + R10K + V15A + Y17H
GFCWRACVYKNGVRACHRRCN -- 512 Y5R + V6A + V8A + V13K + V15A
GFCWRACAYRNGKRACYRRCN -- 513 Y5R + V6A + V8A + V13K + V15S
GFCWRACAYRNGKRSCYRRCN -- 514 Y5R + V6A + V8A + Y95 + Yl7H
GFCWRACASRNGVRVCHRRCN -- 515 Y5R + V6A + V8S + Y9R + V13L
GFCWRACSRRNGLRVCYRRCN -- 516 Y5R + V6A + Y9K + V13A + Y17S
GFCWRACVKRNGARVCSRRCN -- 517 Y5R + V6A + Y9K + V13L + V15S
GFCWRACVKRNGLRSCYRRCN -- 518 Y5R + V6A + Y9R + V13A + V15S
GFCWRACVRRNGARSCYRRCN -- 519 Y5R + V6A + Y9R + V13L + V15S
GFCWRACVRRNGLRSCYRRCN -- 520 Y5R + V6A + Y9S + V13A + V15S
GFCWRACVSRNGARSCYRRCN -- 521 Y5R + V6A + Y9S + V13L + Y17S
GFCWRACVSRNGLRVCSRRCN -- 522 Y5R + V6R + Y9R + V13A + V15S
GFCWRRCVRRNGARSCYRRCN -- 523 Y5R + V8A + R10K + V13K + V15S
GFCWRVCAYKNGKRSCYRRCN 90 524 Y5R + V8A + Y9R + V13L + Y17H
GFCWRVCARRNGLRVCHRRCN -- 525 Y5R + V8A + Y9S + V13A + Y17S
GFCWRVCASRNGARVCSRRCN -- 526 Y5R + V8G + R10K + V15A + Y17H
GFCWRVCGYKNGVRACHRRCN -- 527 Y5R + V8G + V13K + V15A + Y17H
GFCWRVCGYRNGKRACHRRCN -- 528 Y5R + V8S + R10S + G12S + V13K
GFCWRVCSYSNSKRVCYRRCN -- 529 Y5R + V8S + Y9R + V13L + V15S
GFCWRVCSRRNGLRSCYRRCN -- 530 Y5R + Y9R + V13L + V15S + Y17S
GFCWRVCVRRNGLRSCSRRCN -- 531 Y5R + Y9S + V13A + V15K + Y17S
GFCWRVCVSRNGARKCSRRCN -- 532 Y5R + Y9S + V13L + V15S + Y17S
GFCWRVCVSRNGLRSCSRRCN -- 533 F2L + Y5R + V8A + R10S + V13K + V15A
GLCWRVCAYSNGKRACYRRCN -- 534 W4F + Y5N + Y9S + V13A + V15K + Y17H
GFCFNVCVSRNGARKCHRRCN -- 535 W4F + Y5R + V6A + V8A + Y9R + V15S
GFCFRACARRNGVRSCYRRCN -- 536 W4F + Y5R + V6A + V8S + Y9K + V13L
GFCFRACSKRNGLRVCYRRCN -- 537 W4F + Y5R + V6A + Y9K + V13L + V15K
GFCFRACVKRNGLRKCYRRCN -- 538 W4F + Y5R + V6A + Y9K + V13L + Y17H
GFCFRACVKRNGLRVCHRRCN -- 539 W4F + Y5R + V8A + Y9K + V13A + V15S
GFCFRVCAKRNGARSCYRRCN -- 540 W4F + Y5R + V8A + Y9S + V15K + Y17H
GFCFRVCASRNGVRKCHRRCN -- 541 W4F + Y5R + V8S + Y9K + V13A + V15K
GFCFRVCSKRNGARKCYRRCN -- 542 W4G + Y5H + V6R + V8S + Y9R + V15K
GFCGHRCSRRNGVRKCYRRCN -- 543 W45 + Y5H + V6R + V8S + G12S + V15A
GFCSHRCSYRNSVRACYRRCN -- 544 W45 + Y5R + V8S + V13S + V15A + Yl7H
GFCSRVCSYRNGSRACHRRCN -- 545 Y5R + V6A + V8A + Y9S + V13L + Y17S
GFCWRACASRNGLRVCSRRCN -- 546 W45 + Y5N + V6R + V8H + R10S + V13S +
GFCSNRCHYSNGSRACHRRCN -- V15A + Y17H 547 Y5G + V6A + C7V + V8N +
R101 + N11S + GFCWGAVNYTSNCRACKRRCN -- Gl2N + V13C + V15A + Y17K
548 F2S + Y5G + V6A + C7V + V8N + R101 + GSCWGAVNYTSNCRACKRRCN --
N11S + Gl2N + V13C + V15A + Y17K The symbol "--" means "not
analyzed".
Example 2
Efficacy of NZ17074 Against Escherichia coli AID#172 in the
Neutropenic Murine Peritonitis/Sepsis Model and Estimation of
ED50
Introduction
[0269] The purpose of this study was to investigate the
dose-response relationship following intravenous (i.v.)
administration of a single dose of NZ17074 ranging from 0.16-12
mg/kg. The effect was tested against E. coli AID#172 in the
neutropenic peritonitis model. Treatment with 40 mg/kg meropenem
was included as a positive control group. The colony counts in
blood and peritoneal fluid were determined at 5 hours after
treatment.
[0270] The murine peritonitis/sepsis model is a well-recognized
model for studies of antimicrobial activity as described by N.
Frimodt-Moller and J. D. Knudsen in Handbook of Animal Models of
Infection (1999), ed. by O. Zak & M. A. Sande, Academic Press,
San Diego, US.
Materials and Methods
[0271] 30 outbred, NMRI female mice, 25-30 grams (Harlan
Scandinavia) [0272] E. coli AID#172 from Statens Serum Institute,
Copenhagen, Denmark. Clinical isolate from a human wound from 2003.
Multiresistant (Ampicillin, Ceftazidime, Aztreonam, Gentamicin,
Ciprofloxacin) [0273] NZ17074 in Ringer Acetate, pH 6: 1.2 mg/ml,
6.0 ml. The solution was stored at 4.degree. C. until use. Analyses
of the dose formulations used were performed after completion of
the in-life phase of the study and gave the following results:
TABLE-US-00003 [0273] Intended concentration Measured concentration
1.2 mg/ml 1.11 mg/ml 0.6 mg/ml 0.51 mg/ml 0.3 mg/ml 0.24 mg/ml 0.15
mg/ml 0.14 mg/ml 0.075 mg/ml 0.043 mg/ml 0.03 mg/ml 0.010 mg/ml
0.016 mg/ml 0.002 mg/ml
[0274] Vehicle (Ringer Acetate pH 6). The solution was stored at
4.degree. C. until use [0275] MERONEM.RTM. (AstraZeneca, 500 mg
infusion substance, meropenem). Lot no. 09466C [0276] Date of
expire: August 2013 [0277] Water, sterile [0278] 0.9% saline,
sterile [0279] Cyclophosphamide, APODAN.RTM. (A-Pharma, 1 g) Batch
nr. 928491 Date of expire: May 2012 [0280] 5% Horse Blood Agar
plates [0281] Lactose bromthymol blue agar plates
Laboratory Animal Facilities and Housing of Mice
[0282] The temperature and humidity were registered daily in the
animal facilities. The temperature was 21+/-2.degree. C. and can be
regulated by heating and cooling. The humidity was 55+/-10%. The
air changes per hour were approximately 10-20 times, and light/dark
period was in 12-hours interval of 6 a.m.-6 p.m./6 p.m-6 a.m.
[0283] The mice had free access to domestic quality drinking water
and food (2016, Harlan). The mice were housed in Type 3 macrolone
cages with 3 mice/cage. The bedding was Aspen Wood from Tapvei.
Further the animals were offered paper strands from Sizzle-nest as
nesting material. Mice were marked on the tail for individual
identification within the cage. Mice were weighed the day before
dosing.
Preparation of NZ17074 Solutions
[0284] The solution of 1.2 mg/ml was further diluted in PBS vehicle
as follows:
0.6 mg/ml.about.7.5 mg/kg: 1.5 ml of 1.2 mg/ml NZ17074+1.5 ml
vehicle 0.3 mg/ml.about.5.0 mg/kg: 1.5 ml of 0.6 mg/ml NZ17074+1.5
ml vehicle 0.15 mg/ml.about.2.5 mg/kg: 1.5 ml of 0.3 mg/ml
NZ17074+1.5 ml vehicle 0.075 mg/ml.about.1.25 mg/kg: 1.5 ml of 0.15
mg/ml NZ17074+1.5 ml vehicle 0.03 mg/ml.about.0.63 mg/kg: 1.5 ml of
0.075 mg/ml NZ17074+2.25 ml vehicle 0.016 mg/ml.about.0.16 mg/kg:
1.5 ml of 0.03 mg/ml NZ17074+1.5 ml vehicle
Preparation Meropenem Solution
[0285] Treatment with meropenem 40 mg/kg was included as a positive
control group. A total of 500 mg meropenem (one ampoule) was
dissolved in 10 ml water .about.50 mg/ml This stock solution was
further diluted to 4 mg/ml (0.4 ml 50 mg/ml+4.6 ml saline).
Preparation of Cyclophosphamide
[0286] A total of 1 g cyclophosphamide (one ampoule APODAN.RTM.
(A-Pharma, 1 g) 1 g) was dissolved in 50 ml water.about.20 mg/ml on
each day of use. This stock solution was further diluted to 11
mg/ml (16.5 ml 20 mg/ml+13.5 ml saline) for use on day -4 or to 5
mg/kg (8.25 ml 20 mg/ml+21.75 ml saline)) for use on day -1.
Treatment of Mice with Cyclophosphamide
[0287] The mice were rendered neutropenic by injecting 0.5 ml
cyclophosphamide solution intraperitoneally 4 days (200 mg/kg) and
1 day (100 mg/kg) prior to inoculation.
Inoculation of Mice
[0288] Fresh overnight E. coli AID#172 colonies from a 5% Horse
Blood Agar plate were suspended and diluted in sterile saline to
approximately 2.times.10.sup.6CFU/ml. One hour before start of
treatment (time -1 hr) mice were inoculated intraperitoneally with
0.5 ml of the E. coli suspension in the lateral lower quadrant of
the abdomen. Approximately 1/2-1 hour after treatment, mice were
treated orally with 45 microliters neurophen (20 mg ibuprofen/ml
corresponding to 30 mg/kg) as a pain relief.
Treatment of Mice
[0289] The mice were treated i.v. in the lateral tail vein over
approximately 30 seconds with 10 ml/kg with a single dose of
NZ17074, meropenem or vehicle at time 0 hour (see Table 1). The
dosing was based on a mean weight of 30 g. Mice that weighed 28-32
g received 0.30 ml solution. Mice that weighed 27-28 g received
0.25 ml solution and mice that weighed 32.1-36 g received 0.35 ml
solution.
TABLE-US-00004 TABLE 1 Treatment and sampling schedule in the
murine peritonitis model. Inoculation Sampling and mouse no. i.p.
at - 1 hr Intravenous treatment at 0 hr 0 hour 5 hours 0.5 ml of
Vehicle, Ringer acetate 1-2-3 E. coli NZ17074 0.16 mg/kg 4-5-6
AID#172 NZ17074 0.30 mg/kg 7-8-9 1 .times. 10.sup.6 NZ17074 0.75
mg/kg 10-11-12 CFU/ml NZ17074 1.5 mg/kg 13-14-15 NZ17074 3.0 mg/kg
16-17-18 NZ17074 6.0 mg/kg 19-20-21 NZ17074 12 mg/kg 22-23-24
meropenem 40 mg/kg 25-26-27 No treatment 28-29-30 T indicates the
time in relation to treatment. Numbers in the sampling columns are
mouse identification numbers.
Clinical Scoring of Mice
[0290] The mice were observed during the study and scored 0-5 based
on their behaviour and clinical signs. [0291] Score 0: Healthy.
[0292] Score 1: Minor clinical signs of infection and inflammation
e.g. observations of minor signs of distress or changed activity.
[0293] Score 2: Clear signs of infection like, social withdrawal,
lack of curiosity, changed body position, piloerection, or changes
in pattern of movement. [0294] Score 3: Severe signs of infection
like stiff movements, lack of curiosity, changed body position,
piloerection, pain, or changes in pattern of movement. [0295] Score
4: Severe pain and the mouse was sacrificed immediately to minimize
the suffering of the animal. [0296] Score 5: The mouse was
dead.
Sampling
[0297] Colony counts were determined from blood and peritoneal
fluid at 0 and 5 hours. The mice were anaesthetized with
CO.sub.2+O.sub.2 and blood was collected from axillary cutdown in
1.5 ml EDTA coated eppendorf tubes. The mice were sacrificed
immediately after blood sampling and a total of 2 ml sterile saline
was injected i.p. and the abdomen gently massaged before it was
opened and fluid sampled with a pipette. Each sample was then 10
fold diluted in saline and 20-microliter spots were applied on blue
agar plates. All agar plates were incubated 18-22 hours at
35.degree. C. in ambient air.
Results
[0298] The colony counts were performed at the start of treatment
and 5 hours after treatment. The CFU counts and the clinical score
of the mice are shown in Table 3. The CFU numbers are log.sub.10
transformed before performing calculations.
[0299] The CFU/ml in the inoculum was determined to 6.29
log.sub.10. At start of treatment the mean log.sub.10 CFU/ml in
peritoneal fluid was 5.76 and in blood 5.13 and the CFU levels
remained at a similar level in the vehicle group (5.72 and 4.65
log.sub.10 CFU/ml in the peritoneum and blood respectively) at 5
hours after treatment. Slightly lower CFU levels were observed in
blood and peritoneal fluid after treatment with NZ17074 0.16-3.0
mg/kg. Treatment with 6 and 12 mg/kg NZ17074 resulted in CFU levels
significantly lower (p<0.001) than after vehicle treatment both
in peritoneal fluid and in blood (Table 3). Also the meropenem
treatment, 40 mg/kg, resulted in significant reduction compared to
the vehicle treated mice both in blood (p<0.05) and peritoneal
fluid (p<0.01).
[0300] The dose-response curves (data not shown) were calculated in
GraphPad Prism using Sigmoidal dose-response (variable slope). From
these ED50 values were determined to 3.09.+-.2.07 mg/kg in
peritoneal fluid and 3.17.+-.0.53 mg/kg in blood.
[0301] The maximum effect of NZ17074, E.sub.max, was defined as the
log CFU difference between no response and maximum response. No
response was characterised as colony counts at the same level as
determined for vehicle treated mice. The E.sub.max was calculated
as the difference between the "Top plateau" and "Bottom plateau" in
GraphPad Prism using Sigmoidal dose-response to be 4.72 log.sub.10
CFU for the peritoneal fluid and 3.15 log.sub.10 CFU for the
blood.
[0302] In addition the 1, 2 and 3 log killing, defined as the dose
required to obtain 1, 2 or 3 log reduction in bacterial loads
compared to start of treatment, were estimated using GraphPad
Prism. The 1, 2 and 3 log killing of NZ17074 was 1.11 mg/kg, 2.95
mg/kg and 4.73 mg/kg respectively in peritoneal fluid and 0.25
mg/kg, 2.75 mg/kg and 3.78 mg/kg respectively in blood.
[0303] No or only mild clinical score was observed in all of the
treatment groups (Table 3).
Discussion and Conclusion
[0304] The purpose of this study was to investigate the
dose-response relationship following intravenous (i.v.)
administration of a single dose of NZ17074 ranging from 0.16-12
mg/kg. The effect was tested against E. coli AID#172 in the
neutropenic peritonitis/sepsis model.
[0305] The ED50 values for NZ17074 were determined to 3.09.+-.2.07
mg/kg in the peritoneal fluid and 3.17.+-.0.53 mg/kg in the blood.
The 1 log killing was estimated to be 1.11 mg/kg in the peritoneal
fluid and 0.25 mg/kg in the blood. The 2 log killing was estimated
to be 2.95 mg/kg in the peritoneal fluid and 2.76 mg/kg in the
blood. The 3 log killing was estimated to be 4.73 mg/kg in the
peritoneal fluid and 3.78 mg/kg in the blood.
TABLE-US-00005 TABLE 2 Efficacy values for NZ17074 against E. coli
AID#172 calculated in Graph Pad Prism. NZ17074 Peritoneal fluid
Blood TOP 0.325 CFU/ml -0.985 CFU/ml BOTTOM -4.486 CFU/ml -4.138
CFU/ml Emax 4.811 CFU/ml 3.153 CFU/ml ED50 3.086 mg/kg 3.168 mg/kg
R.sup.2 0.7524 0.6889 1 log killing 1.11 mg/kg 0.25 mg/kg 2 log
killing 2.95 mg/kg 2.76 mg/kg 3 log killing 4.73 mg/kg 3.78
mg/kg
TABLE-US-00006 TABLE 3 Colony counts of E. coli AID#172 in blood
and peritoneal fluid from neutropenic mice treated with a single
dose of NZ17074, meropenem or vehicle. Clinical score log.sub.10
CFU Treatment Mouse T = 0 T = 5 mean mean T = 0 hour no. Time hour
hours PF PF Blood Blood Vehicle 1 T = 5 1 1 5.74 5.72 5.05 4.65 2 T
= 5 1 0 5.54 4.78 3 T = 5 1 1 5.88 4.11 NZ17074 4 T = 5 1 1 5.16
5.31 4.27 4.54 0.16 mg/kg 5 T = 5 1 1 4.78 4.19 6 T = 5 1 0 5.98
5.18 NZ17074 7 T = 5 1 0 2.76 4.28 1.40 2.88 0.30 mg/kg 8 T = 5 1 1
5.74 4.63 9 T = 5 1 0 4.27 2.60 NZ17074 10 T = 5 1 0 5.74 5.16 5.07
4.46 0.75 mg/kg 11 T = 5 1 1 4.95 4.30 12 T = 5 1 1 4.78 4.00
NZ17074 13 T = 5 1 0 3.33 4.41 3.51 3.99 1.5 mg/kg 14 T = 5 1 1
4.72 3.92 15 T = 5 1 0 5.18 4.54 NZ17074 18 T = 5 1 1 4.74 3.91
3.86 2.81 3.0 mg/kg 17 T = 5 1 1 4.74 3.57 18 T = 5 1 0 2.24 1.00
NZ17074 19 T = 5 1 1 2.18 2.12*** 1.00 1.00*** 8.0 mg/kg 20 T = 5 1
1 2.18 1.00 21 T = 5 1 1 2.00 1.00 NZ17074 22 T = 5 1 1 1.00
1.36*** 1.00 1.00*** 12 mg/kg 23 T = 5 1 0 1.69 1.00 24 T = 5 1 0
1.40 1.00 Meropenem 25 T = 5 1 1 3.92 2.64** 2.48 2.38* 40 mg/kg 28
T = 5 1 1 1.70 1.70 27 T = 5 1 0 2.30 2.95 28 T = 0 1 5.84 5.78
5.08 None 29 T = 0 1 5.78 4.98 5.13 30 T = 0 1 5.65 5.34 Stars
indicate significantly different from vehicle group (Anova;
multiple comparison). *corresponds to p < 0.05; **corresponds to
p < 0.01; ***corresponds to p < 0.001. Detection limit 1.4
log.sub.10 CFU/ml. Samples with no detectable bacteria is presented
as 1.0 log.sub.10 CFU/ml.
Example 3
Peritonitis/Sepsis Model: Effect Over Time of 7.5 Mg/Kg NZ17074
Against Escherichia coli AID#172 in Neutropenic NMRI Mice
Introduction
[0306] The purpose of this study was to investigate the in vivo
efficacy of NZ17074 following intravenous (i.v.) administration of
a single dose of 7.5 mg/kg. The effect was tested against
Escherichia coli AID#172 in the peritonitis model in neutropenic
NMRI mice to avoid the use of mucin as normally applied in the
murine peritonitis model. The mice were rendered neutropenic by
cyclophosphamide injections. Treatment with 40 mg/kg meropenem was
included as a positive control group and treatment with vehicle was
included as a negative control group. The colony counts in
peritoneal fluid and blood were determined at 2 and 5 hours after
treatment.
Materials and Methods
[0307] 30 outbred, NMRI female mice, 28-32 grams (Harlan
Scandinavia) [0308] Escherichia coli AID#172 from Statens Serum
Institute, Copenhagen, Denmark. Clinical isolate from a human wound
from 2003. Multiresistant (Ampicillin, Ceftazidime, Aztreonam,
Gentamicin, Ciprofloxacin) [0309] NZ17074 in Ringer Acetate pH 6,
1.2 ml 0.75 mg/ml. Analyses of the dose formulation performed after
the study showed a concentration of approx. 0.78 mg/ml. [0310]
Vehicle (Ringer Acetate pH 6) 3 ml. [0311] MERONEM.RTM.
(AstraZeneca, 500 mg meropenem infusion substance). Lot no. 09466C
[0312] Date of expiration: August 2013 [0313] APODAN.RTM.
(A-Pharma, 1 g cyclophosphamide) Batch nr. 928491 [0314] Date of
expiration: May 2012 [0315] Water, sterile [0316] 0.9% saline,
sterile [0317] 5% Horse Blood Agar plates [0318] Lactose bromthymol
blue agar plates
Laboratory Animal Facilities and Housing of Mice
[0319] The temperature and humidity were registered daily in the
animal facilities. The temperature was 21+/-2.degree. C. and can be
regulated by heating and cooling. The humidity was 55+/-10%. The
air changes per hour were approximately 10-20 times, and light/dark
period was in 12-hours interval of 6 a.m.-6 p.m./6 p.m.-6 a.m. The
mice had free access to domestic quality drinking water and food
(2016, Harlan). The mice were housed in Type 3 macrolone cages with
3 mice/cage. The bedding was Aspen Wood from Tapvei. Further the
animals were offered paper strands from Sizzle-nest as nesting
material. Mice were marked on the tail for individual
identification within the cage.
NZ17074 Solution
[0320] A solution of 0.75 mg/ml of each test compound was stored at
+4.degree. C. until one hour before injection, thereafter at room
temperature.
Preparation of Meropenem Solution
[0321] A total of 500 mg meropenem (one ampoule) was dissolved in
10 ml water.about.50 mg/ml the day of use. This stock solution was
further diluted to 4 mg/ml (0.4 ml 50 mg/ml+4.6 ml saline).
Preparation of Cyclophosphamide
[0322] A total of 1 g cyclophosphamide (one ampoule APODAN.RTM.
(A-Pharma)) was dissolved in 50 ml water.about.20 mg/ml on each day
of use. This stock solution was further diluted to 11 mg/ml (16.5
ml of 20 mg/ml+13.5 ml saline) for use on day -4 or to 5.5 mg/ml
(8.25 ml of 20 mg/ml+21.75 ml saline) for use on day -1.
Treatment of Mice with Cyclophosphamide
[0323] The mice were rendered neutropenic by injecting 0.5 ml
cyclophosphamide solution intraperitoneally 4 days (200 mg/kg) and
1 day (100 mg/kg) prior to inoculation.
Inoculation of Mice
[0324] Fresh overnight E. coli AID#172 colonies from a 5% Horse
Blood Agar plate were suspended and diluted in sterile saline to
approximately 2.times.10.sup.6CFU/ml.
[0325] One hour before start of treatment (time -1 hour) mice were
inoculated intraperitoneally with 0.5 ml of the E. coli suspension
in the lateral lower quadrant of the abdomen.
[0326] 2.5 hours after treatment, when clinical signs of infection
were significant, mice were treated orally with 45 microliters
neurophen (20 mg ibuprofen/ml, corresponding to 30 mg/kg) as a pain
relief.
Scoring of Mice
[0327] The mice were clinically scored for signs of infection at
the time of each sampling. [0328] Score 0: Healthy. [0329] Score 1:
Minor clinical signs of infection and inflammation e.g.
observations of minor signs of distress or changed activity. [0330]
Score 2: Clear signs of infection like, social withdrawal, lack of
curiosity, changed body position, piloerection, or changes in
pattern of movement. [0331] Score 3: Severe signs of infection like
stiff movements, lack of curiosity, forced ventilation, changed
body position, piloerection, pain, or changes in pattern movement.
[0332] Score 4: Severe pain and the mouse was sacrificed
immediately to minimize the suffering of the animal. [0333] Score
5: The mouse was dead.
Treatment of Mice
[0334] The mice were treated i.v. in the lateral tail vein over
approximately 30 seconds with a single dose of NZ17074, meropenem
or vehicle at time 0 hour (see Table 1). The dosing was based on a
mean weight of 30 g. Mice that weighed 28-32 g received 0.30 ml
solution. Mice that weighed 27-28 g received 0.25 ml solution and
mice that weighed 32.1-36 g received 0.35 ml solution. Mouse 17
accidently received 0.35 ml although it weighed 29.5 g. This does
not seem to have influenced the results as the CFU levels in this
mouse was very similar to the other two mice in the group.
TABLE-US-00007 TABLE 4 Treatment and sampling schedule in the
murine peritonitis model. Inoculation Treatment Sampling Sampling
Sampling T = -1 hour T = 0 hour T = 0 hour T = 2 hours T = 5 hours
0.5 ml of NZ17074 4, 5, 6 E. coli Meropenem 7, 8, 9 AID#172 Vehicle
10, 11, 12 10.sup.6 CFU/ml (Ringer Acetate) NZ17074 16, 17, 18
Meropenem 19, 20, 21 Vehicle 22, 23, 24 (Ringer Acetate) None 25,
26, 27 None 28, 29, 30 T indicates the time in relation to
treatment. Numbers in the sampling columns are mouse identification
numbers.
Sampling
[0335] Colony counts were determined from blood and peritoneal
fluid at 0, 2 and 5 hours after treatment according to Table 1.
[0336] The mice were anesthetized with O.sub.2+CO.sub.2 and blood
was collected by axilliary cut down. The mice were sacrificed by
cervical dislocation and a total of 2 ml sterile saline was
injected i.p. and the abdomen gently massaged before it was opened
and fluid sampled with a pipette. Each sample was 10 fold diluted
in saline and 20-microliter spots were applied on blood agar
plates. All agar plates were incubated 18-22 hours at 35.degree. C.
in ambient air.
Results
[0337] The colony counts and the clinical scores of the mice are
shown in Table 2. The CFU numbers are log.sub.10 transformed before
performing calculations to obtain a normal distribution.
[0338] The CFU/ml in the inoculum was determined to 6.30
log.sub.10. At start of treatment the mean log.sub.10 CFU/ml in the
peritoneal fluid was 3.57 and in the blood 3.54 and the CFU level
increased to 5.43 and 4.58 in the peritoneal fluid and the blood
respectively after 2 hours in vehicle treated animals and to 5.72
and 4.74 in the peritoneal fluid and the blood respectively after 5
hours in vehicle treated mice, which was as expected.
[0339] At 2 hours after treatment with NZ17074 significantly lower
CFU levels were observed both in the blood and the peritoneal fluid
compared to the vehicle treatment (p<0.001).
[0340] A further reduction of the CFU levels was observed at 5
hours after treatment with NZ17074 both in the blood and in the
peritoneal fluid (p<0.001 compared to vehicle control). The CFU
levels were more the 3 log.sub.10 CFU/ml lower than after vehicle
treatment.
[0341] Also meropenem treatment resulted in significantly
(p<0.01) reduced CFU levels compared to vehicle treatment in the
peritoneal fluid at both 2 and 5 hours after treatment but in the
blood only at 5 hours after treatment. The lack of significance in
the blood at 2 hours after treatment may reflect the large
variability in the vehicle group rather than poor effect of
meropenem.
[0342] The difference in CFU levels after NZ17074 or meropenem
treatment compared to vehicle treatment was:
TABLE-US-00008 NZ17074, 2 hours: peritoneum -1.63 blood -2.50 log
cfu/ml 7.5 mg/kg log cfu/ml 5 hours: peritoneum -3.76 blood -3.74
log cfu/ml log cfu/ml Meropenem 2 hours: peritoneum -1.51 blood
-0.82 log cfu/ml 40 mg/kg log cfu/ml 5 hours: peritoneum -1.51
blood -1.64 log cfu/ml log cfu/ml
All mice had only mild or no symptoms of infection (Table 2).
Discussion and Conclusion
[0343] The purpose of this study was to investigate the efficacy of
NZ17074 following intravenous (i.v.) administration of a single
dose of 7.5 mg/kg in the neutropenic peritonitis model in NMRI
mice. A significant (p<0.001) reduction of more the 3 log.sub.10
CFU/ml compared to vehicle treatment was observed for NZ17074 in
blood and peritoneal fluid at 5 hours after treatment. Also at 2
hours after treatment with NZ17074 a significant reduction
(p<0.001) both in the blood and peritoneal fluid was observed.
Meropenem showed a significant reduction compared to the vehicle
group (p<0.01) both in the blood and in the peritoneal fluid at
5 hours but at 2 hours after treatment only in the peritoneal
fluid.
TABLE-US-00009 TABLE 5 Colony counts of E. coli AID#172 in mice
treated with a single dose of NZ17074, vehicle or meropenem Score
log.sub.10 CFU id Time of T = 0 T = 2 T = 5 mean Mean Treatment no.
sampling hour hours hours PF PF Blood Blood NZ17074 4 T = 5 0 0
2.18 1.96*** 1.00 1.00*** 7.5 mg/kg 5 T = 5 0 1 2.30 1.00 6 T = 5 0
1 1.40 1.00 Meropenem 7 T = 5 0 0 4.38 4.21** 3.20 3.10** 40 mg/kg
8 T = 5 0 0 4.00 2.85 9 T = 5 0 0 4.26 3.26 10 T = 5 0 0 5.39 5.72
4.63 4.74 Vehicle 11 T = 5 0 0 5.99 5.24 12 T = 5 0 0 5.78 4.36
NZ17074 16 T = 2 0 1 4.24 3.79** 2.04 2.08** 7.5 mg/kg 17 T = 2 0 1
3.60 2.20 18 T = 2 0 1 3.54 2.00 Meropenem 19 T = 2 0 1 4.12 3.92**
3.60 3.76 40 mg/kg 20 T = 2 0 1 3.40 3.57 21 T = 2 0 1 4.24 4.11
Vehicle 22 T = 2 0 0 4.89 5.43 3.21 4.58 23 T = 2 0 1 5.65 5.39 24
T = 2 0 0 5.74 5.15 None 25 T = 2 0 0 4.45 5.08 4.39 4.33 26 T = 2
0 0 5.42 4.57 27 T = 2 0 0 5.38 4.02 None 28 T = 0 0 1.88 3.57 1.00
3.54 29 T = 0 0 3.71 4.27 30 T = 0 0 5.13 5.35 PF: peritoneal
fluid. Used inoculum: 1.97 .times. 10.sup.6 CFU/ml. .sup.# Mouse
received 0.35 ml instead of 0.30 ml of test compound *p < 0.05,
**p < 0.01, ***p < 0.001 compared to vehicle group.
Example 4
Neutropenic Thigh Infection Model: Efficacy of NZ17074 Against
Escherichia coli AID#172 and Estimation of ED50
Introduction
[0344] The purpose of this study was to investigate the
dose-response relationship following intravenous (i.v.)
administration of a single dose of NZ17074 ranging from 0.16-12
mg/kg. The effect was tested against E. coli AID#172 in the
neutropenic thigh model. Treatment with 40 mg/kg meropenem was
included as a positive control group. The colony counts in thighs
were determined at 5 hours after treatment.
[0345] The thigh infection model is a well-recognized model for
studies of antimicrobial effect and tissue penetration as described
by S. Gudmundsson & H. Erlensdottir Handbook of Animal Models
of Infection (1999), ed. by O. Zak & M. A. Sande, Academic
Press, San Diego, US and in several publications. Reviewed by D.
Andes & C. Craig: Animal model pharmacokinetics and
pharmacodynamics: a critical review. International Journal of
Antimicrobial Agents 19(4): 261-268.
[0346] Materials and Methods [0347] 40 outbred, NMRI female mice,
25-30 grams (Harlan Scandinavia) [0348] E. coli AID#172 from
Statens Serum Institute, Copenhagen, Denmark: Clinical isolate from
a human wound from 2003. Multiresistant (Ampicillin, Ceftazidime,
Aztreonam, Gentamicin, Ciprofloxacin) [0349] NZ17074 in Ringer
Acetate, pH 6: 1.2 mg/ml, 6.0 ml. The solution was stored at
4.degree. C. until use. Analyses of the dose formulations used were
performed after completion of the in-life phase of the study and
gave the following results:
TABLE-US-00010 [0349] Intended concentration Measured concentration
1.2 mg/ml 1.11 mg/ml 0.6 mg/ml 0.51 mg/ml 0.3 mg/ml 0.24 mg/ml 0.15
mg/ml 0.14 mg/ml 0.075 mg/ml 0.043 mg/ml 0.03 mg/ml 0.010 mg/ml
0.016 mg/ml 0.002 mg/ml
[0350] Vehicle (Ringer Acetate pH 6). The solution was stored at
4.degree. C. until use [0351] MERONEM.RTM. (AstraZeneca, 500 mg
infusion substance, meropenem). Lot no. 09466C [0352] Date of
expire: August 2013 [0353] Water, sterile [0354] 0.9% saline,
sterile [0355] SENDOXAN.RTM. (Cyclophosphamide, Baxter, 1 g) Batch
nr. 0A671C Date of expire: January 2013 [0356] 5% Horse Blood Agar
plates [0357] Lactose bromthymol blue agar plates
Laboratory Animal Facilities and Housing of Mice
[0358] The temperature and humidity were registered daily in the
animal facilities. The temperature was 21+/-2.degree. C. and can be
regulated by heating and cooling. The humidity was 55+/-10%. The
air changes per hour were approximately 10-20 times, and light/dark
period was in 12-hours interval of 6 a.m.-6 p.m./6 p.m-6 a.m.
[0359] The mice had free access to domestic quality drinking water
and food (2016, Harlan). The mice were housed in Type 3 macrolone
cages with 4 mice/cage. The bedding was Aspen Wood from Tapvei.
Further the animals were offered paper strands from Sizzle-nest as
nesting material. Mice were marked on the tail for individual
identification within the cage. Mice were weighed the day before
dosing.
Preparation of NZ17074 Solutions
[0360] The solution of 1.2 mg/ml was further diluted in PBS vehicle
as follows:
0.6 mg/ml.about.7.5 mg/kg: 1.5 ml of 1.2 mg/ml NZ17074+1.5 ml
vehicle 0.3 mg/ml.about.5.0 mg/kg: 1.5 ml of 0.6 mg/ml NZ17074+1.5
ml vehicle 0.15 mg/ml.about.2.5 mg/kg: 1.5 ml of 0.3 mg/ml
NZ17074+1.5 ml vehicle 0.075 mg/ml.about.1.25 mg/kg: 1.5 ml of 0.15
mg/ml NZ17074+1.5 ml vehicle 0.03 mg/ml.about.0.63 mg/kg: 1.5 ml of
0.075 mg/ml NZ17074+2.25 ml vehicle 0.016 mg/ml.about.0.16 mg/kg:
1.5 ml of 0.03 mg/ml NZ17074+1.5 ml vehicle
Preparation Meropenem Solution
[0361] Treatment with meropenem 40 mg/kg was included as a positive
control group.
[0362] A total of 500 mg meropenem (one ampoule) was dissolved in
10 ml water.about.50 mg/ml This stock solution was further diluted
to 4 mg/ml (0.4 ml 50 mg/ml+4.6 ml saline).
Preparation of Cyclophosphamide
[0363] A total of 1 g cyclophosphamide (one ampoule SENDOXAN.RTM.
(Cyclosphosphamide, Baxter, 1 g) was dissolved in 50 ml
water.about.20 mg/ml on each day of use. This stock solution was
further diluted to 11 mg/ml (16.5 ml 20 mg/ml+13.5 ml saline) for
use on day -4 or to 5 mg/kg (8.25 ml 20 mg/ml+21.75 ml saline)) for
use on day -1.
Treatment of Mice with Cyclophosphamide
[0364] The mice were rendered neutropenic by injecting 0.5 ml
cyclophosphamide solution intraperitoneally 4 days (200 mg/kg) and
1 day (100 mg/kg) prior to inoculation.
Inoculation of Mice
[0365] Fresh overnight E. coli AID#172 colonies from a 5% Horse
Blood Agar plate were suspended and diluted in sterile saline to
approximately 2.times.10.sup.7 CFU/ml. One hour before start of
treatment (time -1 hour) mice were inoculated intramuscularly with
0.05 ml of the E. coli suspension in the left hind leg.
Approximately 1/2 hour before inoculation mice were treated orally
with 45 microliters neurophen (20 mg ibuprofen/ml corresponding to
30 mg/kg) as a pain relief.
Treatment of Mice
[0366] The mice were treated i.v. in the lateral tail vein over
approximately 30 seconds with 10 ml/kg with a single dose of
NZ17074, meropenem or vehicle at time 0 hour (see Table 1). The
dosing was based on a mean weight of 30 g. Mice that weighed 28-32
g received 0.30 ml solution. Mice that weighed 27-28 g received
0.25 ml solution and mice that weighed 32.1-36 g received 0.35 ml
solution.
TABLE-US-00011 TABLE 6 Treatment and sampling schedule in the
murine thigh model. Inoculation Sampling and mouse no. i.m. at - 1
hr Intravenous treatment at 0 hr 0 hr 5 hours 0.05 ml of Vehicle,
Ringer acetate 1-2-3-4 E. coli NZ17074 0.16 mg/kg 5-6-7-8 AID#172
NZ17074 0.30 mg/kg 9-10-11-12 2 .times. 10.sup.7 NZ17074 0.75 mg/kg
13-14-15-16 CFU/ml NZ17074 1.5 mg/kg 17-18-19-20 NZ17074 3.0 mg/kg
21-22-23-24 NZ17074 6.0 mg/kg 25-26-27-28 NZ17074 12 mg/kg
29-30-31-32 meropenem 40 mg/kg 33-34-35-36 No treatment 37-38-39-40
T indicates the time in relation to treatment. Numbers in the
sampling columns are mouse identification numbers.
Clinical Scoring of Mice
[0367] The mice were observed during the study and scored 0-5 based
on their behaviour and clinical signs. [0368] Score 0: Healthy.
[0369] Score 1: Minor clinical signs of infection and inflammation
e.g. observations of minor signs of distress or changed activity.
[0370] Score 2: Clear signs of infection like, social withdrawal,
lack of curiosity, changed body position, piloerection, or changes
in pattern of movement. [0371] Score 3: Severe signs of infection
like stiff movements, lack of curiosity, changed body position,
piloerection, pain, or changes in pattern of movement. [0372] Score
4: Severe pain and the mouse was sacrificed immediately to minimize
the suffering of the animal. [0373] Score 5: The mouse was
dead.
Sampling
[0374] Colony counts were determined from thighs at 0 and 5 hours.
The mice were anaesthetized with CO.sub.2+O.sub.2 and sacrificed.
Immediately after, skin was removed and the left hind leg was
collected and frozen at -70.degree. C. After thawing, the thighs
were homogenized using a Dispomix.RTM. Drive. Each sample was then
10 fold diluted in saline and 20-microliter spots were applied on
blue agar plates. All agar plates were incubated 18-22 hours at
35.degree. C. in ambient air.
Results
[0375] The colony counts were performed at the start of treatment
and 5 hours after treatment.
[0376] The CFU counts are shown in Table 3. The CFU numbers are
log.sub.10 transformed before performing calculations.
[0377] The CFU/ml in the inoculum was determined to 7.35 log.sub.10
corresponding to 6.05 log.sub.10 CFU/mouse. The high variability
observed may be caused by suboptimal inoculation of some mice and
resulting in too low CFU values. The lowest value in each group was
therefore excluded from graphs and calculations (se Table 3). At
start of treatment the mean log.sub.10 CFU/ml was 4.93 and
increased to 6.49 log.sub.10 CFU/ml in the vehicle group at 5 hrs
after treatment. Slightly lower CFU levels were observed after
treatment with NZ17074 0.16-3.0 mg/kg. Significantly lower CFU
levels were observed after treatment with 6 mg/kg (p<0.05) and
12 mg/kg (p<0.01) NZ17074 compared to vehicle treatment (Table
3). Meropenem treatment, 40 mg/kg, resulted in slight but not
significant reduction compared to the vehicle treated mice.
[0378] The dose-response curves (not shown) were calculated in
GraphPad Prism using Sigmoidal dose-response (variable slope). From
this the ED50 value was determined to 5.9 mg/kg. However, a bottom
plateau was not obtained and this value may therefore be
underestimated.
[0379] The maximum effect of NZ17074, E.sub.max, was defined as the
log CFU difference between no response and maximum response. No
response was characterised as colony counts at the same level as
determined for vehicle treated mice. The E.sub.max was calculated
as the difference between the "Top plateau" and "Bottom plateau" in
GraphPad Prism using Sigmoidal dose-response to be 2.4
.DELTA.log.sub.10 CFU/ml. In addition the 1 log killing, defined as
the dose required to obtain 1 log reduction in bacterial loads
compared to start of treatment, was estimated using GraphPad Prism
to 6.1 mg/kg. A 2 and 3 log killing was not obtained.
[0380] No clinical signs of infection were observed at any time
point in any of the mice.
TABLE-US-00012 TABLE 7 Efficacy values for NZ17074 against E. coli
AID#172 calculated in Graph Pad Prism TOP 1.1 Dlog.sub.10 CFU/ml
BOTTOM -1.3 Dlog.sub.10 CFU/ml Emax 2.4 Dlog.sub.10 CFU/ml ED50 5.9
mg/kg R.sup.2 0.46 1 log killing 6.1 mg/kg
TABLE-US-00013 TABLE 8 Colony counts of E. coli AID#172 in thighs
from neutropenic mice treated with a single dose of NZ17074,
meropenem or vehicle. log.sub.10 log.sub.10 Treatment mouse Time of
CFU Treatment mouse Time of CFU T = 0 hour no. sampling thigh mean
T = 0 hrs no. sampling thigh mean Vehicle 1 T = 5 5.16 6.49 NZ17074
21 T = 5 5.30 6.07 2 T = 5 6.47 3.0 mg/kg 22 T = 5 6.03 3 T = 5
6.13 23 T = 5 4.85 4 T = 5 6.86 24 T = 5 6.89 NZ17074 5 T = 5 3.18
5.16 NZ17074 25 T = 5 2.75 4.10* 0.16 mg/kg 6 T = 5 6.03 6.0 mg/kg
26 T = 5 4.54 7 T = 5 3.30 27 T = 5 1.48 8 T = 5 6.15 28 T = 5 5.01
NZ17074 9 T = 5 2.00 5.09 NZ17074 29 T = 5 2.48 3.32** 0.30 mg/kg
10 T = 5 5.40 12 mg/kg 30 T = 5 3.27 11 T = 5 3.10 31 T = 5 3.19 12
T = 5 6.78 32 T = 5 3.51 NZ17074 13 T = 5 2.9 6.33 Meropenem 33 T =
5 3.08 4.25 0.75 mg/kg 14 T = 5 5.72 40 mg/kg 34 T = 5 3.81 15 T =
5 7.27 35 T = 5 4.99 16 T = 5 6.00 38 T = 5 3.94 NZ17074 17 T = 5
2.56 5.62 None 37 T = 0 4.98 4.93 1.5 mg/kg 18 T = 5 6.23 38 T = 0
3.81 19 T = 5 4.93 39 T = 0 4.79 20 T = 5 5.70 40 T = 0 5.01 This
value was excluded from calculations as it was considered an
outlier. Stars indicate significantly different from vehicle group
(Annova; multiple comparison). *corresponds to p < 0.05;
**corresponds to p < 0.01. Detection limit 1.4 log.sub.10
CFU/ml.
[0381] The invention described and claimed herein is not to be
limited in scope by the specific aspects herein disclosed, since
these aspects are intended as illustrations of several aspects of
the invention. Any equivalent aspects are intended to be within the
scope of this invention. Indeed, various modifications of the
invention in addition to those shown and described herein will
become apparent to those skilled in the art from the foregoing
description. Such modifications are also intended to fall within
the scope of the appended claims. In the case of conflict, the
present disclosure including definitions will control.
Sequence CWU 1
1
548163DNAArenicola marinaCDS(1)..(63)mat_peptide(1)..(63) 1ggt ttc
tgc tgg tac gtc tgc gtc tac agg aac gga gtc cgc gtc tgc 48Gly Phe
Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15
tac cga cgg tgc aac 63Tyr Arg Arg Cys Asn 20 221PRTArenicola marina
2Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1
5 10 15 Tyr Arg Arg Cys Asn 20 321PRTArtificial sequenceSynthetic
construct 3Gly Ala Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 421PRTArtificial
sequenceSynthetic construct 4Gly Phe Cys Ala Tyr Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
521PRTArtificial sequenceSynthetic construct 5Gly Phe Cys Glu Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 621PRTArtificial sequenceSynthetic construct 6Gly Phe
Cys Gly Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15
Tyr Arg Arg Cys Asn 20 721PRTArtificial sequenceSynthetic construct
7Gly Phe Cys Ser Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1
5 10 15 Tyr Arg Arg Cys Asn 20 821PRTArtificial sequenceSynthetic
construct 8Gly Phe Cys Thr Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 921PRTArtificialSynthetic
antimicrobial peptide 9Gly Phe Cys Tyr Tyr Val Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
1021PRTArtificial sequenceSynthetic construct 10Gly Phe Cys Trp Lys
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 1121PRTArtificialSynthetic antimicrobial peptide 11Gly
Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 1221PRTArtificial sequenceSynthetic
construct 12Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 1321PRTArtificialSynthetic
antimicrobial peptide 13Gly Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
1421PRTArtificialSynthetic antimicrobial peptide 14Gly Phe Cys Trp
Tyr Glu Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 1521PRTArtificialSynthetic antimicrobial peptide
15Gly Phe Cys Trp Tyr Gly Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1
5 10 15 Tyr Arg Arg Cys Asn 20 1621PRTArtificial sequenceSynthetic
construct 16Gly Phe Cys Trp Tyr Leu Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 1721PRTArtificialSynthetic
antimicrobial peptide 17Gly Phe Cys Trp Tyr Asn Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
1821PRTArtificial sequenceSynthetic construct 18Gly Phe Cys Trp Tyr
Arg Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 1921PRTArtificialSynthetic antimicrobial peptide 19Gly
Phe Cys Trp Tyr Ser Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 2021PRTArtificial sequenceSynthetic
construct 20Gly Phe Cys Trp Tyr Trp Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 2121PRTArtificialSynthetic
antimicrobial peptide 21Gly Phe Cys Trp Tyr Val Cys Ala Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
2221PRTArtificial sequenceSynthetic construct 22Gly Phe Cys Trp Tyr
Val Cys Gly Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 2321PRTArtificial sequenceSynthetic construct 23Gly Phe
Cys Trp Tyr Val Cys His Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15
Tyr Arg Arg Cys Asn 20 2421PRTArtificial sequenceSynthetic
construct 24Gly Phe Cys Trp Tyr Val Cys Ser Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 2521PRTArtificialSynthetic
antimicrobial peptide 25Gly Phe Cys Trp Tyr Val Cys Tyr Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
2621PRTArtificial sequenceSynthetic construct 26Gly Phe Cys Trp Tyr
Val Cys Val Ile Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 2721PRTArtificial sequenceSynthetic construct 27Gly Phe
Cys Trp Tyr Val Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15
Tyr Arg Arg Cys Asn 20 2821PRTArtificialSynthetic antimicrobial
peptide 28Gly Phe Cys Trp Tyr Val Cys Val Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 2921PRTArtificial
sequenceSynthetic construct 29Gly Phe Cys Trp Tyr Val Cys Val Tyr
Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
3021PRTArtificialSynthetic antimicrobial peptide 30Gly Phe Cys Trp
Tyr Val Cys Val Tyr Arg Asn Gly Gly Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 3121PRTArtificial sequenceSynthetic construct 31Gly
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Lys Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 3221PRTArtificialSynthetic antimicrobial
peptide 32Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 3321PRTArtificial
sequenceSynthetic construct 33Gly Phe Cys Trp Tyr Val Cys Val Tyr
Arg Asn Gly Pro Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
3421PRTArtificialSynthetic antimicrobial peptide 34Gly Phe Cys Trp
Tyr Val Cys Val Tyr Arg Asn Gly Gln Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 3521PRTArtificialSynthetic antimicrobial peptide
35Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Arg Arg Val Cys 1
5 10 15 Tyr Arg Arg Cys Asn 20 3621PRTArtificial sequenceSynthetic
construct 36Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Ser Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 3721PRTArtificialSynthetic
antimicrobial peptide 37Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn
Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
3821PRTArtificial sequenceSynthetic construct 38Gly Phe Cys Trp Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Gly Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 3921PRTArtificialSynthetic antimicrobial peptide 39Gly
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg His Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 4021PRTArtificial sequenceSynthetic
construct 40Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 4121PRTArtificial
sequenceSynthetic construct 41Gly Phe Cys Trp Tyr Val Cys Val Tyr
Arg Asn Gly Val Arg Asn Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
4221PRTArtificialSynthetic antimicrobial peptide 42Gly Phe Cys Trp
Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 4321PRTArtificial sequenceSynthetic construct 43Gly
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 4421PRTArtificial sequenceSynthetic
construct 44Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 4521PRTArtificialSynthetic
antimicrobial peptide 45Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn
Gly Val Arg Thr Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
4621PRTArtificial sequenceSynthetic construct 46Gly Phe Cys Trp Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg
Cys Asn 20 4721PRTArtificialSynthetic antimicrobial peptide 47Gly
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Lys Arg Arg Cys Asn 20 4821PRTArtificial sequenceSynthetic
construct 48Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Asn Arg Arg Cys Asn 20 4921PRTArtificialSynthetic
antimicrobial peptide 49Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Arg Arg Arg Cys Asn 20
5021PRTArtificial sequenceSynthetic construct 50Gly Phe Cys Trp Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys His 20 5121PRTArtificialSynthetic antimicrobial peptide 51Gly
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Lys 20 5221PRTArtificial sequenceSynthetic
construct 52Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Arg 20 5321PRTArtificialSynthetic
antimicrobial peptide 53Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Ser 20
5421PRTArtificial sequenceSynthetic construct 54Gly Phe Cys Trp Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Thr 20 5521PRTArtificialSynthetic antimicrobial peptide 55Arg
Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Arg 20 5621PRTArtificial sequenceSynthetic
construct 56Gly Phe Cys Phe Tyr Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Arg Arg Arg Cys Asn 20 5721PRTArtificial
sequenceSynthetic construct 57Gly Phe Cys Ala His Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
5821PRTArtificialSynthetic antimicrobial peptide 58Gly Phe Cys Ala
Arg Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 5921PRTArtificial sequenceSynthetic construct 59Gly
Phe Cys Phe Tyr Val Cys Val Arg Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 6021PRTArtificial sequenceSynthetic
construct 60Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 6121PRTArtificialSynthetic
antimicrobial peptide 61Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
6221PRTArtificial sequenceSynthetic construct 62Gly Phe Cys Ser Tyr
Val Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 6321PRTArtificialSynthetic antimicrobial peptide 63Gly
Phe Cys Ser Arg Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 6421PRTArtificial sequenceSynthetic
construct 64Gly Phe Cys Tyr Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 6521PRTArtificialSynthetic
antimicrobial peptide 65Gly Phe Cys Trp Phe Val Cys Val Tyr Arg Asn
Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
6621PRTArtificial sequenceSynthetic construct 66Gly Phe Cys Trp His
Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 6721PRTArtificialSynthetic antimicrobial peptide 67Gly
Phe Cys Trp His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Arg Arg Arg Cys Asn 20 6821PRTArtificial sequenceSynthetic
construct 68Gly Phe Cys Trp Lys Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20 6921PRTArtificial
sequenceSynthetic construct 69Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
7021PRTArtificial sequenceSynthetic construct 70Gly Phe Cys Trp Asn
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg
Cys Asn 20 7121PRTArtificialSynthetic antimicrobial peptide 71Gly
Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg Pro Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 7221PRTArtificial sequenceSynthetic
construct 72Gly Phe Cys Trp Arg Ala Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 7321PRTArtificialSynthetic
antimicrobial peptide 73Gly Phe Cys Trp Arg Val Cys Gly Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
7421PRTArtificial sequenceSynthetic construct 74Gly Phe Cys Trp Arg
Val Cys His Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 7521PRTArtificialSynthetic antimicrobial peptide 75Gly
Phe Cys Trp Arg Val Cys Ser Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 7621PRTArtificial sequenceSynthetic
construct 76Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20 7721PRTArtificialSynthetic
antimicrobial peptide 77Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn
Gly Val Arg Val Cys 1 5 10 15 Asn Arg Arg Cys Asn 20
7821PRTArtificial sequenceSynthetic construct 78Gly Phe Cys Trp Ser
Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 7921PRTArtificialSynthetic antimicrobial peptide 79Gly
Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 8021PRTArtificial sequenceSynthetic
construct 80Gly Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn Gly Lys Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 8121PRTArtificialSynthetic
antimicrobial peptide 81Gly Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn
Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
8221PRTArtificial sequenceSynthetic construct 82Gly Phe Cys Trp Tyr
Ala Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg
Cys Asn 20 8321PRTArtificialSynthetic antimicrobial peptide 83Gly
Phe Cys Trp Tyr Met Cys Gly Tyr Arg Asn Gly Val Arg Val Cys 1 5
10 15 Tyr Arg Arg Cys Asn 20 8421PRTArtificial sequenceSynthetic
construct 84Gly Phe Cys Trp Tyr Val Cys Ala Tyr Arg Asn Gly Val Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 8521PRTArtificialSynthetic
antimicrobial peptide 85Gly Phe Cys Trp Tyr Val Cys Ser Tyr Arg Asn
Gly Lys Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
8621PRTArtificial sequenceSynthetic construct 86Gly Phe Cys Trp Tyr
Val Cys Val Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 8721PRTArtificialSynthetic antimicrobial peptide 87Gly
Phe Cys Trp Tyr Val Cys Val Lys Arg Asn Gly Val Arg Ser Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 8821PRTArtificial sequenceSynthetic
construct 88Gly Phe Cys Trp Tyr Val Cys Val Tyr Lys Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 8921PRTArtificialSynthetic
antimicrobial peptide 89Gly Phe Cys Trp Tyr Val Cys Val Tyr Lys Asn
Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
9021PRTArtificial sequenceSynthetic construct 90Gly Phe Cys Trp Tyr
Val Cys Val Tyr Pro Asn Gly Gly Arg Val Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 9121PRTArtificial sequenceSynthetic construct 91Gly Phe
Cys Trp Tyr Val Cys Val Tyr Arg Arg Gly Val Arg Gln Cys 1 5 10 15
Tyr Arg Arg Cys Asn 20 9221PRTArtificialSynthetic antimicrobial
peptide 92Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Cys Arg Arg Cys Asn 20 9321PRTArtificial
sequenceSynthetic construct 93Gly Phe Cys Trp Tyr Val Cys Val Tyr
Arg Asn Gly Gly Arg Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
9421PRTArtificialSynthetic antimicrobial peptide 94Gly Phe Cys Trp
Tyr Val Cys Val Tyr Arg Asn Gly Val Arg Leu Cys 1 5 10 15 His Arg
Arg Cys Asn 20 9521PRTArtificial sequenceSynthetic construct 95Ala
Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 His Arg Arg Cys Asn 20 9621PRTArtificialSynthetic antimicrobial
peptide 96Asp Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20 9721PRTArtificial
sequenceSynthetic construct 97Phe Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
9821PRTArtificial sequenceSynthetic construct 98His Phe Cys Trp Asn
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg
Cys Asn 20 9921PRTArtificialSynthetic antimicrobial peptide 99Ile
Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 His Arg Arg Cys Asn 20 10021PRTArtificial sequenceSynthetic
construct 100Lys Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val
Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
10121PRTArtificialSynthetic antimicrobial peptide 101Met Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 10221PRTArtificial sequenceSynthetic construct
102Gln Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 10321PRTArtificialSynthetic
antimicrobial peptide 103Arg Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
10421PRTArtificialSynthetic antimicrobial peptide 104Ser Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 10521PRTArtificial sequenceSynthetic construct
105Thr Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 10621PRTArtificial
sequenceSynthetic construct 106Val Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
10721PRTArtificial sequenceSynthetic construct 107Trp Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 10821PRTArtificialSynthetic antimicrobial peptide
108Tyr Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 10921PRTArtificial
sequenceSynthetic construct 109Gly Gly Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
11021PRTArtificial sequenceSynthetic construct 110Gly His Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 11121PRTArtificialSynthetic antimicrobial peptide
111Gly Ile Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 11221PRTArtificial
sequenceSynthetic construct 112Gly Leu Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
11321PRTArtificialSynthetic antimicrobial peptide 113Gly Met Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 11421PRTArtificial sequenceSynthetic construct
114Gly Pro Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 11521PRTArtificialSynthetic
antimicrobial peptide 115Gly Val Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
11621PRTArtificial sequenceSynthetic construct 116Gly Trp Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 11721PRTArtificialSynthetic antimicrobial peptide
117Gly Tyr Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 11821PRTArtificial
sequenceSynthetic construct 118Gly Phe Leu Gln Tyr Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
11921PRTArtificialSynthetic antimicrobial peptide 119Gly Phe Cys
Ala Tyr Ala Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 12021PRTArtificial sequenceSynthetic construct
120Gly Phe Cys Ala Lys Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 12121PRTArtificialSynthetic
antimicrobial peptide 121Gly Phe Cys Ala Arg Val Cys Val Tyr Arg
Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
12221PRTArtificial sequenceSynthetic construct 122Gly Phe Cys Ala
Arg Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 12321PRTArtificial sequenceSynthetic construct
123Gly Phe Cys Ala Arg Val Cys Val Tyr Arg Asn Gly Val Arg Thr Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 12421PRTArtificial
sequenceSynthetic construct 124Gly Phe Cys Ala Arg Val Cys Ser Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
12521PRTArtificial sequenceSynthetic construct 125Gly Phe Cys Ala
Arg Val Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 12621PRTArtificialSynthetic antimicrobial peptide
126Gly Phe Cys Ala Trp Val Cys Val Tyr Arg Asn Gly Val Arg Gln Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 12721PRTArtificial
sequenceSynthetic construct 127Gly Phe Cys Ala Tyr Val Cys Val Arg
Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
12821PRTArtificialSynthetic antimicrobial peptide 128Gly Phe Cys
Phe Tyr Val Cys Ala Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 12921PRTArtificial sequenceSynthetic construct
129Gly Phe Cys Phe His Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 13021PRTArtificialSynthetic
antimicrobial peptide 130Gly Phe Cys Phe Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
13121PRTArtificial sequenceSynthetic construct 131Gly Phe Cys Phe
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 13221PRTArtificial sequenceSynthetic construct
132Gly Phe Cys Phe Arg Val Cys Val Tyr Arg Asn Gly Val Arg Lys Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 13321PRTArtificial
sequenceSynthetic construct 133Gly Phe Cys Phe Arg Val Cys Val Tyr
Arg Asn Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
13421PRTArtificial sequenceSynthetic construct 134Gly Phe Cys Phe
Arg Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 13521PRTArtificialSynthetic antimicrobial peptide
135Gly Phe Cys Phe Arg Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 13621PRTArtificial
sequenceSynthetic construct 136Gly Phe Cys Phe Arg Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Gln Arg Arg Cys Asn 20
13721PRTArtificialSynthetic antimicrobial peptide 137Gly Phe Cys
Phe Tyr Val Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 13821PRTArtificial sequenceSynthetic construct
138Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 Tyr Arg Arg Cys Ala 20 13921PRTArtificialSynthetic
antimicrobial peptide 139Gly Phe Cys Gly His Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Lys 20
14021PRTArtificial sequenceSynthetic construct 140Gly Phe Cys Gly
His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Leu 20 14121PRTArtificialSynthetic antimicrobial peptide
141Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 Tyr Arg Arg Cys Met 20 14221PRTArtificial
sequenceSynthetic construct 142Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Pro 20
14321PRTArtificialSynthetic antimicrobial peptide 143Gly Phe Cys
Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Arg 20 14421PRTArtificialSynthetic antimicrobial
peptide 144Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Ser 20 14521PRTArtificial
sequenceSynthetic construct 145Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Tyr 20
14621PRTArtificialSynthetic antimicrobial peptide 146Gly Phe Cys
Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 14721PRTArtificial sequenceSynthetic construct
147Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Phe Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 14821PRTArtificialSynthetic
antimicrobial peptide 148Gly Phe Cys Gly His Val Cys Val Tyr Arg
Asn Gly Val Arg Gly Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
14921PRTArtificial sequenceSynthetic construct 149Gly Phe Cys Gly
His Val Cys Val Tyr Arg Asn Gly Val Arg His Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 15021PRTArtificialSynthetic antimicrobial peptide
150Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Ile Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 15121PRTArtificial
sequenceSynthetic construct 151Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Leu Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
15221PRTArtificialSynthetic antimicrobial peptide 152Gly Phe Cys
Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Met Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 15321PRTArtificialSynthetic antimicrobial
peptide 153Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg
Asn Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 15421PRTArtificial
sequenceSynthetic construct 154Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
15521PRTArtificialSynthetic antimicrobial peptide 155Gly Phe Cys
Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 15621PRTArtificial sequenceSynthetic construct
156Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 15721PRTArtificialSynthetic
antimicrobial peptide 157Gly Phe Cys Gly His Val Cys Val Tyr Arg
Asn Gly Val Arg Thr Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
15821PRTArtificial sequenceSynthetic construct 158Gly Phe Cys Gly
His Val Cys Val Tyr Arg Asn Gly Val Arg Trp Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 15921PRTArtificialSynthetic antimicrobial peptide
159Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Tyr Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 16021PRTArtificial
sequenceSynthetic construct 160Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Phe Arg Arg Cys Asn 20
16121PRTArtificial sequenceSynthetic construct 161Gly Phe Cys Gly
His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Gly Arg
Arg Cys Asn 20 16221PRTArtificial sequenceSynthetic construct
162Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 Ile Arg Arg Cys Asn 20 16321PRTArtificialSynthetic
antimicrobial peptide 163Gly Phe Cys Gly His Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 Leu Arg Arg Cys Asn 20
16421PRTArtificialSynthetic antimicrobial peptide 164Gly Phe Cys
Gly His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Met
Arg Arg Cys Asn 20 16521PRTArtificialSynthetic antimicrobial
peptide 165Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Thr Arg Arg Cys Asn 20 16621PRTArtificial
sequenceSynthetic construct 166Gly Phe Cys Gly His Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Val Arg Arg Cys Asn 20
16721PRTArtificialSynthetic antimicrobial peptide 167Gly Phe Cys
Gly His
Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Trp Arg Arg
Cys Asn 20 16821PRTArtificial sequenceSynthetic construct 168Gly
Phe Cys Gly Lys Val Cys Val Tyr Arg Asn Gly Val Arg His Cys 1 5 10
15 Tyr Arg Arg Cys Asn 20 16921PRTArtificialSynthetic antimicrobial
peptide 169Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Leu Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
17021PRTArtificialSynthetic antimicrobial peptide 170Gly Phe Cys
Gly Arg Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 17121PRTArtificialSynthetic antimicrobial
peptide 171Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Thr Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20 17221PRTArtificial
sequenceSynthetic construct 172Gly Phe Cys Gly Arg Val Cys Val Arg
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
17321PRTArtificial sequenceSynthetic construct 173Gly Phe Cys Gly
Ser Val Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 17421PRTArtificialSynthetic antimicrobial peptide
174Gly Phe Cys Gly Ser Val Cys Val Tyr Arg Asn Gly Val Arg Lys Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 17521PRTArtificial
sequenceSynthetic construct 175Gly Phe Cys Gly Ser Val Cys Val Tyr
Arg Asn Gly Val Arg Arg Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
17621PRTArtificialSynthetic antimicrobial peptide 176Gly Phe Cys
Gly Tyr Val Cys Val Arg Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 17721PRTArtificial sequenceSynthetic construct
177Gly Phe Cys Ile Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 17821PRTArtificialSynthetic
antimicrobial peptide 178Gly Phe Cys Leu His Val Cys Val Tyr Arg
Asn Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
17921PRTArtificial sequenceSynthetic construct 179Gly Phe Cys Leu
Lys Val Cys Val Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 18021PRTArtificialSynthetic antimicrobial peptide
180Gly Phe Cys Leu Arg Val Cys Val Tyr Arg Asn Gly Val Arg Gln Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 18121PRTArtificial
sequenceSynthetic construct 181Gly Phe Cys Leu Arg Val Cys Val Tyr
Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
18221PRTArtificialSynthetic antimicrobial peptide 182Gly Phe Cys
Met Glu Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 Thr
Arg Arg Cys Asn 20 18321PRTArtificial sequenceSynthetic construct
183Gly Phe Cys Met His Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 18421PRTArtificialSynthetic
antimicrobial peptide 184Gly Phe Cys Met Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
18521PRTArtificialSynthetic antimicrobial peptide 185Gly Phe Cys
Met Arg Val Cys Val Tyr Arg Asn Gly Val Arg Thr Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 18621PRTArtificial sequenceSynthetic construct
186Gly Phe Cys Met Ser Val Cys Val Tyr Arg Asn Gly Val Arg Gln Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 18721PRTArtificialSynthetic
antimicrobial peptide 187Gly Phe Cys Met Ser Val Cys Val Tyr Arg
Asn Gly Val Arg Arg Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
18821PRTArtificialSynthetic antimicrobial peptide 188Gly Phe Cys
Asn Arg Val Cys Val Tyr Arg Asn Gly Val Arg Ile Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 18921PRTArtificial sequenceSynthetic construct
189Gly Phe Cys Ser Lys Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 19021PRTArtificialSynthetic
antimicrobial peptide 190Gly Phe Cys Ser Arg Val Cys Val Tyr Arg
Asn Gly Val Arg Ile Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
19121PRTArtificial sequenceSynthetic construct 191Gly Phe Cys Thr
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 19221PRTArtificialSynthetic antimicrobial peptide
192Gly Phe Cys Thr Arg Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 19321PRTArtificialSynthetic
antimicrobial peptide 193Gly Phe Cys Thr Arg Val Cys Val Tyr Arg
Asn Gly Val Arg Thr Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
19421PRTArtificial sequenceSynthetic construct 194Gly Phe Cys Thr
Ser Val Cys Val Tyr Arg Asn Gly Val Arg His Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 19521PRTArtificialSynthetic antimicrobial peptide
195Gly Phe Cys Thr Tyr Val Cys Val Lys Arg Asn Gly Val Arg Lys Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 19621PRTArtificial
sequenceSynthetic construct 196Gly Phe Cys Val His Val Cys Val Tyr
Arg Asn Gly Val Arg Pro Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
19721PRTArtificial sequenceSynthetic construct 197Gly Phe Cys Val
His Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 19821PRTArtificialSynthetic antimicrobial peptide
198Gly Phe Cys Val Lys Val Cys Val Tyr Arg Asn Gly Val Arg Gln Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 19921PRTArtificial
sequenceSynthetic construct 199Gly Phe Cys Val Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
20021PRTArtificialSynthetic antimicrobial peptide 200Gly Phe Cys
Val Arg Val Cys Val Tyr Arg Asn Gly Val Arg Gly Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 20121PRTArtificial sequenceSynthetic construct
201Gly Phe Cys Val Arg Val Cys Val Tyr Arg Asn Gly Val Arg Pro Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 20221PRTArtificialSynthetic
antimicrobial peptide 202Gly Phe Cys Val Arg Val Cys Val Tyr Arg
Asn Gly Val Arg Gln Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
20321PRTArtificial sequenceSynthetic construct 203Gly Phe Cys Val
Arg Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 20421PRTArtificialSynthetic antimicrobial peptide
204Gly Phe Cys Val Arg Val Cys Val Tyr Arg Asn Gly Val Arg Thr Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 20521PRTArtificial
sequenceSynthetic construct 205Gly Phe Cys Tyr His Val Cys Val Tyr
Arg Asn Gly Val Arg Tyr Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
20621PRTArtificialSynthetic antimicrobial peptide 206Gly Phe Cys
Tyr Lys Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 20721PRTArtificial sequenceSynthetic construct
207Gly Phe Cys Tyr Asn Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 20821PRTArtificialSynthetic
antimicrobial peptide 208Gly Phe Cys Tyr Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
20921PRTArtificial sequenceSynthetic construct 209Gly Phe Cys Tyr
Arg Val Cys Val Tyr Arg Asn Gly Val Arg Thr Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 21021PRTArtificialSynthetic antimicrobial peptide
210Gly Phe Cys Tyr Arg Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 21121PRTArtificial
sequenceSynthetic construct 211Gly Phe Cys Tyr Arg Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
21221PRTArtificialSynthetic antimicrobial peptide 212Gly Phe Cys
Tyr Trp Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 21321PRTArtificial sequenceSynthetic construct
213Gly Phe Cys Trp His Val Cys Val Tyr Arg Asn Gly Ala Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 21421PRTArtificialSynthetic
antimicrobial peptide 214Gly Phe Cys Trp His Val Cys Val Tyr Arg
Asn Gly Ser Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
21521PRTArtificial sequenceSynthetic construct 215Gly Phe Cys Trp
His Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Ser Arg
Arg Cys Asn 20 21621PRTArtificialSynthetic antimicrobial peptide
216Gly Phe Cys Trp His Val Cys Ala Tyr Arg Asn Gly Lys Arg Val Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 21721PRTArtificial
sequenceSynthetic construct 217Gly Phe Cys Trp His Val Cys Ala Tyr
Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
21821PRTArtificialSynthetic antimicrobial peptide 218Gly Phe Cys
Trp His Val Cys Ala Arg Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 21921PRTArtificial sequenceSynthetic construct
219Gly Phe Cys Trp His Val Cys His Tyr Arg Asn Ser Val Arg Val Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 22021PRTArtificialSynthetic
antimicrobial peptide 220Gly Phe Cys Trp His Val Cys Val Ser Arg
Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
22121PRTArtificial sequenceSynthetic construct 221Gly Phe Cys Trp
Lys Val Cys Val Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 Ser Arg
Arg Cys Asn 20 22221PRTArtificialSynthetic antimicrobial peptide
222Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Ala Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 22321PRTArtificial
sequenceSynthetic construct 223Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Asp Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
22421PRTArtificialSynthetic antimicrobial peptide 224Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Glu Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 22521PRTArtificial sequenceSynthetic construct
225Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Phe Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 22621PRTArtificialSynthetic
antimicrobial peptide 226Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn His Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
22721PRTArtificial sequenceSynthetic construct 227Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Lys Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 22821PRTArtificial sequenceSynthetic construct
228Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Arg Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 22921PRTArtificial
sequenceSynthetic construct 229Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Tyr Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
23021PRTArtificialSynthetic antimicrobial peptide 230Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Ala Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 23121PRTArtificialSynthetic antimicrobial
peptide 231Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Gly Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
23221PRTArtificialSynthetic antimicrobial peptide 232Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg His Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 23321PRTArtificial sequenceSynthetic construct
233Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Gln Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 23421PRTArtificialSynthetic
antimicrobial peptide 234Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Arg Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
23521PRTArtificial sequenceSynthetic construct 235Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 23621PRTArtificialSynthetic antimicrobial peptide
236Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Phe Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 23721PRTArtificial
sequenceSynthetic construct 237Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly His Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
23821PRTArtificialSynthetic antimicrobial peptide 238Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Gln Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 23921PRTArtificial sequenceSynthetic construct
239Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Arg Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 24021PRTArtificialSynthetic
antimicrobial peptide 240Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Thr Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
24121PRTArtificial sequenceSynthetic construct 241Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Trp Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 24221PRTArtificialSynthetic antimicrobial peptide
242Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Tyr Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 24321PRTArtificial
sequenceSynthetic construct 243Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
24421PRTArtificialSynthetic antimicrobial peptide 244Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Cys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 24521PRTArtificial sequenceSynthetic construct
245Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Phe Cys
1 5 10 15 His Arg Arg Cys Asn 20 24621PRTArtificialSynthetic
antimicrobial peptide 246Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Gly Cys 1 5 10 15 His Arg Arg Cys Asn 20
24721PRTArtificial sequenceSynthetic construct 247Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg His Cys 1 5 10 15 His Arg
Arg Cys Asn 20 24821PRTArtificialSynthetic antimicrobial peptide
248Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Ile Cys
1 5 10 15 His Arg Arg Cys Asn 20 24921PRTArtificial
sequenceSynthetic construct 249Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Leu Cys 1 5 10 15 His Arg Arg Cys Asn 20
25021PRTArtificialSynthetic antimicrobial peptide 250Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Met Cys 1 5 10 15 His
Arg Arg Cys Asn 20
25121PRTArtificial sequenceSynthetic construct 251Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Asn Cys 1 5 10 15 His Arg
Arg Cys Asn 20 25221PRTArtificialSynthetic antimicrobial peptide
252Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Arg Cys
1 5 10 15 His Arg Arg Cys Asn 20 25321PRTArtificial
sequenceSynthetic construct 253Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Trp Cys 1 5 10 15 His Arg Arg Cys Asn 20
25421PRTArtificialSynthetic antimicrobial peptide 254Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Tyr Cys 1 5 10 15 His
Arg Arg Cys Asn 20 25521PRTArtificial sequenceSynthetic construct
255Gly Phe Cys Trp Asn Ala Cys Val Tyr Arg Asn Gly Val Arg Asn Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 25621PRTArtificialSynthetic
antimicrobial peptide 256Gly Phe Cys Trp Asn Ala Cys Val Tyr Arg
Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
25721PRTArtificial sequenceSynthetic construct 257Gly Phe Cys Trp
Asn Ala Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 25821PRTArtificial sequenceSynthetic construct
258Gly Phe Cys Trp Asn Ala Cys Val Lys Arg Asn Gly Val Arg Val Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 25921PRTArtificialSynthetic
antimicrobial peptide 259Gly Phe Cys Trp Asn Cys Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
26021PRTArtificial sequenceSynthetic construct 260Gly Phe Cys Trp
Asn Phe Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 26121PRTArtificial sequenceSynthetic construct
261Gly Phe Cys Trp Asn His Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 26221PRTArtificialSynthetic
antimicrobial peptide 262Gly Phe Cys Trp Asn Ile Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
26321PRTArtificial sequenceSynthetic construct 263Gly Phe Cys Trp
Asn Leu Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 26421PRTArtificialSynthetic antimicrobial peptide
264Gly Phe Cys Trp Asn Met Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 26521PRTArtificial
sequenceSynthetic construct 265Gly Phe Cys Trp Asn Gln Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
26621PRTArtificial sequenceSynthetic construct 266Gly Phe Cys Trp
Asn Thr Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Asn 20 26721PRTArtificialSynthetic antimicrobial peptide
267Gly Phe Cys Trp Asn Trp Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 26821PRTArtificialSynthetic
antimicrobial peptide 268Gly Phe Cys Trp Asn Tyr Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
26921PRTArtificial sequenceSynthetic construct 269Gly Phe Cys Trp
Asn Val Cys Ala Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr Arg
Arg Cys Asn 20 27021PRTArtificialSynthetic antimicrobial peptide
270Gly Phe Cys Trp Asn Val Cys Ala Tyr Arg Asn Gly Val Arg Ser Cys
1 5 10 15 Tyr Arg Arg Cys Asn 20 27121PRTArtificial
sequenceSynthetic construct 271Gly Phe Cys Trp Asn Val Cys Ala Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
27221PRTArtificialSynthetic antimicrobial peptide 272Gly Phe Cys
Trp Asn Val Cys Phe Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 27321PRTArtificial sequenceSynthetic construct
273Gly Phe Cys Trp Asn Val Cys Gly Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 27421PRTArtificial
sequenceSynthetic construct 274Gly Phe Cys Trp Asn Val Cys Ile Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
27521PRTArtificialSynthetic antimicrobial peptide 275Gly Phe Cys
Trp Asn Val Cys Leu Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 27621PRTArtificial sequenceSynthetic construct
276Gly Phe Cys Trp Asn Val Cys Trp Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Asn 20 27721PRTArtificialSynthetic
antimicrobial peptide 277Gly Phe Cys Trp Asn Val Cys Tyr Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
27821PRTArtificial sequenceSynthetic construct 278Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Ala 20 27921PRTArtificial sequenceSynthetic construct
279Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Cys 20 28021PRTArtificialSynthetic
antimicrobial peptide 280Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Phe 20
28121PRTArtificial sequenceSynthetic construct 281Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Gly 20 28221PRTArtificial sequenceSynthetic construct
282Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys His 20 28321PRTArtificialSynthetic
antimicrobial peptide 283Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Ile 20
28421PRTArtificial sequenceSynthetic construct 284Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Lys 20 28521PRTArtificial sequenceSynthetic construct
285Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Leu 20 28621PRTArtificial
sequenceSynthetic construct 286Gly Phe Cys Trp Asn Val Cys Val Tyr
Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Met 20
28721PRTArtificialSynthetic antimicrobial peptide 287Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Pro 20 28821PRTArtificial sequenceSynthetic construct
288Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Gln 20 28921PRTArtificialSynthetic
antimicrobial peptide 289Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Arg 20
29021PRTArtificial sequenceSynthetic construct 290Gly Phe Cys Trp
Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His Arg
Arg Cys Ser 20 29121PRTArtificialSynthetic antimicrobial peptide
291Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys
1 5 10 15 His Arg Arg Cys Trp 20 29221PRTArtificialSynthetic
antimicrobial peptide 292Gly Phe Cys Trp Asn Val Cys Val Tyr Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Tyr 20
29321PRTArtificialSynthetic antimicrobial peptide 293Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Asp Cys Asn 20 29421PRTArtificialSynthetic antimicrobial
peptide 294Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg His Cys Asn 20
29521PRTArtificialSynthetic antimicrobial peptide 295Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Lys Cys Asn 20 29621PRTArtificialSynthetic antimicrobial
peptide 296Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Met Cys Asn 20
29721PRTArtificialSynthetic antimicrobial peptide 297Gly Phe Cys
Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Thr Cys Asn 20 29821PRTArtificialSynthetic antimicrobial
peptide 298Gly Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Tyr Cys Asn 20
29921PRTArtificialSynthetic antimicrobial peptide 299Gly Phe Cys
Trp Asn Val Cys Val Ala Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 30021PRTArtificialSynthetic antimicrobial
peptide 300Gly Phe Cys Trp Asn Val Cys Val Asp Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
30121PRTArtificialSynthetic antimicrobial peptide 301Gly Phe Cys
Trp Asn Val Cys Val Phe Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 30221PRTArtificialSynthetic antimicrobial
peptide 302Gly Phe Cys Trp Asn Val Cys Val Gly Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
30321PRTArtificialSynthetic antimicrobial peptide 303Gly Phe Cys
Trp Asn Val Cys Val His Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 30421PRTArtificialSynthetic antimicrobial
peptide 304Gly Phe Cys Trp Asn Val Cys Val Ile Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
30521PRTArtificialSynthetic antimicrobial peptide 305Gly Phe Cys
Trp Asn Val Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 30621PRTArtificialSynthetic antimicrobial
peptide 306Gly Phe Cys Trp Asn Val Cys Val Met Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
30721PRTArtificialSynthetic antimicrobial peptide 307Gly Phe Cys
Trp Asn Val Cys Val Gln Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 30821PRTArtificialSynthetic antimicrobial
peptide 308Gly Phe Cys Trp Asn Val Cys Val Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
30921PRTArtificialSynthetic antimicrobial peptide 309Gly Phe Cys
Trp Asn Val Cys Val Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 31021PRTArtificialSynthetic antimicrobial
peptide 310Gly Phe Cys Trp Asn Val Cys Val Thr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
31121PRTArtificialSynthetic antimicrobial peptide 311Gly Phe Cys
Trp Asn Val Cys Val Val Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 31221PRTArtificialSynthetic antimicrobial
peptide 312Gly Phe Cys Trp Asn Val Cys Val Trp Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
31321PRTArtificialSynthetic antimicrobial peptide 313Gly Phe Cys
Trp Arg Val Cys Val Tyr Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 31421PRTArtificialSynthetic antimicrobial
peptide 314Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
31521PRTArtificialSynthetic antimicrobial peptide 315Gly Phe Cys
Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 31621PRTArtificialSynthetic antimicrobial
peptide 316Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
31721PRTArtificialSynthetic antimicrobial peptide 317Gly Phe Cys
Trp Arg Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 31821PRTArtificialSynthetic antimicrobial
peptide 318Gly Phe Cys Trp Arg Ala Cys Val Tyr Arg Asn Ser Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
31921PRTArtificialSynthetic antimicrobial peptide 319Gly Phe Cys
Trp Arg Ala Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 32021PRTArtificialSynthetic antimicrobial
peptide 320Gly Phe Cys Trp Arg Ala Cys Val Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
32121PRTArtificialSynthetic antimicrobial peptide 321Gly Phe Cys
Trp Arg Ala Cys Val Tyr Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 32221PRTArtificialSynthetic antimicrobial
peptide 322Gly Phe Cys Trp Arg Ala Cys Val Lys Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
32321PRTArtificialSynthetic antimicrobial peptide 323Gly Phe Cys
Trp Arg Cys Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 32421PRTArtificialSynthetic antimicrobial
peptide 324Gly Phe Cys Trp Arg Ser Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
32521PRTArtificialSynthetic antimicrobial peptide 325Gly Phe Cys
Trp Arg Val Cys Ala Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 32621PRTArtificialSynthetic antimicrobial
peptide 326Gly Phe Cys Trp Arg Val Cys Gly Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
32721PRTArtificialSynthetic antimicrobial peptide 327Gly Phe Cys
Trp Arg Val Cys His Tyr Arg Asn Ser Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 32821PRTArtificialSynthetic antimicrobial
peptide 328Gly Phe Cys Trp Arg Val Cys His Tyr Arg Asn Gly Lys Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
32921PRTArtificialSynthetic antimicrobial peptide 329Gly Phe Cys
Trp Arg Val Cys Ser Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 33021PRTArtificialSynthetic antimicrobial
peptide 330Gly Phe Cys Trp Arg Val Cys Ser Tyr Arg Asn Gly Ser Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
33121PRTArtificialSynthetic antimicrobial peptide 331Gly Phe Cys
Trp Arg Val Cys Ser Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 33221PRTArtificialSynthetic antimicrobial
peptide 332Gly Phe Cys Trp Arg Val Cys Ser Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
33321PRTArtificialSynthetic antimicrobial peptide 333Gly Phe Cys
Trp Arg Val Cys Ser Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 33421PRTArtificialSynthetic antimicrobial
peptide 334Gly Phe Cys Trp Arg Val Cys Val Arg Arg Asn Gly Ala Arg
Val Cys 1 5
10 15 Tyr Arg Arg Cys Asn 20 33521PRTArtificialSynthetic
antimicrobial peptide 335Gly Phe Cys Trp Arg Val Cys Val Arg Arg
Asn Gly Val Arg Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
33621PRTArtificialSynthetic antimicrobial peptide 336Gly Phe Cys
Trp Arg Val Cys Val Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 33721PRTArtificialSynthetic antimicrobial
peptide 337Gly Phe Cys Trp Arg Val Cys Val Ser Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
33821PRTArtificialSynthetic antimicrobial peptide 338Gly Phe Cys
Trp Tyr Ala Cys Val Tyr Arg Asn Ser Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 33921PRTArtificialSynthetic antimicrobial
peptide 339Gly Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn Gly Ala Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
34021PRTArtificialSynthetic antimicrobial peptide 340Gly Phe Cys
Trp Tyr Ala Cys Val Tyr Arg Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 34121PRTArtificialSynthetic antimicrobial
peptide 341Gly Phe Cys Trp Tyr Ala Cys Val Tyr Arg Asn Gly Lys Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
34221PRTArtificialSynthetic antimicrobial peptide 342Gly Phe Cys
Trp Tyr Ala Cys Val Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 34321PRTArtificialSynthetic antimicrobial
peptide 343Gly Phe Cys Trp Tyr Ala Cys Ala Tyr Arg Asn Gly Val Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
34421PRTArtificialSynthetic antimicrobial peptide 344Gly Phe Cys
Trp Tyr Arg Cys His Tyr Ser Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 34521PRTArtificialSynthetic antimicrobial
peptide 345Gly Phe Cys Trp Tyr Ser Cys Val Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
34621PRTArtificialSynthetic antimicrobial peptide 346Gly Phe Cys
Trp Tyr Thr Cys Val Lys Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 34721PRTArtificialSynthetic antimicrobial
peptide 347Gly Phe Cys Trp Tyr Val Cys Ala Tyr Lys Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
34821PRTArtificialSynthetic antimicrobial peptide 348Gly Phe Cys
Trp Tyr Val Cys Ala Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 34921PRTArtificialSynthetic antimicrobial
peptide 349Gly Phe Cys Trp Tyr Val Cys Ala Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
35021PRTArtificialSynthetic antimicrobial peptide 350Gly Phe Cys
Trp Tyr Val Cys Ala Arg Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 35121PRTArtificialSynthetic antimicrobial
peptide 351Gly Phe Cys Trp Tyr Val Cys Ala Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
35221PRTArtificialSynthetic antimicrobial peptide 352Gly Phe Cys
Trp Tyr Val Cys Phe Tyr Arg Asn His Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 35321PRTArtificialSynthetic antimicrobial
peptide 353Gly Phe Cys Trp Tyr Val Cys Val Phe Arg Asn Gly Val Arg
Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
35421PRTArtificialSynthetic antimicrobial peptide 354Gly Phe Cys
Trp Tyr Val Cys Val Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 35521PRTArtificialSynthetic antimicrobial
peptide 355Gly Phe Cys Trp Tyr Val Cys Val Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
35621PRTArtificialSynthetic antimicrobial peptide 356Gly Phe Cys
Trp Tyr Val Cys Val Tyr Lys Asn Gly Lys Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 35721PRTArtificialSynthetic antimicrobial
peptide 357Gly Phe Cys Trp Tyr Val Cys Val Tyr Arg Asn Gly Lys Arg
Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
35821PRTArtificialSynthetic antimicrobial peptide 358Arg Phe Cys
Trp Asn Val Cys Val Tyr Arg His Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 35921PRTArtificialSynthetic antimicrobial
peptide 359Arg Phe Cys Trp Asn Val Cys Val Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg His Cys Asn 20
36021PRTArtificialSynthetic antimicrobial peptide 360Gly Phe Cys
Ala Tyr Ala Cys Val Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 36121PRTArtificialSynthetic antimicrobial
peptide 361Gly Phe Cys Ala His Val Cys Val Tyr Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
36221PRTArtificialSynthetic antimicrobial peptide 362Gly Phe Cys
Ala His Val Cys Val Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 36321PRTArtificialSynthetic antimicrobial
peptide 363Gly Phe Cys Ala Arg Val Cys Ala Lys Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
36421PRTArtificialSynthetic antimicrobial peptide 364Gly Phe Cys
Ala Arg Val Cys Val Lys Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 36521PRTArtificialSynthetic antimicrobial
peptide 365Gly Phe Cys Ala Arg Val Cys Val Arg Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
36621PRTArtificialSynthetic antimicrobial peptide 366Gly Phe Cys
Ala Arg Val Cys Val Arg Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 36721PRTArtificialSynthetic antimicrobial
peptide 367Gly Phe Cys Phe Tyr Ala Cys Val Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
36821PRTArtificialSynthetic antimicrobial peptide 368Gly Phe Cys
Phe Tyr Val Cys Ala Ser Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 36921PRTArtificialSynthetic antimicrobial
peptide 369Gly Phe Cys Phe His Val Cys Ala Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
37021PRTArtificialSynthetic antimicrobial peptide 370Gly Phe Cys
Phe His Val Cys Ser Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 37121PRTArtificialSynthetic antimicrobial
peptide 371Gly Phe Cys Phe Asn Ala Cys Val Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
37221PRTArtificialSynthetic antimicrobial peptide 372Gly Phe Cys
Phe Asn Val Cys Ala Arg Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 37321PRTArtificialSynthetic antimicrobial
peptide 373Gly Phe Cys Phe Arg Val Cys Val Tyr Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 His Arg Arg Cys Asn 20
37421PRTArtificialSynthetic antimicrobial peptide 374Gly Phe Cys
Phe Arg Val Cys Val Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 37521PRTArtificialSynthetic antimicrobial
peptide 375Gly Phe Cys Phe Arg Ala Cys Val Lys Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
37621PRTArtificialSynthetic antimicrobial peptide 376Gly Phe Cys
Phe Arg Ser Cys Val Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 37721PRTArtificialSynthetic antimicrobial
peptide 377Gly Phe Cys Phe Arg Ser Cys Val Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
37821PRTArtificialSynthetic antimicrobial peptide 378Gly Phe Cys
Phe Arg Val Cys Ala Tyr Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 37921PRTArtificialSynthetic antimicrobial
peptide 379Gly Phe Cys Phe Arg Val Cys Ala Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
38021PRTArtificialSynthetic antimicrobial peptide 380Gly Phe Cys
Phe Arg Val Cys Ala Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 38121PRTArtificialSynthetic antimicrobial
peptide 381Gly Phe Cys Phe Arg Val Cys Val Lys Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
38221PRTArtificialSynthetic antimicrobial peptide 382Gly Phe Cys
Phe Tyr Val Cys Val Arg Arg Asn Gly Val Arg Ser Cys 1 5 10 15 His
Arg Arg Cys Asn 20 38321PRTArtificialSynthetic antimicrobial
peptide 383Gly Phe Cys Gly His Val Cys Val Tyr Arg Asn Gly Val Arg
Met Cys 1 5 10 15 Tyr Arg Arg Cys His 20
38421PRTArtificialSynthetic antimicrobial peptide 384Gly Phe Cys
Gly Lys Val Cys Val Arg Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 38521PRTArtificialSynthetic antimicrobial
peptide 385Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn Gly Lys Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
38621PRTArtificialSynthetic antimicrobial peptide 386Gly Phe Cys
Gly Arg Val Cys Val Tyr Arg Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 38721PRTArtificialSynthetic antimicrobial
peptide 387Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn Gly Lys Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
38821PRTArtificialSynthetic antimicrobial peptide 388Gly Phe Cys
Gly Arg Val Cys Val Arg Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 38921PRTArtificialSynthetic antimicrobial
peptide 389Gly Phe Cys Thr Arg Val Cys Val Arg Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
39021PRTArtificialSynthetic antimicrobial peptide 390Gly Phe Cys
Trp His Val Cys Val Tyr Lys Asn Gly Lys Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 39121PRTArtificialSynthetic antimicrobial
peptide 391Gly Phe Cys Trp His Ala Cys Val Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
39221PRTArtificialSynthetic antimicrobial peptide 392Gly Phe Cys
Trp His Val Cys Ala Tyr Arg Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 39321PRTArtificialSynthetic antimicrobial
peptide 393Gly Phe Cys Trp His Val Cys Ala Lys Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
39421PRTArtificialSynthetic antimicrobial peptide 394Gly Phe Cys
Trp His Val Cys Ala Arg Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 39521PRTArtificialSynthetic antimicrobial
peptide 395Gly Phe Cys Trp His Val Cys Ala Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
39621PRTArtificialSynthetic antimicrobial peptide 396Gly Phe Cys
Trp His Val Cys Ser Lys Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 39721PRTArtificialSynthetic antimicrobial
peptide 397Gly Phe Cys Trp His Val Cys Val Arg Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
39821PRTArtificialSynthetic antimicrobial peptide 398Gly Phe Cys
Trp His Val Cys Val Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 39921PRTArtificialSynthetic antimicrobial
peptide 399Gly Phe Cys Trp His Val Cys Val Arg Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
40021PRTArtificialSynthetic antimicrobial peptide 400Gly Phe Cys
Trp His Val Cys Val Ser Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 40121PRTArtificialSynthetic antimicrobial
peptide 401Gly Phe Cys Trp Lys Ala Cys Val Tyr Lys Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
40221PRTArtificialSynthetic antimicrobial peptide 402Gly Phe Cys
Trp Lys Ala Cys Val Tyr Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 40321PRTArtificialSynthetic antimicrobial
peptide 403Gly Phe Cys Trp Lys Ala Cys Ala Tyr Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
40421PRTArtificialSynthetic antimicrobial peptide 404Gly Phe Cys
Trp Lys Val Cys Val Lys Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 40521PRTArtificialSynthetic antimicrobial
peptide 405Gly Phe Cys Trp Lys Val Cys Val Arg Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
40621PRTArtificialSynthetic antimicrobial peptide 406Gly Phe Cys
Trp Asn Ala Cys Ala Tyr Arg Asn Gly Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 40721PRTArtificialSynthetic antimicrobial
peptide 407Gly Phe Cys Trp Asn Ala Cys Ala Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
40821PRTArtificialSynthetic antimicrobial peptide 408Gly Phe Cys
Trp Asn Ala Cys Val Arg Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 40921PRTArtificialSynthetic antimicrobial
peptide 409Gly Phe Cys Trp Asn Phe Cys Val Tyr Arg Tyr Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
41021PRTArtificialSynthetic antimicrobial peptide 410Gly Phe Cys
Trp Asn Val Cys Ala Tyr Arg Gln Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 41121PRTArtificialSynthetic antimicrobial
peptide 411Gly Phe Cys Trp Asn Val Cys Ala Tyr Arg Asn Gly Lys Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
41221PRTArtificialSynthetic antimicrobial peptide 412Gly Phe Cys
Trp Asn Val Cys Val Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 41321PRTArtificialSynthetic antimicrobial
peptide 413Gly Phe Cys Trp Arg Val Cys Val Tyr Arg Asn Ser Lys Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
41421PRTArtificialSynthetic antimicrobial peptide 414Gly Phe Cys
Trp Arg Val Cys Val Tyr Lys Asn Gly Lys Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 41521PRTArtificialSynthetic antimicrobial
peptide 415Gly Phe Cys Trp Arg Ala Cys Val Tyr Arg Asn Gly Lys Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
41621PRTArtificialSynthetic antimicrobial peptide 416Gly Phe Cys
Trp Arg Ala Cys Val Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 41721PRTArtificialSynthetic antimicrobial
peptide 417Gly Phe Cys Trp Arg Ala Cys Ala Tyr Arg Asn Gly Lys Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
41821PRTArtificialSynthetic antimicrobial peptide 418Gly Phe Cys
Trp Arg
Ala Cys Ala Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 Tyr Arg Arg
Cys Asn 20 41921PRTArtificialSynthetic antimicrobial peptide 419Gly
Phe Cys Trp Arg Ala Cys Ala Tyr Arg Asn Gly Val Arg Val Cys 1 5 10
15 His Arg Arg Cys Asn 20 42021PRTArtificialSynthetic antimicrobial
peptide 420Gly Phe Cys Trp Arg Ala Cys Ala Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
42121PRTArtificialSynthetic antimicrobial peptide 421Gly Phe Cys
Trp Arg Ala Cys His Tyr Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 42221PRTArtificialSynthetic antimicrobial
peptide 422Gly Phe Cys Trp Arg Ala Cys Val Arg Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
42321PRTArtificialSynthetic antimicrobial peptide 423Gly Phe Cys
Trp Arg Ser Cys Val Tyr Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 42421PRTArtificialSynthetic antimicrobial
peptide 424Gly Phe Cys Trp Arg Val Cys Ala Tyr Arg Asn Ser Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
42521PRTArtificialSynthetic antimicrobial peptide 425Gly Phe Cys
Trp Arg Val Cys Ala Tyr Ser Asn Gly Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 42621PRTArtificialSynthetic antimicrobial
peptide 426Gly Phe Cys Trp Arg Val Cys Ala Tyr Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
42721PRTArtificialSynthetic antimicrobial peptide 427Gly Phe Cys
Trp Arg Val Cys Ala Tyr Arg Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 42821PRTArtificialSynthetic antimicrobial
peptide 428Gly Phe Cys Trp Arg Val Cys Ala Tyr Arg Asn Gly Lys Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
42921PRTArtificialSynthetic antimicrobial peptide 429Gly Phe Cys
Trp Arg Val Cys Ala Tyr Arg Asn Gly Val Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 43021PRTArtificialSynthetic antimicrobial
peptide 430Gly Phe Cys Trp Arg Val Cys Ala Tyr Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
43121PRTArtificialSynthetic antimicrobial peptide 431Gly Phe Cys
Trp Arg Val Cys Ala Lys Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 43221PRTArtificialSynthetic antimicrobial
peptide 432Gly Phe Cys Trp Arg Val Cys Ala Lys Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
43321PRTArtificialSynthetic antimicrobial peptide 433Gly Phe Cys
Trp Arg Val Cys Ala Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 43421PRTArtificialSynthetic antimicrobial
peptide 434Gly Phe Cys Trp Arg Val Cys Ala Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
43521PRTArtificialSynthetic antimicrobial peptide 435Gly Phe Cys
Trp Arg Val Cys Ala Ser Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 43621PRTArtificialSynthetic antimicrobial
peptide 436Gly Phe Cys Trp Arg Val Cys Gly Tyr Arg Asn Ser Lys Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
43721PRTArtificialSynthetic antimicrobial peptide 437Gly Phe Cys
Trp Arg Val Cys His Tyr Arg Asn Ser Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 43821PRTArtificialSynthetic antimicrobial
peptide 438Gly Phe Cys Trp Arg Val Cys His Tyr Lys Asn Gly Lys Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
43921PRTArtificialSynthetic antimicrobial peptide 439Gly Phe Cys
Trp Arg Val Cys His Tyr Ser Asn Gly Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 44021PRTArtificialSynthetic antimicrobial
peptide 440Gly Phe Cys Trp Arg Val Cys Ser Lys Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
44121PRTArtificialSynthetic antimicrobial peptide 441Gly Phe Cys
Trp Arg Val Cys Val Lys Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 44221PRTArtificialSynthetic antimicrobial
peptide 442Gly Phe Cys Trp Arg Val Cys Val Lys Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
44321PRTArtificialSynthetic antimicrobial peptide 443Gly Phe Cys
Trp Arg Val Cys Val Arg Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 44421PRTArtificialSynthetic antimicrobial
peptide 444Gly Phe Cys Trp Arg Val Cys Val Arg Arg Asn Gly Ala Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
44521PRTArtificialSynthetic antimicrobial peptide 445Gly Phe Cys
Trp Arg Val Cys Val Arg Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 44621PRTArtificialSynthetic antimicrobial
peptide 446Gly Phe Cys Trp Arg Val Cys Val Arg Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
44721PRTArtificialSynthetic antimicrobial peptide 447Gly Phe Cys
Trp Arg Val Cys Val Arg Arg Asn Gly Val Arg Ser Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 44821PRTArtificialSynthetic antimicrobial
peptide 448Gly Phe Cys Trp Arg Val Cys Val Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Ser Arg His Cys Asn 20
44921PRTArtificialSynthetic antimicrobial peptide 449Gly Phe Cys
Trp Arg Val Cys Val Ser Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 45021PRTArtificialSynthetic antimicrobial
peptide 450Gly Phe Cys Trp Tyr Ala Cys Ala Lys Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
45121PRTArtificialSynthetic antimicrobial peptide 451Gly Phe Cys
Trp Tyr Ala Cys Val Ser Arg Asn Gly Leu Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 45221PRTArtificialSynthetic antimicrobial
peptide 452Gly Phe Cys Trp Tyr Val Cys Ala Tyr Ser Asn Gly Val Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
45321PRTArtificialSynthetic antimicrobial peptide 453Gly Phe Cys
Trp Tyr Val Cys Ala Arg Arg Asn Gly Leu Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 45421PRTArtificialSynthetic antimicrobial
peptide 454Gly Phe Cys Trp Tyr Val Cys Val Lys Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 His Arg Arg Cys Asn 20
45521PRTArtificialSynthetic antimicrobial peptide 455Gly Phe Cys
Ala Arg Val Cys Val Lys Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 45621PRTArtificialSynthetic antimicrobial
peptide 456Gly Phe Cys Ala Arg Val Cys Val Lys Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
45721PRTArtificialSynthetic antimicrobial peptide 457Gly Phe Cys
Ala Arg Val Cys Val Ser Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 45821PRTArtificialSynthetic antimicrobial
peptide 458Gly Phe Cys Ala Tyr Val Cys Val Ser Arg Asn Gly Ala Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
45921PRTArtificialSynthetic antimicrobial peptide 459Gly Phe Cys
Phe His Val Cys Ala Arg Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 46021PRTArtificialSynthetic antimicrobial
peptide 460Gly Phe Cys Phe His Val Cys Ala Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
46121PRTArtificialSynthetic antimicrobial peptide 461Gly Phe Cys
Phe His Val Cys Val Lys Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 46221PRTArtificialSynthetic antimicrobial
peptide 462Gly Phe Cys Phe Lys Val Cys Ser Tyr Arg Asn Gly Leu Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
46321PRTArtificialSynthetic antimicrobial peptide 463Gly Phe Cys
Phe Lys Val Cys Ser Lys Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 46421PRTArtificialSynthetic antimicrobial
peptide 464Gly Phe Cys Phe Asn Val Cys Ala Arg Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
46521PRTArtificialSynthetic antimicrobial peptide 465Gly Phe Cys
Phe Arg Val Cys Val Tyr Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 46621PRTArtificialSynthetic antimicrobial
peptide 466Gly Phe Cys Phe Arg Ala Cys Ala Tyr Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
46721PRTArtificialSynthetic antimicrobial peptide 467Gly Phe Cys
Phe Arg Ala Cys Thr Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 46821PRTArtificialSynthetic antimicrobial
peptide 468Gly Phe Cys Phe Arg Ala Cys Val Lys Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
46921PRTArtificialSynthetic antimicrobial peptide 469Gly Phe Cys
Phe Arg Ala Cys Val Arg Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 47021PRTArtificialSynthetic antimicrobial
peptide 470Gly Phe Cys Phe Arg Ala Cys Val Ser Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
47121PRTArtificialSynthetic antimicrobial peptide 471Gly Phe Cys
Phe Arg Ser Cys Ala Arg Arg Asn Gly Val Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 47221PRTArtificialSynthetic antimicrobial
peptide 472Gly Phe Cys Phe Arg Ser Cys Ala Ser Arg Asn Gly Val Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
47321PRTArtificialSynthetic antimicrobial peptide 473Gly Phe Cys
Phe Arg Val Cys Ala Tyr Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 47421PRTArtificialSynthetic antimicrobial
peptide 474Gly Phe Cys Phe Arg Val Cys Ala Tyr Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
47521PRTArtificialSynthetic antimicrobial peptide 475Gly Phe Cys
Phe Arg Val Cys Ala Tyr Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 47621PRTArtificialSynthetic antimicrobial
peptide 476Gly Phe Cys Phe Arg Val Cys Ala Tyr Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 His Arg Arg Cys Asn 20
47721PRTArtificialSynthetic antimicrobial peptide 477Gly Phe Cys
Phe Arg Val Cys Ala Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 47821PRTArtificialSynthetic antimicrobial
peptide 478Gly Phe Cys Phe Arg Val Cys Ala Lys Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
47921PRTArtificialSynthetic antimicrobial peptide 479Gly Phe Cys
Phe Arg Val Cys Ala Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 48021PRTArtificialSynthetic antimicrobial
peptide 480Gly Phe Cys Phe Arg Val Cys Ala Ser Arg Asn Gly Val Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
48121PRTArtificialSynthetic antimicrobial peptide 481Gly Phe Cys
Phe Arg Val Cys Ser Tyr Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 48221PRTArtificialSynthetic antimicrobial
peptide 482Gly Phe Cys Phe Arg Val Cys Ser Tyr Arg Asn Gly Leu Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
48321PRTArtificialSynthetic antimicrobial peptide 483Gly Phe Cys
Phe Arg Val Cys Ser Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 48421PRTArtificialSynthetic antimicrobial
peptide 484Gly Phe Cys Phe Arg Val Cys Ser Lys Arg Asn Gly Val Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
48521PRTArtificialSynthetic antimicrobial peptide 485Gly Phe Cys
Phe Arg Val Cys Ser Arg Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 48621PRTArtificialSynthetic antimicrobial
peptide 486Gly Phe Cys Phe Arg Val Cys Ser Ser Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
48721PRTArtificialSynthetic antimicrobial peptide 487Gly Phe Cys
Phe Arg Val Cys Ser Ser Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 48821PRTArtificialSynthetic antimicrobial
peptide 488Gly Phe Cys Phe Arg Val Cys Val Lys Arg Asn Gly Ala Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
48921PRTArtificialSynthetic antimicrobial peptide 489Gly Phe Cys
Phe Arg Val Cys Val Arg Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 49021PRTArtificialSynthetic antimicrobial
peptide 490Gly Phe Cys Phe Tyr Val Cys Val Ser Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 His Arg Arg Cys Asn 20
49121PRTArtificialSynthetic antimicrobial peptide 491Gly Phe Cys
Gly Lys Val Cys Val Lys Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 49221PRTArtificialSynthetic antimicrobial
peptide 492Gly Phe Cys Gly Arg Val Cys Val Tyr Arg Asn Ser Lys Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
49321PRTArtificialSynthetic antimicrobial peptide 493Gly Phe Cys
Gly Arg Val Cys Val Tyr Lys Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 49421PRTArtificialSynthetic antimicrobial
peptide 494Gly Phe Cys Ser Tyr Ser Cys Ala Tyr Arg Asn Gly Ser Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
49521PRTArtificialSynthetic antimicrobial peptide 495Gly Phe Cys
Ser Asn Ser Cys Val Lys Arg Asn Gly Val Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 49621PRTArtificialSynthetic antimicrobial
peptide 496Gly Phe Cys Thr Asn Val Cys Ala Lys Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
49721PRTArtificialSynthetic antimicrobial peptide 497Gly Phe Cys
Trp His Ala Cys Val Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 49821PRTArtificialSynthetic antimicrobial
peptide 498Gly Phe Cys Trp His Ala Cys Val Arg Arg Asn Gly Leu Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
49921PRTArtificialSynthetic antimicrobial peptide 499Gly Phe Cys
Trp His Ala Cys Val Arg Arg Asn Gly Leu Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 50021PRTArtificialSynthetic antimicrobial
peptide 500Gly Phe Cys Trp His Val Cys Ala Tyr Lys Asn Gly Val Arg
Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
50121PRTArtificialSynthetic antimicrobial peptide 501Gly Phe Cys
Trp His Val Cys Ala Arg Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20
50221PRTArtificialSynthetic antimicrobial peptide 502Gly Phe Cys
Trp Lys Arg Cys Val Tyr Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 50321PRTArtificialSynthetic antimicrobial
peptide 503Gly Phe Cys Trp Lys Ser Cys Val Arg Arg Asn Gly Leu Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
50421PRTArtificialSynthetic antimicrobial peptide 504Gly Phe Cys
Trp Lys Val Cys Ala Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 50521PRTArtificialSynthetic antimicrobial
peptide 505Gly Phe Cys Trp Lys Val Cys Ser Ser Arg Asn Gly Leu Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
50621PRTArtificialSynthetic antimicrobial peptide 506Gly Phe Cys
Trp Lys Val Cys Val Ser Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 50721PRTArtificialSynthetic antimicrobial
peptide 507Gly Phe Cys Trp Asn Val Cys Ala Arg Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 His Arg Arg Cys Asn 20
50821PRTArtificialSynthetic antimicrobial peptide 508Gly Phe Cys
Trp Asn Val Cys Val Arg Arg Asn Gly Leu Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 50921PRTArtificialSynthetic antimicrobial
peptide 509Gly Phe Cys Trp Arg Val Cys Val Tyr Ser Asn Gly Lys Arg
Ser Cys 1 5 10 15 His Arg Arg Cys Asn 20
51021PRTArtificialSynthetic antimicrobial peptide 510Gly Phe Cys
Trp Arg Ala Cys Val Tyr Lys Asn Ser Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 51121PRTArtificialSynthetic antimicrobial
peptide 511Gly Phe Cys Trp Arg Ala Cys Val Tyr Lys Asn Gly Val Arg
Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
51221PRTArtificialSynthetic antimicrobial peptide 512Gly Phe Cys
Trp Arg Ala Cys Ala Tyr Arg Asn Gly Lys Arg Ala Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 51321PRTArtificialSynthetic antimicrobial
peptide 513Gly Phe Cys Trp Arg Ala Cys Ala Tyr Arg Asn Gly Lys Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
51421PRTArtificialSynthetic antimicrobial peptide 514Gly Phe Cys
Trp Arg Ala Cys Ala Ser Arg Asn Gly Val Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 51521PRTArtificialSynthetic antimicrobial
peptide 515Gly Phe Cys Trp Arg Ala Cys Ser Arg Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
51621PRTArtificialSynthetic antimicrobial peptide 516Gly Phe Cys
Trp Arg Ala Cys Val Lys Arg Asn Gly Ala Arg Val Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 51721PRTArtificialSynthetic antimicrobial
peptide 517Gly Phe Cys Trp Arg Ala Cys Val Lys Arg Asn Gly Leu Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
51821PRTArtificialSynthetic antimicrobial peptide 518Gly Phe Cys
Trp Arg Ala Cys Val Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 51921PRTArtificialSynthetic antimicrobial
peptide 519Gly Phe Cys Trp Arg Ala Cys Val Arg Arg Asn Gly Leu Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
52021PRTArtificialSynthetic antimicrobial peptide 520Gly Phe Cys
Trp Arg Ala Cys Val Ser Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 52121PRTArtificialSynthetic antimicrobial
peptide 521Gly Phe Cys Trp Arg Ala Cys Val Ser Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
52221PRTArtificialSynthetic antimicrobial peptide 522Gly Phe Cys
Trp Arg Arg Cys Val Arg Arg Asn Gly Ala Arg Ser Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 52321PRTArtificialSynthetic antimicrobial
peptide 523Gly Phe Cys Trp Arg Val Cys Ala Tyr Lys Asn Gly Lys Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
52421PRTArtificialSynthetic antimicrobial peptide 524Gly Phe Cys
Trp Arg Val Cys Ala Arg Arg Asn Gly Leu Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 52521PRTArtificialSynthetic antimicrobial
peptide 525Gly Phe Cys Trp Arg Val Cys Ala Ser Arg Asn Gly Ala Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
52621PRTArtificialSynthetic antimicrobial peptide 526Gly Phe Cys
Trp Arg Val Cys Gly Tyr Lys Asn Gly Val Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 52721PRTArtificialSynthetic antimicrobial
peptide 527Gly Phe Cys Trp Arg Val Cys Gly Tyr Arg Asn Gly Lys Arg
Ala Cys 1 5 10 15 His Arg Arg Cys Asn 20
52821PRTArtificialSynthetic antimicrobial peptide 528Gly Phe Cys
Trp Arg Val Cys Ser Tyr Ser Asn Ser Lys Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 52921PRTArtificialSynthetic antimicrobial
peptide 529Gly Phe Cys Trp Arg Val Cys Ser Arg Arg Asn Gly Leu Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
53021PRTArtificialSynthetic antimicrobial peptide 530Gly Phe Cys
Trp Arg Val Cys Val Arg Arg Asn Gly Leu Arg Ser Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 53121PRTArtificialSynthetic antimicrobial
peptide 531Gly Phe Cys Trp Arg Val Cys Val Ser Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
53221PRTArtificialSynthetic antimicrobial peptide 532Gly Phe Cys
Trp Arg Val Cys Val Ser Arg Asn Gly Leu Arg Ser Cys 1 5 10 15 Ser
Arg Arg Cys Asn 20 53321PRTArtificialSynthetic antimicrobial
peptide 533Gly Leu Cys Trp Arg Val Cys Ala Tyr Ser Asn Gly Lys Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
53421PRTArtificialSynthetic antimicrobial peptide 534Gly Phe Cys
Phe Asn Val Cys Val Ser Arg Asn Gly Ala Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 53521PRTArtificialSynthetic antimicrobial
peptide 535Gly Phe Cys Phe Arg Ala Cys Ala Arg Arg Asn Gly Val Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
53621PRTArtificialSynthetic antimicrobial peptide 536Gly Phe Cys
Phe Arg Ala Cys Ser Lys Arg Asn Gly Leu Arg Val Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 53721PRTArtificialSynthetic antimicrobial
peptide 537Gly Phe Cys Phe Arg Ala Cys Val Lys Arg Asn Gly Leu Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
53821PRTArtificialSynthetic antimicrobial peptide 538Gly Phe Cys
Phe Arg Ala Cys Val Lys Arg Asn Gly Leu Arg Val Cys 1 5 10 15 His
Arg Arg Cys Asn 20 53921PRTArtificialSynthetic antimicrobial
peptide 539Gly Phe Cys Phe Arg Val Cys Ala Lys Arg Asn Gly Ala Arg
Ser Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
54021PRTArtificialSynthetic antimicrobial peptide 540Gly Phe Cys
Phe Arg Val Cys Ala Ser Arg Asn Gly Val Arg Lys Cys 1 5 10 15 His
Arg Arg Cys Asn 20 54121PRTArtificialSynthetic antimicrobial
peptide 541Gly Phe Cys Phe Arg Val Cys Ser Lys Arg Asn Gly Ala Arg
Lys Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
54221PRTArtificialSynthetic antimicrobial peptide 542Gly Phe Cys
Gly His Arg Cys Ser Arg Arg Asn Gly Val Arg Lys Cys 1 5 10 15 Tyr
Arg Arg Cys Asn 20 54321PRTArtificialSynthetic antimicrobial
peptide 543Gly Phe Cys Ser His Arg Cys Ser Tyr Arg Asn Ser Val Arg
Ala Cys 1 5 10 15 Tyr Arg Arg Cys Asn 20
54421PRTArtificialSynthetic antimicrobial peptide 544Gly Phe Cys
Ser Arg Val Cys Ser Tyr Arg Asn Gly Ser Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 54521PRTArtificialSynthetic antimicrobial
peptide 545Gly Phe Cys Trp Arg Ala Cys Ala Ser Arg Asn Gly Leu Arg
Val Cys 1 5 10 15 Ser Arg Arg Cys Asn 20
54621PRTArtificialSynthetic antimicrobial peptide 546Gly Phe Cys
Ser Asn Arg Cys His Tyr Ser Asn Gly Ser Arg Ala Cys 1 5 10 15 His
Arg Arg Cys Asn 20 54721PRTArtificialSynthetic antimicrobial
peptide 547Gly Phe Cys Trp Gly Ala Val Asn Tyr Thr Ser Asn Cys Arg
Ala Cys 1 5 10 15 Lys Arg Arg Cys Asn 20
54821PRTArtificialSynthetic antimicrobial peptide 548Gly Ser Cys
Trp Gly Ala Val Asn Tyr Thr Ser Asn Cys Arg Ala Cys 1 5 10 15 Lys
Arg Arg Cys Asn 20
* * * * *